Patent Application
20220340597
The present invention relates to organic compounds useful for therapy and/or prophylaxis in a mammal, and in particular to antagonist of TLR7 and/or TLR8 and/or TLR9 useful for treating systemic lupus erythematosus or lupus nephritis.
Autoimmune connective tissue disease (CTD) include prototypical autoimmune syndromes such as Systemic Lupus Erythematosus (SLE), primary Sjögren's syndrome (pSjS), mixed connective tissue disease (MCTD), Dermatomyositis/Polymyositis (DM/PM), Rheumatoid Arthritis (RA), and systemic sclerosis (SSc). With the exception of RA, no really effective and safe therapies are available to patients. SLE represents the prototypical CTD with a prevalence of 20-150 per 100,000 and causes broad inflammation and tissue damage in distinct organs, from commonly observed symptoms in the skin and joints to renal, lung, or heart failure. Traditionally, SLE has been treated with nonspecific anti-inflammatory or immunosuppressive drugs. However, long term usage of immunosuppressive drug, e.g. corticosteroids is only partially effective, and is associated with undesirable toxicity and side effects. Belimumab is the only FDA-approved drug for lupus in the last 50 years, despite its modest and delayed efficacy in only a fraction of SLE patients (Navarra, S. V. et al Lancet 2011, 377, 721). Other biologics, such as anti-CD20 mAbs, mAbs against or soluble receptors of specific cytokines, have failed in most clinical studies. Thus, novel therapies are required that provide sustained improvement in a greater proportion of patient groups and are safer for chronic use in many autoimmune as well as autoinflammation diseases.
Toll Like Receptors (TLR) are an important family of pattern recognition receptors (PRR) which can initiate broad immune responses in a wide variety of immune cells. As natural host defense sensors, endosomal TLRs 7, 8 and 9 recognize nucleic acids derived from viruses, bacteria; specifically, TLR7/8 and TLR9 recognize single-stranded RNA (ssRNA) and single-stranded CpG-DNA, respectively. However, aberrant nucleic acid sensing of TRL7,8,9 is considered as a key node in a broad of autoimmune and auto-inflammatory diseases (Krieg, A. M. et al. Immunol. Rev. 2007, 220, 251. Jiménez-Dalmaroni, M. J. et al Autoimmun Rev. 2016, 15, 1. Chen, J. Q., et al. Clinical Reviews in Allergy & Immunology 2016, 50, 1). Anti-RNA and anti-DNA antibodies are well established diagnostic markers of SLE, and these antibodies can deliver both self-RNA and self-DNA to endosomes. While self-RNA complexes can be recognized by TLR7 and TLR8, self-DNA complexes can trigger TLR9 activation. Indeed, defective clearance of self-RNA and self-DNA from blood and/or tissues is evident in SLE (Systemic Lupus Erythematosus) patients. TLR7 and TLR9 have been reported to be upregulated in SLE tissues, and correlate with chronicity and activity of lupus nephritis, respectively. In B cells of SLE patients, TLR7 expression correlates with anti-RNP antibody production, while TLR9 expression with IL-6 and anti-dsDNA antibody levels. Consistently, in lupus mouse models, TLR7 is required for anti-RNA antibodies, and TLR9 is required for anti-nucleosome antibody. On the other hand, overexpression of TLR7 or human TLR8 in mice promotes autoimmunity and autoinflammation. Moreover, activation of TLR8 specifically contributes to inflammatory cytokine secretion of mDC/macrophages, neutrophil NETosis, induction of Th17 cells, and suppression of Treg cells. In addition to the described role of TLR9 in promoting autoantibody production of B cells, activation of TLR9 by self-DNA in pDC also leads to induction of type I IFNs and other inflammatory cytokines. Given these roles of TLR9 in both pDC and B cells, both as key contributors to the pathogenesis of autoimmune diseases, and the extensive presence of self-DNA complexes that could readily activate TLR9 in many patients with autoimmune diseases, it may have extra benefit to further block self-DNA mediated TLR9 pathways on top of inhibition of TLR7 and TLR8 pathways. Taken together, TLR7, 8, and 9 pathways represent new therapeutic targets for the treatment of autoimmune and auto-inflammatory diseases, for which no effective steroid-free and non-cytotoxic oral drugs exist, and inhibition of all these pathways from the very upstream may deliver satisfying therapeutic effects. As such, we invented oral compounds that target and suppress TLR7, TLR8 and TLR9 for the treatment of autoimmune and auto-inflammatory diseases.
The present invention relates to novel compounds of formula (I) or (Ia) or (Ib),
wherein
wherein R4 is C1-6alkyl, C1-6alkoxy, haloC1-6alkyl, halogen, nitro or cyano; R4a is C1-6alkyl or C3-7cycloalkyl; R5, R5a and R5b are independently selected from H and deuterium; R6 is H or halogen;
Another object of the present invention is related to novel compounds of formula (I) or (Ia), their manufacture, medicaments based on a compound in accordance with the invention and their production as well as the use of compounds of formula (I) or (Ia) as TLR7 and/or TLR8 and/or TLR9 antagonist, and for the treatment or prophylaxis of systemic lupus erythematosus or lupus nephritis. The compounds of formula (I) or (Ia) show superior TLR7 and/or TLR8 and/or TLR9 antagonism activity. In addition, the compounds of formula (I) or (Ia) also show good cytotoxicity, phototoxicity, solubility, hPBMC, human microsome stability and SDPK profiles, as well as low CYP inhibition.
The term “C1-6alkyl” denotes a saturated, linear or branched chain alkyl group containing 1 to 6, particularly 1 to 4 carbon atoms, for example methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl and the like. Particular “C1-6alkyl” groups are methyl, ethyl and n-propyl.
The term “halogen” and “halo” are used interchangeably herein and denote fluoro, chloro, bromo, or iodo.
The term “haloC1-6alkyl” denotes a C1-6alkyl group wherein at least one of the hydrogen atoms of the C1-6alkyl group has been replaced by same or different halogen atoms, particularly fluoro atoms. Examples of haloC1-6alkyl include monofluoro-, difluoro- or trifluoro-methyl, -ethyl or -propyl, for example 3,3,3-trifluoropropyl, 2-fluoroethyl, trifluoroethyl, fluoromethyl, difluoromethyl, difluoroethyl or trifluoromethyl.
The term “halopyrrolidinyl” denotes a pyrrolidinyl substituted once, twice or three times by halogen. Examples of halopyrrolidinyl include, but not limited to, difluoropyrrolidinyl and fluoropyrrolidinyl.
The term “C3-7cycloalkyl” denotes a saturated carbon ring containing from 3 to 7 carbon atoms, particularly from 3 to 6 carbon atoms, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and the like. Particular “C3-7cycloalkyl” groups are cyclopropyl, cyclopentyl and cyclohexyl.
The term “aryl” denotes an aromatic hydrocarbon mono- or bicyclic ring system of 5 to 12 ring atoms. Examples of aryl include, but not limited to, phenyl and naphthyl. Aryl can be further substituted by substituents include, but not limited to, C1-6alkyl; 3,4,4a,5,7,7a-hexahydro-2H-pyrrolo[3,4-b][1,4]oxazinyl; 1,4-diazepanyl; 2,6-diazaspiro[3.3]heptanyl substituted by C1-6alkyl; 5-oxa-2,8-diazaspiro[3.5]nonanyl; amino-1,4-oxazepanyl; azetidinyl substituted by one or two substituents independently selected from amino and C1-6alkyl; piperazinyl unsubstituted or substituted by C1-6alkyl; and pyrrolidinyl substituted by one or two substituents independently selected from amino, C1-6alkoxy and halogen.
The term “heteroaryl” denotes an aromatic heterocyclic mono- or bicyclic ring system of 5 to 12 ring atoms, comprising 1, 2, 3 or 4 heteroatoms selected from N, O and S, the remaining ring atoms being carbon. Examples of heteroaryl moieties include, but not limited to, pyrrolyl, furanyl, thienyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyridinyl, pyrazinyl, pyrazolyl, pyridazinyl, pyrimidinyl, triazinyl, isoxazolyl, benzofuranyl, isothiazolyl, benzothienyl, indolyl, isoindolyl, isobenzofuranyl, benzimidazolyl, benzoxazolyl, benzoisoxazolyl, benzothiazolyl, benzoisothiazolyl, benzooxadiazolyl, benzothiadiazolyl, benzotriazolyl, purinyl, quinolinyl, isoquinolinyl, quinazolinyl or quinoxalinyl. Heteroaryl can be further substituted by substituents include, but not limited to, C1-6alkyl; 3,4,4a,5,7,7a-hexahydro-2H-pyrrolo[3,4-b][1,4]oxazinyl; 1,4-diazepanyl; 2,6-diazaspiro[3.3]heptanyl substituted by C1-6alkyl; 5-oxa-2,8-diazaspiro[3.5]nonanyl; amino-1,4-oxazepanyl; azetidinyl substituted by one or two substituents independently selected from amino and C1-6alkyl; piperazinyl unsubstituted or substituted by C1-6alkyl; and pyrrolidinyl substituted by one or two substituents independently selected from amino, C1-6alkoxy and halogen.
The term “heterocyclyl” or “heterocyclic” denotes a monovalent saturated or partly unsaturated mono or bicyclic ring system of 3 to 12 ring atoms, comprising 1 to 5 ring heteroatoms selected from N, O and S, the remaining ring atoms being carbon. In particular embodiments, heterocyclyl is a monovalent saturated monocyclic ring system of 4 to 7 ring atoms, comprising 1, 2, or 3 ring heteroatoms selected from N, O and S, the remaining ring atoms being carbon. Examples for monocyclic saturated heterocyclyl are aziridinyl, oxiranyl, azetidinyl, oxetanyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothienyl, pyrazolidinyl, imidazolidinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, piperidinyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperazinyl, morpholinyl, thiomorpholinyl, 1,1-dioxo-thiomorpholin-4-yl, azepanyl, diazepanyl, homopiperazinyl, oxazepanyl. Examples for bicyclic saturated heterocyclic ring are azabicyclo[3.2.1]octyl, quinuclidinyl, oxaazabicyclo[3.2.1]octanyl, azabicyclo[3.3.1]nonanyl, oxaaza-bicyclo[3.3.1]nonanyl, azabicyclo[3.1.0]hexanyl, oxodiazaspiro[3.4]octanyl, acetyloxodiazaspiro[3.4]octanyl, thiaazabicyclo[3.3.1]nonanyl, oxoazaspiro[2.4]heptanyl, oxoazaspiro[3.4]octanyl, oxoazabicyclo[3.1.0]hexanyl and dioxotetrahydropyrrolo[1,2-a]pyrazinyl. Examples for bicyclic heterocyclyl include, but not limited to; 2,5-diazabicyclo[2.2.1]heptanyl; 3,4,4a,5,7,7a-hexahydro-2H-pyrrolo[3,4-b][1,4]oxazinyl; 3,6-diazabicyclo[3.1.1]heptanyl; 3,8-diazabicyclo[3.2.1]octanyl; 5-oxa-2,8-diazaspiro[3.5]nonanyl; 9-oxa-3,7-diazabicyclo[3.3.1]nonanyl; 2,6-diazaspiro[3.3]heptanecarbonyl; 1,2,3,4-tetrahydroisoquinolinyl; 5,6,7,8-tetrahydro-1,6-naphthyridinyl; 5,6,7,8-tetrahydro-2,6-naphthyridinyl; 5,6,7,8-tetrahydro-2,7-naphthyridinyl; isoindolinyl.
The term “cis-isomers” and “trans-isomers” denote the relative stereochemistry of the molecule or moiety. For example: Intermediate B
as the “trans-isomers” refers to a mixture of
similarly, Intermediate A
as the “cis-isomers” refers to a mixture of
The way of showing relative stereochemistry also applies to the final compounds.
The term “pharmaceutically acceptable salts” denotes salts which are not biologically or otherwise undesirable. Pharmaceutically acceptable salts include both acid and base addition salts.
The term “pharmaceutically acceptable acid addition salt” denotes those pharmaceutically acceptable salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, carbonic acid, phosphoric acid, and organic acids selected from aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic, and sulfonic classes of organic acids such as formic acid, acetic acid, propionic acid, glycolic acid, gluconic acid, lactic acid, pyruvic acid, oxalic acid, malic acid, maleic acid, maloneic acid, succinic acid, fumaric acid, tartaric acid, citric acid, aspartic acid, ascorbic acid, glutamic acid, anthranilic acid, benzoic acid, cinnamic acid, mandelic acid, embonic acid, phenylacetic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, and salicyclic acid.
The term “pharmaceutically acceptable base addition salt” denotes those pharmaceutically acceptable salts formed with an organic or inorganic base. Examples of acceptable inorganic bases include sodium, potassium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, and aluminum salts. Salts derived from pharmaceutically acceptable organic nontoxic bases includes salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, 2-diethylaminoethanol, trimethamine, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purines, piperizine, piperidine, N-ethylpiperidine, and polyamine resins.
The term “A pharmaceutically active metabolite” denotes a pharmacologically active product produced through metabolism in the body of a specified compound or salt thereof. After entry into the body, most drugs are substrates for chemical reactions that may change their physical properties and biologic effects. These metabolic conversions, which usually affect the polarity of the compounds of the invention, alter the way in which drugs are distributed in and excreted from the body. However, in some cases, metabolism of a drug is required for therapeutic effect.
The term “therapeutically effective amount” denotes an amount of a compound or molecule of the present invention that, when administered to a subject, (i) treats or prevents the particular disease, condition or disorder, (ii) attenuates, ameliorates or eliminates one or more symptoms of the particular disease, condition, or disorder, or (iii) prevents or delays the onset of one or more symptoms of the particular disease, condition or disorder described herein. The therapeutically effective amount will vary depending on the compound, the disease state being treated, the severity of the disease treated, the age and relative health of the subject, the route and form of administration, the judgement of the attending medical or veterinary practitioner, and other factors.
The term “pharmaceutical composition” denotes a mixture or solution comprising a therapeutically effective amount of an active pharmaceutical ingredient together with pharmaceutically acceptable excipients to be administered to a mammal, e.g., a human in need thereof.
Antagonist of TLR7 and/or TLR8 and/or TLR9
The present invention relates to (i) a compound of formula (I),
wherein
wherein R4 is C1-6alkyl, C1-6alkoxy, haloC1-6alkyl, halogen, nitro or cyano; R4a is C1-6alkyl or C3-7cycloalkyl; R5, R5a and R5b are independently selected from H and deuterium; R6 is H or halogen;
A further embodiment of present invention is (ii) a compound of formula (I), wherein
A further embodiment of present invention is (iii) a compound of formula (Ib),
wherein
wherein R4 is C1-6alkyl, C1-6alkoxy, haloC1-6alkyl, halogen, nitro or cyano; R4a is C1-6alkyl or C3-7cycloalkyl; R5, R5a and R5b are independently selected from H and deuterium; R6 is H or halogen;
A further embodiment of present invention is (iv) a compound of formula (I) or (Ia) or (Ib), or a pharmaceutically acceptable salt thereof, according to any one of (i) to (iii), wherein R1 is
wherein R4 is cyano; R4a is C1-6alkyl; R5 is H or deuterium; R6 is H.
A further embodiment of present invention is (v) a compound of formula (I) or (Ia) or (Ib), or a pharmaceutically acceptable salt thereof, according to any one of (i) to (iv), wherein R2 is C1-6alkyl.
A further embodiment of present invention is (vi) a compound of formula (I) or (Ia) or (Ib), or a pharmaceutically acceptable salt thereof, according to any one of (i) to (v), wherein
wherein R4 is cyano; R4a is C1-6alkyl; R5 is H or deuterium; R6 is H;
A further embodiment of present invention is (vii) a compound of formula (I) or (Ia) or (Ib), or a pharmaceutically acceptable salt thereof, according to any one of (i) to (vi), wherein R1 is
wherein R4 is cyano; R5 is H or deuterium.
A further embodiment of present invention is (viii) a compound of formula (I) or (Ia) or (Ib), or a pharmaceutically acceptable salt thereof, according to any one of (i) to (vii), wherein Ring A is 1,2,3,4-tetrahydroisoquinolinyl;
A further embodiment of present invention is (ix) a compound of formula (I) or (Ia), or a pharmaceutically acceptable salt thereof, according to any one of (i) to (viii), wherein ring A is 1,2,3,4-tetrahydroisoquinolinyl; morpholinylphenyl; piperazinylpyridinyl; (amino(C1-6alkoxy)pyrrolidinyl)pyridinyl; (aminohalopyrrolidinyl)pyridinyl; piperazinyl(C1-6alkyl)pyridinyl; (amino(C1-6alkoxy)pyrrolidinyl)pyridinyl; (aminohalopyrrolidinyl)pyridinyl; (C1-6alkyl-2,6-diazaspiro[3.3]heptanyl)pyridinyl; (amino(C1-6alkyl)azetidinyl)pyridinyl; C1-6alkyl(amino(C1-6alkyl)azetidinyl)pyridinyl; 3,4,4a,5,7,7a-hexahydro-2H-pyrrolo[3,4-b][1,4]oxazinyl(C1-6alkyl)pyridinyl; (3,4,4a,5,7,7a-hexahydro-2H-pyrrolo[3,4-b][1,4]oxazinyl)pyridinyl; C1-6 alkyl(amino(C1-6alkyl)azetidinyl)pyrimidinyl or C1-6alkyl(amino(C1-6alkoxy)pyrrolidinyl)pyrimidinyl.
A further embodiment of present invention is (ix″) a compound of formula (I) or (Ia), or a pharmaceutically acceptable salt thereof, according to any one of (i) to (viii), wherein ring A is 1,2,3,4-tetrahydroisoquinolinyl; morpholinylphenyl; piperazinylpyridinyl; (amino(C1-6alkoxy)pyrrolidinyl)pyridinyl; (aminohalopyrrolidinyl)pyridinyl; piperazinyl(C1-6alkyl)pyridinyl; (amino(C1-6alkoxy)pyrrolidinyl)pyridinyl; (aminohalopyrrolidinyl)pyridinyl; (C1-6alkyl-2,6-diazaspiro[3.3]heptanyl)pyridinyl; (amino(C1-6alkyl)azetidinyl)pyridinyl; C1-6alkyl(amino(C1-6alkyl)azetidinyl)pyridinyl; C1-6alkyl(3,4,4a,5,7,7a-hexahydro-2H-pyrrolo[3,4-b][1,4]oxazinyl)pyridinyl; C1-6alkyl(amino(C1-6alkyl)azetidinyl)pyrimidinyl or C1-6 alkyl(amino(C1-6alkoxy)pyrrolidinyl)pyrimidinyl.
A further embodiment of present invention is (x) a compound of formula (I) or (Ia) or (Ib), or a pharmaceutically acceptable salt thereof, according to any one of (i) to (ix), wherein ring A is 1,2,3,4-tetrahydroisoquinolin-7-yl; morpholin-2-ylphenyl; (3,4,4a,5,7,7a-hexahydro-2H-pyrrolo[3,4-b][1,4]oxazin-6-yl)-2-methyl-3-pyridinyl; (3,4,4a,5,7,7a-hexahydro-2H-pyrrolo[3,4-b][1,4]oxazin-6-yl)-3-pyridinyl; (3-amino-4-fluoro-pyrrolidin-1-yl)-3-pyridinyl; (3-amino-4-fluoro-pyrrolidin-1-yl)-3-pyridinyl; (3-amino-4-methoxy-pyrrolidin-1-yl)-3-pyridinyl; (3-amino-4-methoxy-pyrrolidin-1-yl)-3-pyridinyl; 2-methyl-6-piperazin-1-yl-3-pyridinyl; 6-(3-amino-3-methyl-azetidin-1-yl)-2-methyl-3-pyridinyl; 6-(3-amino-3-methyl-azetidin-1-yl)-3-pyridinyl; 6-(6-methyl-2,6-diazaspiro[3.3]heptan-2-yl)-3-pyridinyl; 6-piperazin-1-yl-3-pyridinyl; (3-amino-4-methoxy-pyrrolidin-1-yl)-6-methyl-pyrimidin-4-yl or (3-amino-3-methyl-azetidin-1-yl)-6-methyl-pyrimidin-4-yl.
A further embodiment of present invention is (x″) a compound of formula (I) or (Ia) or (Ib), or a pharmaceutically acceptable salt thereof, according to any one of (i) to (ix) and (ix″), wherein ring A is 1,2,3,4-tetrahydroisoquinolin-7-yl; morpholin-2-ylphenyl; (3,4,4a,5,7,7a-hexahydro-2H-pyrrolo[3,4-b][1,4]oxazin-6-yl)-2-methyl-3-pyridinyl; (3-amino-4-fluoro-pyrrolidin-1-yl)-3-pyridinyl; (3-amino-4-fluoro-pyrrolidin-1-yl)-3-pyridinyl; (3-amino-4-methoxy-pyrrolidin-1-yl)-3-pyridinyl; (3-amino-4-methoxy-pyrrolidin-1-yl)-3-pyridinyl; 2-methyl-6-piperazin-1-yl-3-pyridinyl; 6-(3-amino-3-methyl-azetidin-1-yl)-2-methyl-3-pyridinyl; 6-(3-amino-3-methyl-azetidin-1-yl)-3-pyridinyl; 6-(6-methyl-2,6-diazaspiro[3.3]heptan-2-yl)-3-pyridinyl; 6-piperazin-1-yl-3-pyridinyl; (3-amino-4-methoxy-pyrrolidin-1-yl)-6-methyl-pyrimidin-4-yl or (3-amino-3-methyl-azetidin-1-yl)-6-methyl-pyrimidin-4-yl.
A further embodiment of present invention is (xi) a compound of formula (I) or (Ia) or (Ib), or a pharmaceutically acceptable salt thereof, according to any one of (i) to (x), wherein
wherein R4 is cyano; R5 is H or deuterium;
A further embodiment of present invention is (xii) a compound of formula (I) or (Ia) or (Ib) according to any one of (i) to (xi), wherein
wherein R4 is cyano; R5 is H or deuterium;
A further embodiment of present invention is (xii″) a compound of formula (I) or (Ia) or (Ib) according to any one of (i) to (xi), (ix″) and (x″), wherein
wherein R4 is cyano; R5 is H or deuterium;
A further embodiment of present invention is (xiii) a compound of formula (I) or (Ia) or (Ib) according to any one of (i) to (xii), wherein
wherein R4 is cyano; R5 is H or deuterium;
A further embodiment of present invention is (xiii″) a compound of formula (I) or (Ia) or (Ib) according to any one of (i) to (xii), (ix″), (x″) and (xii″), wherein
wherein R4 is cyano; R5 is H or deuterium;
The present invention relates to (i′) a compound of formula (I),
wherein
wherein R4 is C1-6alkyl, C1-6alkoxy, haloC1-6alkyl, halogen, nitro or cyano; R4a is C1-6alkyl or C3-7cycloalkyl; R5, R5a and R5b are independently selected from H and deuterium; R6 is H or halogen;
A further embodiment of present invention is (ii′) a compound of formula (I), wherein
A further embodiment of present invention is (iii′) a compound of formula (Ia),
wherein
wherein R4 is C1-6alkyl, C1-6 alkoxy, haloC1-6alkyl, halogen, nitro or cyano; R4a is C1-6alkyl or C3-7cycloalkyl; R5, R5a and R5b are independently selected from H and deuterium; R6 is H or halogen;
A further embodiment of present invention is (iv′) a compound of formula (I) or (Ia) or (Ib), or a pharmaceutically acceptable salt thereof, according to any one of (i′) to (iii′), wherein
wherein R4 is cyano; R5 is H or deuterium; R6 is H or halogen.
A further embodiment of present invention is (v′) a compound of formula (I) or (Ia) or (Ib) according to any one of (i′) to (iv′), wherein
wherein R4 is cyano; R5 is H or deuterium; R6 is H or fluoro;
A further embodiment of present invention is (vi′) a compound of formula (I) or (Ia) or (Ib), or a pharmaceutically acceptable salt thereof, according to any one of (i′) to (v′), wherein
wherein R4 is cyano; R5 is H or deuterium.
A further embodiment of present invention is (vii′) a compound of formula (I) or (Ia) or (Ib), or a pharmaceutically acceptable salt thereof, according to any one of (i′) to (vi′), wherein R2 is C1-6alkyl.
A further embodiment of present invention is (viii′) a compound of formula (I) or (Ia) or (Ib), or a pharmaceutically acceptable salt thereof, according to any one of (i′) to (vii′), wherein R2 is methyl.
A further embodiment of present invention is (ix′) a compound of formula (I) or (Ia) or (Ib), or a pharmaceutically acceptable salt thereof, according to any one of (i′) to (viii′), wherein Ring A is 1,2,3,4-tetrahydroisoquinolinyl or
wherein
A further embodiment of present invention is (x′) a compound of formula (I) or (Ia) or (Ib), or a pharmaceutically acceptable salt thereof, according to any one of (i′) to (ix′), wherein
wherein
A further embodiment of present invention is (xi′) a compound of formula (I) or (Ia) or (Ib), or a pharmaceutically acceptable salt thereof, according to any one of (i′) to (x′), wherein ring A is 1,2,3,4-tetrahydroisoquinolin-7-yl; 3-amino-3-methyl-azetidin-1-yl(methyl)pyrimidinyl; 3-amino-3-methyl-azetidin-1-ylpyridinyl; 3-amino-4-fluoro-pyrrolidin-1-ylpyridinyl; 3-amino-4-fluoro-pyrrolidin-1-ylpyridinyl; 3-amino-4-methoxy-pyrrolidin-1-yl(methyl)pyrimidinyl; 3-amino-4-methoxy-pyrrolidin-1-ylpyridinyl; 3-amino-4-methoxy-pyrrolidin-1-ylpyridinyl; 6-methyl-2,6-diazaspiro[3.3]heptan-2-ylpyridinyl; piperazin-1-yl(methyl)pyridinyl; or piperazin-1-ylpyridinyl.
A further embodiment of present invention is (xii′) a compound of formula (I) or (Ia) or (Ib) according to any one of (i′) to (xi′), wherein
wherein R4 is cyano; R5 is H or deuterium;
wherein
or a pharmaceutically acceptable salt thereof.
A further embodiment of present invention is (xiii′) a compound of formula (I) or (Ia) or (Ib) according to any one of (i′) to (xii′), wherein
wherein R4 is cyano; R5 is H or deuterium;
or a pharmaceutically acceptable salt thereof.
Another embodiment of present invention is a compound of formula (I) or (Ia) or (Ib) selected from the following:
or a pharmaceutically acceptable salt thereof.
The compounds of the present invention can be prepared by any conventional means. Suitable processes for synthesizing these compounds as well as their starting materials are provided in the schemes below and in the examples. All substituents, in particular, R1 to R5 are as defined above unless otherwise indicated. Furthermore, and unless explicitly otherwise stated, all reactions, reaction conditions, abbreviations and symbols have the meanings well known to a person of ordinary skill in organic chemistry.
General synthetic routes for preparing the compound of formula (I), (VII) and (XI) are shown below.
Wherein n is 0, 1 or 2; X is halogen; Y is halogen or methanesulfonate; R7 and R8 is aryl or heteroaryl; R9 and R10 together with the nitrogen atom they are attached to form a heterocyclyl.
The synthesis of compounds of the present invention started from halide II. Buchwald-Hartwig amination reaction between halide II and compound of formula III with a catalyst, such as Ruphos Pd-G2, and a base, such as Cs2CO3 provides compound of formula IV (ref. Acc. Chem. Res. 1998, 31, 805-818; Chem. Rev. 2016, 116, 12564-12649; Topics in Current Chemistry, 2002, 219, 131-209; and references cited therein). Alternatively, compound of formula IV can also be obtained via nucleophilic substitution between halide II and compound of formula III in the presence of a base, such as DIPEA, NaHCO3 and K2CO3. Boc deprotection of compound of formula IV in acidic condition (such as HCl in EtOAc and TFA in DCM) gives compound V, which can be transformed into compound of formula VII via either nucleophilic substitution with compound of formula VI in the presence of a base, such as DIPEA NaHCO3 and K2CO3, or Buchwald-Hartwig amination reaction with compound of formula VI followed by appropriate deprotection. Meanwhile, compound of formula V can react with compound of formula VIII via nucleophilic substitution to give compound of formula IX. Buchwald-Hartwig amination reaction or nucleophilic substitution between compound of formula IX and amine X, followed by appropriate deprotection can provide compound of formula XI.
Compounds of formula (Ia) can be synthesized according to Scheme 1 using chiral starting materials.
Compounds of this invention can be obtained as mixtures of diastereomers or enantiomers, which can be separated by methods well known in the art, e.g. (chiral) HPLC or SFC.
This invention also relates to a process for the preparation of a compound of formula (I) or (Ia) comprising any one of the following steps:
and amine (X),
and compound of formula (VI),
wherein n is 0, 1 or 2; X is halogen; Y is halogen or methanesulfonate; R7 and R8 is aryl or heteroaryl; R9 and R10 together with the nitrogen atom they are attached to form a heterocyclyl.
A compound of formula (I) or (Ia) when manufactured according to the above process is also an object of the invention.
The present invention provides compounds that can be used as TLR7 and/or TLR8 and/or TLR9 antagonist, which inhibits pathway activation through TLR7 and/or TLR8 and/or TLR9 as well as respective downstream biological events including, but not limited to, innate and adaptive immune responses mediated through the production of all types of cytokines and all forms of auto-antibodies. Accordingly, the compounds of the invention are useful for blocking TLR7 and/or TLR8 and/or TLR9 in all types of cells that express such receptor(s) including, but not limited to, plasmacytoid dendritic cell, B cell, T cell, macrophage, monocyte, neutrophil, keratinocyte, epithelial cell. As such, the compounds can be used as a therapeutic or prophylactic agent for systemic lupus erythematosus and lupus nephritis.
The present invention provides methods for treatment or prophylaxis of systemic lupus erythematosus and lupus nephritis in a patient in need thereof.
Another embodiment includes a method of treating or preventing systemic lupus erythematosus and lupus nephritis in a mammal in need of such treatment, wherein the method comprises administering to said mammal a therapeutically effective amount of a compound of formula (I), a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof.
The invention will be more fully understood by reference to the following examples. They should not, however, be construed as limiting the scope of the invention.
The invention will be more fully understood by reference to the following examples. They should not, however, be construed as limiting the scope of the invention.
Abbreviations used herein are as follows:
ACN: acetonitrile
Boc2O: di-tert butyl dicarbonate
BINAP: 2,2′-Bis(diphenylphosphino)-1,1′-dinaphthalene
DCM: dichloromethane
DCE: dichloroethane
DIPEA or DIEA: N,N-diisopropylethylamine
DIBAL-H: Diisobutylaluminium hydride
DIAD: diisopropyl azodicarboxylate
DMA: N,N-Dimethylacetylamine
DMAP: 4-dimethylaminopyridine
DMF: N,N-Dimethylformamide
DPPP: 1,3-Bis(diphenylphosphino)propane
EA or EtOAc: ethyl acetate
FA: formic acid
HATU: 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate
IC50: half inhibition concentration
IPA: isopropanol
LCMS liquid chromatography-mass spectrometry
MS: mass spectrometry
NBS: N-bromosuccinimide
PE: petroleum ether
prep-HPLC: preparative high performance liquid chromatography
prep-TLC: preparative thin layer chromatography
PPh3: triphenylphosphine
Pd2(dba)3: tris(dibenzylideneacetone)dipalladium(0)
Rf: retention factor
rt: room temperature
RT: retention time
RuPhos Pd G2: chloro(2-dicyclohexylphosphino-2′,6′-diisopropoxy-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) 2nd generation
Selectfluor 1-chloromethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane
bis(tetrafluoroborate)
SFC: supercritical fluid chromatography
tBuXPhos Pd G3: Methanesulfonato(2-di-t-butylphosphino-2′,4′,6′-tri-i-propyl-1,1′-biphenyl)(2′-amino-1,1′-biphenyl-2-yl)palladium(II)
TEA: trimethylamine
TFA: trifluoroacetic acid
THF: tetrahydrofuran
TLC: thin layer chromatography
XantPhos: 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene
XPhos: 2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl
XPhos Pd G2: chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II)
v/v volume ratio
LYSA lyophilisation solubility assay
Intermediates and final compounds were purified by flash chromatography using one of the following instruments: i) Biotage SP1 system and the Quad 12/25 Cartridge module. ii) ISCO combi-flash chromatography instrument. Silica gel brand and pore size: i) KP-SIL 60 Å, particle size: 40-60 μm; ii) CAS registry NO: Silica Gel: 63231-67-4, particle size: 47-60 micron silica gel; iii) ZCX from Qingdao Haiyang Chemical Co., Ltd, pore: 200-300 or 300-400.
Intermediates and final compounds were purified by preparative HPLC on reversed phase column using XBridge™ Prep-C18 (5 μm, OBD™ 30×100 mm) column, SunFire™ Prep-C18 (5 μm, OBD™ 30×100 mm) column, Phenomenex Synergi-C18 (10 μm, 25×150 mm) or Phenomenex Gemini-C18 (10 μm, 25×150 mm). Waters AutoP purification System (Sample Manager 2767, Pump 2525, Detector: Micromass ZQ and UV 2487, solvent system: acetonitrile and 0.1% ammonium hydroxide in water; acetonitrile and 0.1% FA in water or acetonitrile and 0.1% TFA in water). Or Gilson-281 purification System (Pump 322, Detector: UV 156, solvent system: acetonitrile and 0.05% ammonium hydroxide in water; acetonitrile and 0.225% FA in water; acetonitrile and 0.05% HCl in water; acetonitrile and 0.075% TFA in water; or acetonitrile and water).
For SFC chiral separation, intermediates were separated by chiral column (Daicel chiralpak IC, 5 μm, 30×250 mm), AS (10 μm, 30×250 mm) or AD (10 μm, 30×250 mm) using Mettler Toledo Multigram III system SFC, Waters 80Q preparative SFC or Thar 80 preparative SFC, solvent system: CO2 and IPA (0.5% TEA in IPA) or CO2 and MeOH (0.1% NH3.H2O in MeOH), back pressure 100 bar, detection UV@254 or 220 nm.
LC/MS spectra of compounds were obtained using a LC/MS (Waters™ Alliance 2795-Micromass ZQ, Shimadzu Alliance 2020-Micromass ZQ or Agilent Alliance 6110-Micromass ZQ), LC/MS conditions were as follows (running time 3 or 1.5 mins):
Acidic condition I: A: 0.1% TFA in H2O; B: 0.1% TFA in acetonitrile;
Acidic condition II: A: 0.0375% TFA in H2O; B: 0.01875% TFA in acetonitrile;
Basic condition I: A: 0.1% NH3.H2O in H2O; B: acetonitrile;
Basic condition II: A: 0.025% NH3.H2O in H2O; B: acetonitrile;
Neutral condition: A: H2O; B: acetonitrile.
Mass spectra (MS): generally only ions which indicate the parent mass are reported, and unless otherwise stated the mass ion quoted is the positive mass ion (MH)+.
NMR Spectra were obtained using Bruker Avance 400 MHz.
The microwave assisted reactions were carried out in a Biotage Initiator Sixty microwave synthesizer. All reactions involving air-sensitive reagents were performed under an argon or nitrogen atmosphere. Reagents were used as received from commercial suppliers without further purification unless otherwise noted.
The following examples are intended to illustrate the meaning of the present invention but should by no means represent a limitation within the meaning of the present invention:
The title compound was prepared according to the following scheme:
To a solution of 6-methylpyrazine-2-carboxylic acid (compound A-1, 150 g, 1086 mmol) in Methanol (1600 mL) was added thionyl chloride (388 g, 3258 mmol) dropwise at 0° C., then the reaction was stirred at 25° C. for 16 hours. The reaction mixture was concentrated and the residue was dissolved in ice water (1 L). The mixture was basified to pH=8, extracted with DCM (500 mL) twice. The combined organic layer was dried over Na2SO4 and concentrated to give compound A-2 (161 g) as a yellow solid. LCMS (M+H)+: 153.
To a solution of methyl 6-methylpyrazine-2-carboxylate (compound A-2, 40 g, 262 mmol) in methanol (900 mL) was added acetic acid (32 g, 526 mmol) and platinum(IV) oxide (4 g, 18 mmol). The reaction mixture was stirred at 50° C. for 48 hours under hydrogen atmosphere (50 psi). A total of 4 batches of the same scale reaction were combined and filtered. The filtrate was concentrated under vacuum to give compound A-3 (165 g) as a brown oil. LCMS (M+H)+: 159.
To a solution of methyl 6-methylpiperazine-2-carboxylate (compound A-3, 240 g, 863 mmol) and benzaldehyde (92 g, 863 mmol) in Methanol (2500 mL) was added sodium cyanoborohydride (163 g, 2590 mmol) in batches slowly at 0° C. in 30 minutes. After the reaction mixture was stirred at 20° C. for 12 hours, water (500 mL) was added. The mixture was extracted with EA (1500 mL), and the combined organic layer was dried and concentrated. The residue was purified by silica gel column to give compound A-4 (225 g, crude) as a yellow oil. LCMS (M+H)+: 249.
A solution of Boc-glycine (193 g, 1099 mmol), HATU (418 g, 1099 mmol) and DIPEA (451 mL, 2537 mmol) in DMF (500 mL) was stirred at 20° C. for 30 minutes. Then methyl 4-benzyl-6-methyl-piperazine-2-carboxylate (compound A-4, 210 g, 846 mmol) in DMF (100 mL) was added, and the reaction mixture was stirred at 20° C. for 15 hours under nitrogen atmosphere. The reaction mixture was diluted with water and extracted with EtOAc. The organic layer was dried and concentrated. The residue was purified by column chromatography to give compound A-5 (260 g) as a yellow oil. LCMS (M+H)+: 406.
To a solution of methyl 4-benzyl-1-[2-(tert-butoxycarbonylamino)acetyl]-6-methyl-piperazine-2-carboxylate (compound A-5, 230 g, 567 mmol) in methanol (2300 mL) was added HCl in methanol (1150 mL, 4M) slowly at 0° C. Then the mixture was stirred at 20° C. for 16 hours. The reaction mixture was concentrated in vacuo to give compound A-6 (150 g, crude) as a light yellow solid. LCMS (M+H)+: 306.
A mixture of methyl 1-(2-aminoacetyl)-4-benzyl-6-methyl-piperazine-2-carboxylate hydrochloride (compound A-6, 150 g) and triethylamine (306 mL, 2194 mmol) in methanol (400 mL) was stirred at 70° C. for 2 hours. The reaction mixture was concentrated and the residue was purified by flash column chromatography to give compound A-7 (55 g) as a yellow solid. LCMS (M+H)+: 274.
To a solution of 2-benzyl-4-methyl-1,3,4,7,8,9a-hexahydropyrazino[1,2-a]pyrazine-6,9-dione (compound A-7, 27 g, 100 mmol) in THF (700 mL) was added lithium aluminum hydride powder (38 g, 1006 mmol) slowly at 0° C. in 30 minutes. The reaction mixture was stirred at 0° C. for 6 hours, then diluted with THF (1000 mL), quenched successively with H2O (60 mL), 15% aq. NaOH (38 mL) and H2O (67 mL) under ice water bath. The reaction mixture was filtered and the filtrate was dried over Na2SO4 and concentrated to give compound A-8 (23 g) as a yellow oil. LCMS (M+H)+: 246.
A mixture of (2-benzyl-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrazino[1,2-a]pyrazine (compound A-8, 45.0 g, 117.4 mmol), DIPEA (51.1 mL, 293.5 mmol) and Boc2O (30.7 g, 140.8 mmol) in DCM (450 mL) was stirred at 20° C. for 16 hours. The reaction mixture was concentrated and the residue was purified by silica gel and prep-HPLC to give compound A-9-cis (26.0 g) as a colorless oil and compound A-9-trans (17.0 g) as a yellow oil. LCMS (M+H)+: 346.
Compound A-9-cis, 1H NMR (400 MHz, CHLOROFORM-d) δ ppm: 7.36-7.30 (m, 4H), 7.28-7.26 (m, 1H), 4.10-3.94 (m, 1H), 3.86-3.70 (m, 1H), 3.57-3.40 (m, 2H), 3.16-2.85 (m, 2H), 2.82-2.67 (m, 2H), 2.58 (br s, 1H), 2.42-2.17 (m, 2H), 2.04-1.74 (m, 3H), 1.46 (s, 9H), 1.05 (br d, J=5.6 Hz, 3H).
Compound A-9-trans, 1H NMR (400 MHz, CHLOROFORM-d) δ ppm: 7.35-7.29 (m, 4H), 7.28-7.23 (m, 1H), 4.09-3.70 (m, 2H), 3.55-3.36 (m, 2H), 3.05 (br s, 2H), 2.71 (br d, J=10.3 Hz, 2H), 2.62 (br d, J=9.5 Hz, 4H), 2.44 (br s, 1H), 2.02-1.76 (m, 1H), 1.45 (s, 9H), 1.16 (br d, J=6.4 Hz, 3H).
For compound A-9-cis, the NOESY correlation of C3′-H and C5′-H was observed. For compound A-9-trans, the NOESY correlation of C3′-H and C5′-H was not observed.
To a solution of tert-butyl cis-2-benzyl-4-methyl-3,4,6,7,9,9a-hexahydro-1H-pyrazino[1,2-a]pyrazine-8-carboxylate (compound A-9-cis, 26.0 g, 75.3 mmol) in THF (500 mL) was added wet Pd/C (5.0 g), the mixture was stirred at 50° C. for 3 hours under hydrogen atmosphere. The reaction mixture was filtered and the filtrate was concentrated to give compound A-10 (16.5 g) as a yellow oil. LCMS (M+H)+: 256.
A mixture of 5-bromoquinoline-8-carbonitrile (1.3 g, 5.6 mmol), tert-butyl cis-2-benzyl-4-methyl-3,4,6,7,9,9a-hexahydro-1H-pyrazino[1,2-a]pyrazine-8-carboxylate (compound A-9-cis, 1.6 g, 6.2 mmol), Cs2CO3 (5.5 g, 16.9 mmol) and RuPhos Pd G2 (875.0 mg, 1.1 mmol) in dioxane (20 mL) was stirred at 90° C. for 16 hours. Then the reaction mixture was filtered and concentrated. The residue was purified by silica gel column to give compound A-11 (1.5 g) as a yellow foam, LCMS (M+H)+: 408.
A mixture of tert-butyl cis-2-(8-cyano-5-quinolyl)-4-methyl-3,4,6,7,9,9a-hexahydro-1H-pyrazino[1,2-a]pyrazine-8-carboxylate (compound A-11, 1.6 g, 3.9 mmol) in 1 M HCl in EA (100 mL) was stirred at rt for 16 hours, then the reaction was concentrated. The residue was dissolved in NaOH (2 N, 100 mL) and extracted with EA (100 mL) twice. The organic layer was dried and concentrated to give Intermediate A (900 mg) as a light brown foam, LCMS (M+H)+: 308.
The preparation of Intermediate B was the same as Intermediate A by using compound A-9-trans instead of compound A-9-cis in step 10. Intermediate B (900 mg) was obtained as a light brown foam, LCMS (M+H)+: 308.
The title compound was prepared according to the following scheme:
SFC (Gradient: 30% in EtOH (0.1% NH3H2O) in CO2. Column: Daicel ChiralPak AD, 250×50 mm, 10 μm) separation of Compound A-11 (8.0 g) gave compound C-1 (second peak, 3.5 g) and compound C-2 (first peak, 3.0 g) as yellow solids. A mixture of tert-butyl (4R,9aR)-2-(8-cyano-5-quinolyl)-4-methyl-3,4,6,7,9,9a-hexahydro-1H-pyrazino[1,2-a]pyrazine-8-carboxylate (compound C-1, 3.5 g, 8.6 mmol) in 1 M HCl in EA (100 mL) was stirred at rt for 16 hours, then the reaction was concentrated. The residue was dissolved in NaOH (2 N, 100 mL), extracted with EA (100 mL×2). The organic layer was dried and concentrated to give Intermediate C (2.5 g) as a light brown foam, LCMS (M+H)+: 308.
The title compound was prepared according to the following scheme:
SFC (Gradient: 30% in EtOH (0.1% NH3.H2O) in CO2. Column: Phenomenex cellulose-2, 250×30 mm, 10 μm) separation of Compound B-2 (2.4 g) gave compound D-1 (second peak, 0.9 g) and compound D-2 (first peak, 0.9 g) as yellow solids. A mixture of tert-butyl (4R,9aS)-2-(8-cyano-5-quinolyl)-4-methyl-3,4,6,7,9,9a-hexahydro-1H-pyrazino[1,2-a]pyrazine-8-carboxylate (compound D-1, 0.9 g, 2.1 mmol) in 1 M HCl in EA (20 mL) was stirred at rt for 16 hours, then the reaction was concentrated. The residue was dissolved in NaOH (2 N, 20 mL), and then extracted with EA (20 mL) twice. The organic layer was dried and concentrated to give Intermediate D (550.0 mg) as a light brown foam, LCMS (M+H)+: 308.
The title compound was prepared according to the following scheme:
A mixture of 4-chloropyrazolo[1,5-a]pyridine-7-carbonitrile (compound E-1, 1.0 g, 5.6 mmol), tert-butyl cis-6-methyl-1,3,4,6,7,8,9,9a-octahydropyrazino[1,2-a]pyrazine-2-carboxylate (compound A-10, 1.6 g, 6.2 mmol), Cs2CO3 (5.5 g, 16.9 mmol) and Ruphos Pd G2 (875.0 mg, 1.1 mmol) in Dioxane (20 mL) was stirred at 90° C. for 16 hours. Then the reaction was concentrated and the residue was purified by silica gel to give compound E-2 (2.0 g) as a light yellow solid. LCMS (M+H)+: 397.
SFC (Gradient: 35% in IPA (0.1% NH3H2O) in CO2. Column: Daicel ChiralPak AD, 250×20 mm, 5 μm) separation of Compound E-2 (2.0 g) gave compound E-3 (second peak, 0.9 g) and compound E-4 (first peak, 0.9 g) as light yellow solids. A solution of tert-butyl (4R,9aR)-2-(7-cyanopyrazolo[1,5-a]pyridin-4-yl)-4-methyl-3,4,6,7,9,9a-hexahydro-1H-pyrazino[1,2-a]pyrazine-8-carboxylate (compound E-3, 0.9 g, 2.3 mmol) in 1 M HCl in EA (30 mL) was stirred at rt for 16 hours, then the reaction was concentrated to give Intermediate E (0.7 g) as a light yellow solid. LCMS (M+H)+: 297.
The title compound was prepared according to the following scheme:
A solution of ethyl (1E)-N-(2,4,6-trimethylphenyl)sulfonyloxyethanimidate (compound F-4, 200 g, 700 mmol) in 1,4-dioxane (500 mL) was added perchloric acid (110 mL) dropwise in 0.5 hours and stirred for 1 hour at 0° C. 1000 mL ice-water was added and the mixture was filtered. The filter cake was dissolved in 1.5 L EtOAc, dried over Na2SO4 and stirred for 30 minutes. The organic layer was concentrated (keep the temperature below 25° C.) to give crude product. The crude product was recrystallized (petroleum/EtOAc=10/1) to give compound F-5 (110 g) as a white solid. LCMS (M+H)+: 216.
A solution of amino 2,4,6-trimethylbenzenesulfonate (compound F-5, 110 g, 511 mmol) and 2-bromo-5-fluoropyridine (60 g, 341 mmol) in DCM (1800 mL) was stirred at 10° C. for 18 hours. The mixture was concentrated and the residue was recrystallized in EtOAc to give compound F-6 (90 g) as a white solid. LCMS (M+H)+: 191.
A solution of 2-bromo-5-fluoro-pyridin-1-ium-1-amine; 2,4,6-trimethylbenzenesulfonate (compound F-6, 90 g, 230 mmol); K2CO3 (64 g, 460 mmol) and ethyl propiolate (28 mL, 276 mmol) in DMF (1300 mL) was stirred at 10° C. for 18 hours. The reaction was diluted with water, extracted with EtOAc. The organic layer was dried over Na2SO4 and concentrated, and the residue was purified by chromatography to give compound F-7 (11 g) as a yellow solid. LCMS (M+H)+: 287.
The mixture of ethyl 7-bromo-4-fluoro-pyrazolo[1,5-a]pyridine-3-carboxylate (compound F-7, 5.2 g, 18.1 mmol), NaOH (2.1 g, 54.3 mmol) in EtOH (90.0 mL) and water (70.0 mL) was stirred at 60° C. for 2 hours. The reaction mixture was concentrated and then diluted with water.
The pH of the reaction suspension was adjusted to 4 with 1 M HCl, a grey solid precipitated, which was collected by filtration to give compound F-8 (4.0 g) as a grey solid. LCMS (M+H)+: 259.
To a solution of 7-bromo-4-fluoro-pyrazolo[1,5-a]pyridine-3-carboxylic acid (compound F-8, 4.0 g, 15.4 mmol) and KF (3.6 g, 61.8 mmol) in 1,2-dichloroethane (60.0 mL) and water (50.0 mL) was added Selectfluor (10.9 g, 30.9 mmol). The reaction was stirred at 70° C. for 18 hours, then quenched with water, extracted with DCM twice. The combined organic layer was dried over Na2SO4 and concentrated to give crude compound F-9 (2.8 g) as a grey solid. LCMS (M+H)+: 233.
A solution of 7-bromo-3,4-difluoro-pyrazolo[1,5-a]pyridine (compound F-9, 2.8 g, 12.0 mmol) and zinc cyanide (5.6 g, 48.0 mmol) in DMF (70.0 mL) was added tetrakis(triphenylphosphine)palladium (1.4 g, 1.2 mmol) and stirred at 120° C. for 18 hours under N2 atmosphere. The mixture was quenched with water and extracted with EtOAc twice. The combined organic layer was dried and concentrated, and the residue was purified by column chromatography to give compound F-10 (810.0 mg) as a white solid. LCMS (M+H)+: 180.
1H NMR (400 MHz, CHLOROFORM-d) δ ppm: 8.00 (d, J=3.6 Hz, 1H), 7.31 (dd, J=4.7, 8.0 Hz, 1H), 6.83 (t, J=8.4 Hz, 1H).
A mixture of 3,4-difluoropyrazolo[1,5-a]pyridine-7-carbonitrile (compound F-10, 250 mg, 1.4 mmol), tert-butyl (6R,9aR)-6-methyloctahydro-2H-pyrazino[1,2-a]pyrazine-2-carboxylate (compound F-3, 392 mg, 1.5 mmol) and DIPEA (731 μL, 4.2 mmol) in DMSO (10.0 mL) was stirred at 120° C. for 16 hours. Then the reaction was diluted with EA, washed with water and brine. The organic layer was dried and concentrated to give compound F-11 (0.5 g) as a yellow oil. LCMS (M+H)+: 415.
A mixture of tert-butyl (4R,9aR)-2-(7-cyanopyrazolo[1,5-a]pyridin-4-yl)-4-methyl-3,4,6,7,9,9a-hexahydro-1H-pyrazino[1,2-a]pyrazine-8-carboxylate (compound F-11, 0.5 g, 1.2 mmol) in 1 M HCl in EA (20.0 mL) was stirred at rt for 16 hours, then the reaction was concentrated to give Intermediate F (400 mg) as a yellow solid.
The compound F-3 was prepared according to the following scheme:
SFC (Gradient: 10% in EtOH (0.1% NH3H2O) in CO2. Column: Daicel ChiralPak AD, 250×20 mm, 5 μm) separation of Compound A-9-cis (5.0 g) gave compound F-1 (second peak, 2.2 g) and compound F-2 (first peak, 2.2 g) as light yellow oil. A mixture of tert-butyl (4R,9aR)-2-benzyl-4-methyl-3,4,6,7,9,9a-hexahydro-1H-pyrazino[1,2-a]pyrazine-8-carboxylate (compound F-1, 2.2 g, 6.4 mmol) and Pd(OH)2/C (0.9 g) in THF (50.0 mL) was stirred at 50° C. for 6 hours under H2. Then the reaction was filtered, and the filtrate was concentrated to give compound F-3 (1.5) as a black oil. LCMS (M+H)+: 256. The stereochemistry of compound F-3 was confirmed by its derivative (compound P).
The title compound was prepared according to the following scheme:
To a solution of 2-bromo-5-fluoroaniline (50 g, 263 mmol) and methyl 3,3-dimethoxypropionate, (45 mL, 316 mmol) in THF (150 mL) was added NaHMDS in THF (394 mL, 394 mmol) dropwise at 0° C. The mixture was stirred at the temperature for 10 minutes, and then it was warmed up to 15° C. and stirred for 18 hours. The reaction was quenched with sat. aqueous solution of NH4Cl and concentrated to about 300 mL. The solution was diluted with water and extracted with EtOAc. The organic layer was dried over Na2SO4 and concentrated to give compound G-2 (100 g) as a brown oil. LCMS (M+H)+: 306.
A solution of N-(2-bromo-5-fluoro-phenyl)-3,3-dimethoxy-propanamide (compound G-2, 100 g, 238 mmol) in DCM (500 mL) was added to concentrated sulfuric acid (300 mL) at 0° C. The mixture was stirred at 15° C. for 2 hours, then poured slowly into 2000 mL ice-water, and a yellow precipitate appeared. The mixture was filtered, and the wet-cake was washed with 500 mL water, 200 mL isopropyl alcohol and 300 mL PE. The solid was dried to give compound G-3 (50 g) as a yellow solid. LCMS (M+H)+: 242.
Step 3: Preparation of 5-fluoro-2-oxo-1H-quinoline-8-carbonitrile (Compound G-4) A solution of 8-bromo-5-fluoro-1H-quinolin-2-one (compound G-3, 50 g, 206 mmol), zinc cyanide (4820 mg, 412 mmol), Pd(PPh3)4 (2428 mg, 21 mmol) in DMF was stirred at 120° C. for 5 hours. The reaction mixture was diluted with water and extracted with DCM. The organic layer was dried and concentrated to give the crude product, which was purified by flash column to give compound G-4 (29 g) as a yellow solid. LCMS (M+H)+: 189.
To a solution of 5-fluoro-2-oxo-1H-quinoline-8-carbonitrile (compound G-4, 17 g, 90 mmol) and 2,6-dimethylpyridine (39 g, 361 mmol) in DCM was added trifluoromethanesulfonic anhydride (51 g, 181 mmol) dropwise at 0° C. The mixture was stirred at 0° C. for 1 hour, and then the reaction was diluted with water, extracted with DCM. The organic layer was dried and concentrated. The residue was purified by flash column to give compound G-5 (23.0 g) as a yellow solid. LCMS (M+H)+: 321.
To a solution of (8-cyano-5-fluoro-2-quinolyl) trifluoromethanesulfonate (compound G-5, 23 g, 72 mmol) in THF (230 mL) and deuterium oxide (100 mL) was added potassium carbonate (20 g, 144 mmol) and Pd/C (6 g). The mixture was stirred at 40° C. for 5 hours under deuterium atmosphere (balloon). The mixture was filtered, and the filtrate was concentrated and purified by flash column to give compound G-6 (11 g) as a light yellow solid. LCMS (M+H)+: 174.
The title compound was prepared in analogy to the preparation of Intermediate F by using 2-deuterio-5-fluoro-quinoline-8-carbonitrile (compound G-6) instead of 3,4-difluoropyrazolo[1,5-a]pyridine-7-carbonitrile (compound F-10). Intermediate G (400 mg) was obtained as a yellow solid. LCMS (M+H)+: 309.
The title compound was prepared according to the following scheme:
SFC (Gradient: 8% in MeOH (0.1% NH3.H2O) in CO2. Column: Daicel ChiralPak AD, 250×50 mm, 10 μm) separation of Compound A-9-trans (7.0 g) gave compound K-1 (first peak, 3.4 g) and compound K-2 (second peak, 2.7 g) as light yellow oil.
A mixture of tert-butyl (4S,9aR)-2-benzyl-4-methyl-3,4,6,7,9,9a-hexahydro-1H-pyrazino[1,2-a]pyrazine-8-carboxylate (compound K-1, 3.4 g, 9.8 mmol) and Pd(OH)2/C (0.8 g) in THF was stirred at 50° C. for 2 hours under H2. Then the reaction mixture was filtered, and the filtrate was concentrated to give compound K-3 (2.5 g) as a black oil, LCMS (M+H)+: 256. The stereochemistry of K-3 was confirmed by its derivative (compound N).
The title compound was prepared in analogy to the preparation of Intermediate G by using tert-butyl (6S,9aR)-6-methyl-1,3,4,6,7,8,9,9a-octahydropyrazino[1,2-a]pyrazine-2-carboxylate (compound K-3) instead of tert-butyl (6R,9aR)-6-methyl-1,3,4,6,7,8,9,9a-octahydropyrazino[1,2-a]pyrazine-2-carboxylate (compound F-3). Intermediate K (700 mg) was obtained as a yellow solid. LCMS (M+H)+: 309.
The title compound was prepared according to the following scheme:
2-chloronicotinic acid (compound L-1, 1.0 kg, 6347 mmol) was dissolved in 33% monomethylamine (386349 mmol) solution in ethanol. The reaction mixture was stirred in the autoclave at 80° C. for 80 hours. The reaction mixture was concentrated in vacuo to afford compound L-2 (1.4 kg, crude). LCMS (M+H)+: 153.
A solution of 2-(methylamino)pyridine-3-carboxylic acid (compound L-2, 1.4 kg, crude) in acetic anhydride (10.0 L, 105789 mmol) and acetic acid (5.0 L) was heated to reflux for 2 hours. The reaction mixture was concentrated in vacuo to afford compound L-3 (1.8 kg, crude). LCMS (M+H)+: 219.
To a solution of (1-methyl-2-oxo-1,8-naphthyridin-4-yl) acetate (compound L-3, 1.8 kg, crude) in methanol (12.0 L) was added a solution of potassium carbonate (1.9 kg, 13748 mmol) in water (3.6 L). The mixture was stirred at 25° C. for 2 hours. Then the reaction mixture was concentrated under reduced pressure to remove the MeOH. The residue was acidified with HCl solution (6 N) to pH=4-5, extracted with EA (1500 mL) for three times. The combined organic layers were washed with sat. brine (1500 mL), dried over Na2SO4, and concentrated in vacuo to afford compound L-4 (450 g, 40.2% yield). LCMS (M+H)+: 177, 1H NMR (400 MHz, DMSO-d6) δ ppm 11.68 (s, 1H), 8.63 (dd, J=4.60, 1.8 Hz, 1H), 8.22 (dd, J=7.8, 1.80 Hz, 1H), 7.27 (dd, J=7.8, 4.6 Hz, 1H), 5.93 (s, 1H), 3.59 (s, 3H).
A solution of 4-hydroxy-1-methyl-1,8-naphthyridin-2-one (compound L-4, 150.0 g, 850 mmol) in phosphorus oxychloride (300 mL) was stirred at 100° C. for 2 hours. The reaction mixture was concentrated in reduced pressure to remove the phosphorus oxychloride. The residue was neutralized by adding saturated aqueous NaHCO3 at room temperature to pH=7-8, and the mixture was extracted with DCM (1000 mL) twice. The combined organic layer was washed with sat. brine (500 mL), dried over Na2SO4 and concentrated in vacuo to give a crude product, which was purified by silica gel chromatography (PE/EtOAc=1:0 to 7:1) to afford compound L-5 (39 g, 24% yield). LCMS (M+H)+: 195, 1H NMR (400 MHz, DMSO-d6) δ ppm 8.75 (dd, J=4.6, 1.6 Hz, 1H), 8.32 (dd, J=7.9, 1.7 Hz, 1H), 7.44 (dd, J=8.0, 4.6 Hz, 1H), 7.03 (s, 1H), 3.66 (s, 3H).
The title compound was prepared in analogy to the preparation of Intermediate F by using 4-chloro-1-methyl-1,8-naphthyridin-2-one (compound L-5) instead of 3,4-difluoropyrazolo[1,5-a]pyridine-7-carbonitrile (compound F-10). Intermediate L (1.8 g) was obtained as a yellow solid. LCMS (M+H)+: 314.
The title compound was prepared in analogy to the preparation of Intermediate F by using 4-chloro-1-methyl-1,8-naphthyridin-2-one instead of 3,4-difluoropyrazolo[1,5-a]pyridine-7-carbonitrile (compound F-10) and tert-butyl (6S,9aR)-6-methyl-1,3,4,6,7,8,9,9a-octahydropyrazino[1,2-a]pyrazine-2-carboxylate (compound K-3) instead of tert-butyl (6R,9aR)-6-methyl-1,3,4,6,7,8,9,9a-octahydropyrazino[1,2-a]pyrazine-2-carboxylate (compound F-3). Intermediate M (1.7 g) was obtained as a yellow solid. LCMS (M+H)+: 314.
A mixture of 4-[(4S,9aS)-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrazino[1,2-a]pyrazin-2-yl]-1-methyl-1,8-naphthyridin-2-one (Intermediate M, 200 mg, 638 μmol), phenyl N-(3,4,5-trifluorophenyl)carbamate (171 mg, 638 μmol) and DIPEA (412 mg, 3.2 mmol) in DMF (5 mL) was stirred at 60° C. overnight, then the reaction was diluted with EA, washed with water and brine, the organic layer was dried and concentrated, the residue was purified by silica gel to give Compound N as a yellow solid, 250 mg. LCMS (M+H)+: 487.
A mixture of 5-[(4R,9aS)-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrazino[1,2-a]pyrazin-2-yl]-2-deuterio-quinoline-8-carbonitrile (Intermediate G, 100 mg, 324 μmol), phenyl (3,4,5-trifluorophenyl)carbamate (86.6 mg, 324 μmol) and DIPEA (170 μl, 973 μmol) in DMF (5 mL) was stirred at 50° C. for 2 hours. Then the reaction was diluted with EA, washed with water and brine, the organic layer was dried and concentrated, the residue was purified by silica gel to give compound P as a light yellow solid, 100 mg. LCMS (M+H)+: 482.
The title compound was prepared according to the following scheme:
To a solution of tert-butyl 7-(hydroxymethyl)-3,4-dihydro-1H-isoquinoline-2-carboxylate (compound 1a, 1.35 g, 5.13 mmol) in DCM (30 mL) was added carbon tetrabromide (2.55 g, 7.69 mmol) at 0° C. Then a solution of triphenylphosphine (2.02 g, 7.69 mmol) in DCM (5 mL) was added dropwise at 0° C. and the resulting mixture was stirred at 25° C. for 30 minutes. The reaction was concentrated and the residue was purified by flash column chromatography to afford compound 1b (1.20 g) as a light yellow solid. LCMS (M-56+H)+: 270, LCMS (M-56+2+H)+: 272.
A mixture of 5-[cis-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrazino[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile (Intermediate A, 30 mg, 98 μmol), tert-butyl 7-(bromomethyl)-3,4-dihydro-1H-isoquinoline-2-carboxylate (compound 1b, 38 mg, 117 μmol) and sodium bicarbonate (25 mg, 293 μmol) in DMF (2 mL) was stirred at 100° C. for 16 hours. Then the reaction was filtered and the filtrate was purified by HPLC to give compound 1c as a light yellow solid (30 mg), LCMS (M+H)+: 553.
A mixture of tert-butyl 7-[[cis-2-(8-cyano-5-quinolyl)-4-methyl-3,4,6,7,9,9a-hexahydro-1H-pyrazino[1,2-a]pyrazin-8-yl]methyl]-3,4-dihydro-1H-isoquinoline-2-carboxylate (compound 1c, 30 mg, 54 μmol) in 1 M HCl in EA (5 mL) was stirred at rt for 16 hours, then the reaction was concentrated to give Example 1 as a light yellow solid (26 mg). LCMS (M+H)+: 453, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 8.99 (dd, J=1.5, 4.6 Hz, 1H), 8.81 (dd, J=1.4, 8.6 Hz, 1H), 8.21 (d, J=8.1 Hz, 1H), 7.74 (dd, J=4.5, 8.6 Hz, 1H), 7.55-7.41 (m, 2H), 7.38 (d, J=8.1 Hz, 1H), 7.30 (d, J=7.9 Hz, 1H), 4.55-4.38 (m, 2H), 4.37-4.25 (m, 3H), 4.17-4.03 (m, 1H), 3.87-3.53 (m, 8H), 3.44-3.32 (m, 4H), 3.07 (t, J=6.2 Hz, 2H), 1.54-1.36 (m, 3H).
The title compound was prepared according to the following scheme:
A mixture of 5-[cis-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrazino[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile (Intermediate A, 30 mg, 98 μmol), tert-butyl 5-bromo-3,4-dihydro-1H-isoquinoline-2-carboxylate (compound 2a, 46 mg, 146 μmol), RuPhos Pd G2 (8 mg, 10 μmol) and Cs2CO3 (95 mg, 293 μmol) in dioxane (5 mL) was charged with N2, then the mixture was heated to 100° C. overnight. After cooling, the solid was filtered off and washed with EA (10 mL). The filtrate was concentrated and the residue was purified by prep-HPLC to give compound 2b as a light yellow solid (25 mg), LCMS (M+H)+: 539.
A mixture of tert-butyl 5-[cis-2-(8-cyano-5-quinolyl)-4-methyl-3,4,6,7,9,9a-hexahydro-1H-pyrazino[1,2-a]pyrazin-8-yl]-3,4-dihydro-1H-isoquinoline-2-carboxylate (compound 2b, 25 mg, 46 μmol) in 1 M HCl in EA (5 mL) was stirred at rt for 16 hours, then the reaction was concentrated to give Example 2 as a light red solid (19 mg). LCMS (M+H)+: 439, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 9.11 (dd, J=1.1, 4.4 Hz, 1H), 8.96 (d, J=7.5 Hz, 1H), 8.32 (d, J=8.1 Hz, 1H), 7.86 (dd, J=4.6, 8.5 Hz, 1H), 7.50 (d, J=8.1 Hz, 1H), 7.40-7.31 (m, 1H), 7.26 (d, J=7.8 Hz, 1H), 7.10 (d, J=7.7 Hz, 1H), 4.40 (s, 2H), 4.19 (br t, J=10.2 Hz, 1H), 4.09-3.97 (m, 2H), 3.87-3.72 (m, 2H), 3.63-3.37 (m, 8H), 3.30-3.13 (m, 3H), 1.58 (d, J=6.5 Hz, 3H).
The title compound was prepared according to the following scheme:
A mixture of 2-bromo-4-(bromomethyl)pyridine (compound 3a, 49 mg, 195 μmol), 5-(4-methyloctahydro-2H-pyrazino[1,2-a]pyrazin-2-yl)quinoline-8-carbonitrile (intermediate A, 30 mg, 98 μmol) and K2CO3 (41 mg, 293 μmol) in MeCN (5 mL) was stirred at rt for 16 hours. Then the reaction mixture was concentrated, and the residue was purified by silica gel column to give compound 3b as a light yellow foam (30 mg). LCMS (M+H)+: 477, LCMS (M+2+H)+: 479.
A mixture of 5-[cis-8-[(2-bromo-4-pyridyl)methyl]-4-methyl-3,4,6,7,9,9a-hexahydro-1H-pyrazino[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile (compound 3b, 30 mg, 63 μmol), tert-butyl piperazine-1-carboxylate (59 mg, 314 μmol), Cs2CO3 (61 mg, 189 μmol) and RuPhos Pd G2 (9 mg, 13 μmol) in dioxane (5 mL) was stirred at 100° C. for 16 hours. Then the reaction mixture was concentrated and the residue was purified by silica gel column to give compound 3c as a light yellow foam (20 mg). LCMS (M+H)+: 583.
A mixture of tert-butyl 4-[4-[[cis-2-(8-cyano-5-quinolyl)-4-methyl-3,4,6,7,9,9a-hexahydro-1H-pyrazino[1,2-a]pyrazin-8-yl]methyl]-2-pyridyl]piperazine-1-carboxylate (compound 3c, 20 mg, 34 μmol) in 1 M HCl in EA (5 mL) was stirred at rt for 16 hours. After the reaction mixture was concentrated, the residue was dissolved in NaOH (1M, 5 mL) and extracted with DCM (10 mL). The organic layer was dried and concentrated, and the residue was lyophilized to give Example 3 as a light yellow powder (10 mg). LCMS (M+H)+: 483, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 8.96 (dd, J=1.7, 4.3 Hz, 1H), 8.60 (dd, J=1.7, 8.6 Hz, 1H), 8.12 (d, J=8.1 Hz, 1H), 8.04 (d, J=5.1 Hz, 1H), 7.62 (dd, J=4.3, 8.6 Hz, 1H), 7.21 (d, J=8.1 Hz, 1H), 6.82 (s, 1H), 6.73 (d, J=5.3 Hz, 1H), 3.54-3.44 (m, 6H), 3.40 (br d, J=11.0 Hz, 1H), 3.33-3.22 (m, 2H), 3.00-2.89 (m, 5H), 2.84-2.70 (m, 5H), 2.37-2.22 (m, 2H), 2.09-1.92 (m, 1H), 1.15 (d, J=5.7 Hz, 3H).
The title compound was prepared according to the following scheme:
Example 4 was prepared in analogy to the preparation of Example 2 by using compound 4a instead of compound 2a. Example 4 was obtained as a light brown solid (26 mg). LCMS (M+H)+: 425, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 9.03 (dd, J=1.7, 4.2 Hz, 1H), 8.74 (dd, J=1.7, 8.6 Hz, 1H), 8.23 (d, J=7.9 Hz, 1H), 7.72 (dd, J=4.3, 8.6 Hz, 1H), 7.51-7.34 (m, 2H), 7.19 (dd, J=7.6, 16.0 Hz, 2H), 4.70 (s, 2H), 4.64 (s, 2H), 4.21-3.89 (m, 3H), 3.85-3.71 (m, 2H), 3.62-3.37 (m, 4H), 3.25-3.10 (m, 2H), 1.54 (d, J=6.6 Hz, 3H).
Example 5 was prepared in analogy to the preparation of Example 1 by using Intermediate C instead of Intermediate A. Example 5 was obtained as an orange solid (113 mg). LCMS (M+H)+: 453, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 9.09 (dd, J=1.5, 4.5 Hz, 1H), 8.88 (dd, J=1.6, 8.6 Hz, 1H), 8.30 (d, J=8.1 Hz, 1H), 7.83 (dd, J=4.5, 8.6 Hz, 1H), 7.65-7.53 (m, 2H), 7.48 (d, J=8.1 Hz, 1H), 7.42 (d, J=7.9 Hz, 1H), 4.63-4.48 (m, 2H), 4.48-4.36 (m, 3H), 4.22 (br d, J=13.1 Hz, 1H), 3.98-3.60 (m, 8H), 3.58-3.39 (m, 4H), 3.19 (t, J=6.3 Hz, 2H), 1.56 (d, J=6.4 Hz, 3H).
The title compound was prepared according to the following scheme:
To a solution of tert-butyl 3-bromo-7,8-dihydro-5H-1,6-naphthyridine-6-carboxylate (compound 6a, 3.2 g, 10.2 mmol) in methanol (50.0 mL) was added 1,3-bis(diphenylphosphino)propane (1.7 g, 4.1 mmol), triethylamine (7.1 mL, 51.1 mmol) and palladium (II) acetate (0.9 mg, 4.0 mmol). The mixture was purged with nitrogen for three times. Then the reaction mixture was stirred at 100° C. for 16 hours under the carbon monoxide (2280 mmHg). The reaction mixture was filtered and the filtrate was concentrated under reduce pressure. The residue was purified by chromatography column to give compound 6b (2.6 g) as a light yellow solid. LCMS (M+H)+: 293.
To a solution of 06-tert-butyl O3-methyl 7,8-dihydro-5H-1,6-naphthyridine-3,6-dicarboxylate (compound 6b, 2.5 g, 8.5 mmol) in DCM (30.0 mL) was added DIBAL-H (17.0 mL, 17.0 mmol) at 0° C. The reaction mixture was then stirred at 0° C. for 2 hours. The reaction mixture was quenched with aqueous potassium sodium tartrate solution and extracted with DCM. The combined organic layer was washed with brine, dried and concentrated. The residue was purified by chromatography column to give compound 6c (1.1 g) as a yellow solid. LCMS (M+H)+: 265, 1H NMR (400 MHz, CHLOROFORM-d) δ ppm: 8.38 (s, 1H), 7.46 (s, 1H), 5.30 (s, 1H), 4.71 (s, 2H), 4.60 (s, 2H), 3.75 (t, J=5.9 Hz, 2H), 2.99 (br t, J=5.7 Hz, 2H), 1.50 (s, 9H).
A mixture of tert-butyl 3-(hydroxymethyl)-7,8-dihydro-5H-1,6-naphthyridine-6-carboxylate (compound 6c, 200 mg, 757 μmol), DIPEA (396 μl, 2270 μmol) and methanesulfonic anhydride (264 mg, 1510 μmol) in DCM (10 mL) was stirred at rt for 16 hours. Then the reaction was diluted with DCM, washed with water, K2CO3 (1N in water) and brine, the organic layer was dried and concentrated to give compound 6d as a light yellow oil (200 mg). LCMS (M+H)+: 343.
A mixture of tert-butyl 3-(methylsulfonyloxymethyl)-7,8-dihydro-5H-1,6-naphthyridine-6-carboxylate (compound 6d, 111 mg, 325 μmol), 5-[(4R,9aS)-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrazino[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile (Intermediate C, 50 mg, 163 μmol) and K2CO3 (67 mg, 488 μmol) in MeCN (5 mL) was stirred at rt for 16 hours. Then the reaction was concentrated, the residue was purified by prep-HPLC to give compound 6e as a light yellow solid (15 mg). LCMS (M+H)+: 554.
A mixture of tert-butyl 3-[[(4R,9aS)-2-(8-cyano-5-quinolyl)-4-methyl-3,4,6,7,9,9a-hexahydro-1H-pyrazino[1,2-a]pyrazin-8-yl]methyl]-7,8-dihydro-5H-1,6-naphthyridine-6-carboxylate (compound 6e, 15 mg, 27 μmol) in 1 M HCl in EA (2 mL) was stirred at rt for 16 hours. Then the reaction was concentrated to give Example 6 as an orange solid (15 mg). LCMS (M+H)+: 454. 1H NMR (400 MHz, METHANOL-d4) δ ppm: 9.08 (d, J=3.8 Hz, 1H), 8.94-8.83 (m, 2H), 8.55 (s, 1H), 8.28 (d, J=7.9 Hz, 1H), 7.82 (dd, J=4.4, 8.4 Hz, 1H), 7.45 (d, J=8.1 Hz, 1H), 4.68 (s, 2H), 4.21-3.95 (m, 4H), 3.94-3.86 (m, 1H), 3.80-3.65 (m, 4H), 3.54-3.46 (m, 2H), 3.45-3.35 (m, 5H), 3.13-3.00 (m, 1H), 2.86-2.75 (m, 1H), 1.54 (d, J=6.5 Hz, 3H).
The title compound was prepared according to the following scheme:
A mixture of 1-bromo-4-(2-bromoethyl)benzene (compound 7a, 51.5 mg, 195 μmol), 5-[(4R,9aS)-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrazino[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile (Intermediate C, 40 mg, 130 μmol) and K2CO3 (54 mg, 390 μmol) in MeCN (3 mL) was stirred at 80° C. for 16 hours. Then the reaction mixture was filtered and concentrated to give compound 7b as a light yellow solid (60 mg), LCMS (M+H)+: 491.
Example 7 was prepared in analogy to the preparation of Example 3 by using 5-[(4R,9aS)-8-[2-(4-bromophenyl)ethyl]-4-methyl-3,4,6,7,9,9a-hexahydro-1H-pyrazino[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile (compound 7b) instead of compound 3b. Example 7 was obtained as an orange solid (58 mg). LCMS (M+H)+: 496, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 9.12 (dd, J=1.5, 4.6 Hz, 1H), 8.96 (dd, J=1.6, 8.6 Hz, 1H), 8.34 (d, J=8.1 Hz, 1H), 7.88 (dd, J=4.5, 8.6 Hz, 1H), 7.52 (d, J=8.1 Hz, 1H), 7.31 (d, J=8.6 Hz, 2H), 7.08 (d, J=8.7 Hz, 2H), 4.48-4.36 (m, 1H), 4.26 (br d, J=13.2 Hz, 1H), 4.14-3.94 (m, 3H), 3.88-3.75 (m, 3H), 3.72-3.62 (m, 2H), 3.59-3.48 (m, 4H), 3.48-3.38 (m, 8H), 3.22-3.09 (m, 2H), 1.58 (d, J=6.4 Hz, 3H).
Example 8 was prepared in analogy to the preparation of Example 3 by using Intermediate C instead of Intermediate A and 2-bromo-5-(bromomethyl)pyridine instead of compound 3a. Example 8 was obtained as an orange solid (17 mg). LCMS (M+H)+: 483, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 9.09 (dd, J=1.4, 4.5 Hz, 1H), 8.87 (dd, J=1.5, 8.6 Hz, 1H), 8.37-8.24 (m, 3H), 7.82 (dd, J=4.5, 8.6 Hz, 1H), 7.49 (dd, J=8.7, 14.3 Hz, 2H), 4.43-4.11 (m, 4H), 4.09-4.03 (m, 4H), 3.99-3.86 (m, 1H), 3.80-3.66 (m, 4H), 3.58-3.47 (m, 6H), 3.45-3.38 (m, 3H), 1.55 (d, J=6.48 Hz, 3H).
Example 9 was prepared in analogy to the preparation of Example 2 by using Intermediate C instead of Intermediate A and compound 4a instead of compound 2a. Example 9 was obtained as an orange solid (65 mg). LCMS (M+H)+: 425, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 9.08 (dd, J=1.6, 4.4 Hz, 1H), 8.84 (dd, J=1.6, 8.6 Hz, 1H), 8.28 (d, J=8.1 Hz, 1H), 7.78 (dd, J=4.4, 8.6 Hz, 1H), 7.54-7.40 (m, 2H), 7.21 (dd, J=7.8, 14.4 Hz, 2H), 4.73 (s, 2H), 4.66 (s, 2H), 4.16 (br t, J=10.9 Hz, 1H), 4.10-3.96 (m, 2H), 3.86-3.74 (m, 2H), 3.62-3.53 (m, 2H), 3.51-3.37 (m, 4H), 3.28-3.19 (m, 1H), 1.58 (d, J=6.48 Hz, 3H).
Example 10 was prepared in analogy to the preparation of Example 1 by using Intermediate C instead of Intermediate A and tert-butyl 6-(bromomethyl)-3,4-dihydro-1H-isoquinoline-2-carboxylate instead of compound 1b. Example 10 was obtained as a light yellow solid (46 mg). LCMS (M+H)+: 453, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 9.07 (dd, J=1.6, 4.4 Hz, 1H), 8.81 (dd, J=1.6, 8.7 Hz, 1H), 8.27 (d, J=7.9 Hz, 1H), 7.78 (dd, J=4.4, 8.6 Hz, 1H), 7.60-7.55 (m, 2H), 7.44 (d, J=7.9 Hz, 1H), 7.38 (d, J=7.8 Hz, 1H), 4.59-4.46 (m, 2H), 4.43 (s, 2H), 4.36-4.26 (m, 1H), 4.17 (br d, J=13.3 Hz, 1H), 3.94-3.67 (m, 6H), 3.65-3.48 (m, 4H), 3.44-3.35 (m, 2H), 3.26-3.17 (m, 2H), 1.53 (d, J=6.4 Hz, 3H).
The title compound was prepared according to the following scheme:
A mixture of 2-(6-chloropyridin-3-yl)acetic acid (compound 11a, 4 g, 23 mmol) in borane tetrahydrofuran complex (47 mL, 47 mmol) was stirred at rt for 1 hour. After the reaction was quenched with MeOH, the mixture was concentrated and the residue was purified by silica gel column to give compound 11b as a colorless oil (4 g), LCMS (M+H)+: 158.
To a mixture of 2-(6-chloro-3-pyridyl)ethanol (compound 11b, 4.0 g, 25.4 mmol) and DIPEA (13.3 ml, 76.1 mmol) in DCM (50.0 mL) was added methanesulfonic anhydride (6.6 g, 38.1 mmol) slowly at rt. After the reaction mixture was stirred at rt for 15 minutes, it was diluted with NaHCO3 and extracted with EtOAc. The organic layer was dried and concentrated to give compound 11c as a light brown oil (5.0 g), LCMS (M+H)+: 236.
A mixture of 2-(6-chloro-3-pyridyl)ethyl methanesulfonate (compound 11c, 173 mg, 732 μmol), 5-[(4R,9aS)-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrazino[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile (Intermediate C, 150 mg, 488 μmol) and potassium carbonate (202 mg, 1460 μmol) in MeCN (10 mL) was stirred at 80° C. for 16 hours. Then the reaction was concentrated, and the residue was purified by silica gel column to give compound 11d as a light yellow solid (150 mg), LCMS (M+H)+: 447.
A mixture of 5-[(4R,9aS)-8-[2-(6-chloro-3-pyridyl)ethyl]-4-methyl-3,4,6,7,9,9a-hexahydro-1H-pyrazino[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile (compound 11d, 60 mg, 134 μmol), tert-butyl piperazine-1-carboxylate (38 mg, 201 μmol), cesium carbonate (131 mg, 403 μmol) and RuPhos Pd G2 (19 mg, 27 μmol) in dioxane (5 mL) was stirred at 110° C. for 16 hours. Then the reaction was concentrated and the residue was purified by prep-HPLC to give compound 11e as a light yellow powder (35 mg), LCMS (M+H)+: 597.
A mixture of 5-[(4R,9aS)-4-methyl-8-[2-[6-(4-methylpiperazin-1-yl)-3-pyridyl]ethyl]-3,4,6,7,9,9a-hexahydro-TH-pyrazino[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile (compound 11e, 35 mg, 59 μmol) in 1 M HCl in EA (5 mL) was stirred at rt for 16 hours. Then the reaction was concentrated, and the residue was lyophilized to give Example 11 as an orange solid (32 mg). LCMS (M+H)+: 497. 1H NMR (400 MHz, METHANOL-d4) δ ppm: 9.08 (dd, J=1.6, 4.3 Hz, 1H), 8.83 (dd, J=1.6, 8.6 Hz, 1H), 8.28 (d, J=7.9 Hz, 1H), 8.24-8.11 (m, 2H), 7.80 (dd, J=4.4, 8.7 Hz, 1H), 7.52 (d, J=9.4 Hz, 1H), 7.46 (d, J=7.9 Hz, 1H), 4.38-4.24 (m, 1H), 4.23-4.12 (m, 1H), 4.07-3.95 (m, 6H), 3.92-3.81 (m, 1H), 3.78-3.63 (m, 3H), 3.63-3.47 (m, 8H), 3.47-3.38 (m, 2H), 3.27-3.19 (m, 2H), 1.54 (d, J=6.5 Hz, 3H).
Example 12 was prepared in analogy to the preparation of Example 11 by using tert-butyl N-[(3R,4R)-4-methoxypyrrolidin-3-yl]carbamate instead of tert-butyl piperazine-1-carboxylate. Example 12 was obtained as an orange solid (34 mg). LCMS (M+H)+: 527, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 9.08 (dd, J=1.6, 4.4 Hz, 1H), 8.82 (dd, J=1.6, 8.6 Hz, 1H), 8.28 (d, J=8.1 Hz, 1H), 8.16 (dd, J=2.1, 9.4 Hz, 1H), 8.07 (d, J=1.6 Hz, 1H), 7.79 (dd, J=4.3, 8.6 Hz, 1H), 7.46 (d, J=8.1 Hz, 1H), 7.24 (d, J=9.3 Hz, 1H), 4.36-4.23 (m, 2H), 4.21-4.09 (m, 4H), 4.05-3.94 (m, 2H), 3.91-3.82 (m, 2H), 3.81-3.64 (m, 4H), 3.63-3.45 (m, 7H), 3.43-3.36 (m, 2H), 3.26-3.18 (m, 2H), 1.54 (d, J=6.4 Hz, 3H).
The title compound was prepared according to the following scheme:
Example 13 was prepared in analogy to the preparation of Example 11 by using compound 13a instead of compound 11b and tert-butyl N-[(3R,4R)-4-methoxypyrrolidin-3-yl]carbamate instead of tert-butyl piperazine-1-carboxylate. Example 13 was obtained as an orange solid (22 mg). LCMS (M+H)+: 527, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 9.07 (dd, J=1.5, 4.3 Hz, 1H), 8.85 (dd, J=1.5, 8.6 Hz, 1H), 8.27 (d, J=7.9 Hz, 1H), 8.12 (d, J=2.7 Hz, 1H), 7.91-7.86 (m, 1H), 7.80 (td, J=4.1, 8.5 Hz, 2H), 7.45 (d, J=8.1 Hz, 1H), 4.31-4.23 (m, 1H), 4.17 (br s, 1H), 4.04 (br dd, J=3.7, 6.8 Hz, 2H), 3.96 (dd, J=5.5, 11.1 Hz, 1H), 3.92-3.82 (m, 2H), 3.79-3.65 (m, 4H), 3.64-3.59 (m, 1H), 3.57-3.46 (m, 5H), 3.45-3.35 (m, 7H), 3.11-2.98 (m, 1H), 1.59-1.46 (m, 3H).
Example 15 was prepared in analogy to the preparation of Example 3 by using Intermediate C instead of Intermediate A, 2-bromo-5-(bromomethyl)pyridine instead of compound 3a and tert-butyl 1,4-diazepane-1-carboxylate instead of tert-butyl piperazine-1-carboxylate. Example 15 was obtained as a light yellow solid (23 mg). LCMS (M+H)+: 497, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 9.08 (dd, J=1.5, 4.5 Hz, 1H), 8.86 (dd, J=1.6, 8.6 Hz, 1H), 8.36-8.24 (m, 3H), 7.82 (dd, J=4.5, 8.6 Hz, 1H), 7.51 (d, J=9.4 Hz, 1H), 7.49-7.44 (m, 1H), 4.50-4.39 (m, 1H), 4.35-4.28 (m, 1H), 4.25-4.14 (m, 4H), 3.97-3.87 (m, 3H), 3.87-3.69 (m, 4H), 3.61-3.38 (m, 9H), 2.40-2.34 (m, 2H), 1.55 (d, J=6.4 Hz, 3H).
Example 16 was prepared in analogy to the preparation of Example 2 by using Intermediate D instead of Intermediate A and tert-butyl 5-chloro-3,4-dihydro-2,6-naphthyridine-2(1H)-carboxylate instead of compound 2a. Example 16 was obtained as an orange solid (20 mg). LCMS (M+H)+: 440, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 9.10 (dd, J=1.6, 4.4 Hz, 1H), 8.99 (dd, J=1.3, 8.6 Hz, 1H), 8.31 (d, J=8.1 Hz, 1H), 8.26 (d, J=5.9 Hz, 1H), 7.86 (dd, J=4.5, 8.6 Hz, 1H), 7.51 (d, J=8.1 Hz, 1H), 7.28 (d, J=5.9 Hz, 1H), 4.57 (s, 3H), 4.09-3.74 (m, 7H), 3.67-3.47 (m, 5H), 3.28-3.17 (m, 3H), 1.85 (br d, J=4.9 Hz, 3H).
Example 17 was prepared in analogy to the preparation of Example 11 by using tert-butyl N-[(3R,4S)-4-fluoropyrrolidin-3-yl]carbamate instead of tert-butyl piperazine-1-carboxylate.
Example 17 was obtained as an orange solid (8 mg). LCMS (M+H)+: 515, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 9.28-9.06 (m, 2H), 8.42 (d, J=8.2 Hz, 1H), 8.20 (dd, J=2.0, 9.4 Hz, 1H), 8.14 (d, J=1.6 Hz, 1H), 8.02 (dd, J=4.9, 8.6 Hz, 1H), 7.60 (d, J=8.2 Hz, 1H), 7.26 (d, J=9.3 Hz, 1H), 5.73 (t, J=2.8 Hz, 0.5H), 5.60 (t, J=2.9 Hz, 0.5H), 4.64-4.49 (m, 1H), 4.44-4.26 (m, 3H), 4.24-4.03 (m, 5H), 3.97-3.48 (m, 10H), 3.32-3.25 (m, 2H), 1.61 (d, J=6.5 Hz, 3H).
Example 18 was prepared in analogy to the preparation of Example 11 by using tert-butyl N-[(3R,4R)-4-fluoropyrrolidin-3-yl]carbamate instead of tert-butyl piperazine-1-carboxylate. Example 18 was obtained as an orange solid (5 mg). LCMS (M+H)+: 515, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 8.95 (dd, J=1.5, 4.3 Hz, 1H), 8.67 (dd, J=1.6, 8.6 Hz, 1H), 8.14 (d, J=7.9 Hz, 1H), 8.06 (dd, J=2.1, 9.3 Hz, 1H), 7.98 (d, J=1.6 Hz, 1H), 7.65 (dd, J=4.4, 8.6 Hz, 1H), 7.32 (d, J=8.1 Hz, 1H), 7.15 (d, J=9.3 Hz, 1H), 5.55 (br, 0.5H), 5.42 (br, 0.5H), 4.32-4.08 (m, 3H), 4.07-3.91 (m, 3H), 3.89-3.74 (m, 3H), 3.71-3.54 (m, 3H), 3.50-3.25 (m, 7H), 3.14-3.04 (m, 2H), 1.38 (d, J=6.4 Hz, 3H).
Example 19 was prepared in analogy to the preparation of Example 11 by using compound 13c instead of compound 11d and tert-butyl N-[(3R,4S)-4-fluoropyrrolidin-3-yl]carbamate instead of tert-butyl piperazine-1-carboxylate. Example 19 was obtained as an orange solid (48 mg). LCMS (M+H)+: 515, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 9.11 (dd, J=1.5, 4.5 Hz, 1H), 8.94 (dd, J=1.5, 8.7 Hz, 1H), 8.32 (d, J=7.9 Hz, 1H), 8.15 (d, J=2.8 Hz, 1H), 7.95-7.78 (m, 3H), 7.50 (d, J=8.1 Hz, 1H), 5.65 (br, 0.5H), 5.52 (br, 0.5H), 4.40-4.12 (m, 3H), 4.11-4.02 (m, 1H), 4.02-3.84 (m, 5H), 3.84-3.73 (m, 2H), 3.68-3.38 (m, 10H), 1.56 (d, J=6.4 Hz, 3H).
Example 20 was prepared in analogy to the preparation of Example 11 by using compound 13c instead of compound 11d and tert-butyl (2S)-2-methylpiperazine-1-carboxylate instead of tert-butyl piperazine-1-carboxylate. Example 20 was obtained as an orange solid (37 mg). LCMS (M+H)+: 511, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 9.10 (d, J=3.9 Hz, 1H), 8.92 (br d, J=8.4 Hz, 1H), 8.50 (s, 1H), 8.31 (d, J=8.1 Hz, 1H), 8.25-8.19 (m, 1H), 7.95 (d, J=9.0 Hz, 1H), 7.84 (dd, J=4.6, 8.4 Hz, 1H), 7.49 (d, J=8.1 Hz, 1H), 4.37-4.24 (m, 1H), 4.18-4.06 (m, 3H), 3.95-3.70 (m, 5H), 3.64-3.35 (m, 12H), 3.29-3.20 (m, 1H), 3.16-3.06 (m, 1H), 1.55 (d, J=6.2 Hz, 3H), 1.46 (d, J=6.5 Hz, 3H).
The title compound was prepared according to the following scheme:
Example 21 was prepared in analogy to the preparation of Example 11 by using compound 21a instead of compound 11b and tert-butyl (2S)-2-methylpiperazine-1-carboxylate instead of tert-butyl piperazine-1-carboxylate. Example 21 was obtained as an orange solid (14 mg). LCMS (M+H)+: 511, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 9.11 (dd, J=1.5, 4.5 Hz, 1H), 8.95 (dd, J=1.5, 8.7 Hz, 1H), 8.33 (d, J=8.1 Hz, 1H), 8.00 (dd, J=7.4, 8.9 Hz, 1H), 7.86 (dd, J=4.5, 8.6 Hz, 1H), 7.51 (d, J=8.1 Hz, 1H), 7.29 (d, J=8.9 Hz, 1H), 7.10 (d, J=7.3 Hz, 1H), 4.70-4.51 (m, 2H), 4.49-4.36 (m, 1H), 4.29-3.94 (m, 4H), 3.87-3.71 (m, 5H), 3.69-3.38 (m, 11H), 1.57 (d, J=6.5 Hz, 3H), 1.47 (d, J=6.5 Hz, 3H).
A mixture of 5-[(4R,9aS)-8-[2-(6-chloro-3-pyridyl)ethyl]-4-methyl-3,4,6,7,9,9a-hexahydro-1H-pyrazino[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile (compound 11d, 50 mg, 112 μmol), 2-methyl-2,6-diazaspiro[3.3]heptane (12 mg, 112 μmol), cesium carbonate (109 mg, 336 μmol) and RuPhos Pd G2 (16 mg, 22 μmol) in dioxane (5 mL) was stirred at 110° C. for 16 hours. Then the reaction was concentrated and the residue was purified by prep-HPLC to give Example 22 as a light yellow solid (13 mg). LCMS (M+H)+: 523, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 9.03 (dd, J=1.6, 4.3 Hz, 1H), 8.66 (dd, J=1.6, 8.6 Hz, 1H), 8.20 (d, J=8.1 Hz, 1H), 7.96 (d, J=1.8 Hz, 1H), 7.78 (dd, J=2.0, 9.0 Hz, 1H), 7.68 (dd, J=4.2, 8.6 Hz, 1H), 7.31 (d, J=7.9 Hz, 1H), 6.69 (d, J=8.9 Hz, 1H), 4.64-4.52 (m, 2H), 4.44-4.26 (m, 6H), 3.71-3.46 (m, 6H), 3.26-3.17 (m, 2H), 3.10-2.88 (m, 9H), 2.84-2.63 (m, 2H), 1.28 (br d, J=6.1 Hz, 3H).
Example 24 was prepared in analogy to the preparation of Example 11 by using tert-butyl N-[(3R,4S)-4-methoxypyrrolidin-3-yl]carbamate instead of tert-butyl piperazine-1-carboxylate. Example 24 was obtained as an orange solid (17 mg). LCMS (M+H)+: 527, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 9.07 (dd, J=1.5, 4.3 Hz, 1H), 8.80 (dd, J=1.5, 8.5 Hz, 1H), 8.27 (d, J=7.9 Hz, 1H), 8.15 (dd, J=2.1, 9.3 Hz, 1H), 8.06 (d, J=1.6 Hz, 1H), 7.78 (dd, J=4.3, 8.6 Hz, 1H), 7.44 (d, J=8.1 Hz, 1H), 7.23 (d, J=9.4 Hz, 1H), 4.41-4.35 (m, 1H), 4.28-4.07 (m, 4H), 4.02-3.90 (m, 3H), 3.89-3.67 (m, 6H), 3.65-3.38 (m, 9H), 3.25-3.14 (m, 2H), 1.52 (d, J=6.4 Hz, 3H).
Example 25 was prepared in analogy to the preparation of Example 11 by using tert-butyl N-[(3S,4S)-4-methoxypyrrolidin-3-yl]carbamate instead of tert-butyl piperazine-1-carboxylate. Example 25 was obtained as an orange solid (23 mg). LCMS (M+H)+: 527, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 9.09 (dd, J=1.6, 4.4 Hz, 1H), 8.84 (dd, J=1.6, 8.7 Hz, 1H), 8.29 (d, J=8.1 Hz, 1H), 8.16 (dd, J=2.1, 9.4 Hz, 1H), 8.08 (d, J=1.6 Hz, 1H), 7.81 (dd, J=4.5, 8.6 Hz, 1H), 7.47 (d, J=7.9 Hz, 1H), 7.24 (d, J=9.3 Hz, 1H), 4.40-4.28 (m, 2H), 4.23-4.07 (m, 4H), 4.02 (br d, J=13.8 Hz, 2H), 3.96-3.81 (m, 2H), 3.80-3.68 (m, 4H), 3.65-3.50 (m, 7H), 3.48-3.37 (m, 2H), 3.27-3.18 (m, 2H), 1.55 (d, J=6.4 Hz, 3H).
Example 26 was prepared in analogy to the preparation of Example 3 by using 5-[(4R,9aS)-8-[2-(4-bromophenyl)ethyl]-4-methyl-3,4,6,7,9,9a-hexahydro-1H-pyrazino[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile (compound 7b) instead of compound 3b and tert-butyl N-[(3R,4R)-4-methoxypyrrolidin-3-yl]carbamate instead of tert-butyl piperazine-1-carboxylate. Example 26 was obtained as a brown solid (27 mg). LCMS (M+H)+: 526, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 9.01 (dd, J=1.4, 4.6 Hz, 1H), 8.87 (dd, J=1.3, 8.6 Hz, 1H), 8.23 (d, J=8.1 Hz, 1H), 7.78 (dd, J=4.6, 8.6 Hz, 1H), 7.41 (d, J=8.2 Hz, 1H), 7.12 (d, J=8.6 Hz, 2H), 6.57 (d, J=8.7 Hz, 2H), 4.31 (br d, J=1.3 Hz, 1H), 4.14 (br d, J=13.0 Hz, 1H), 4.03-3.85 (m, 4H), 3.81-3.63 (m, 5H), 3.60-3.48 (m, 3H), 3.45-3.29 (m, 8H), 3.15 (dd, J=3.5, 10.7 Hz, 1H), 3.06-2.93 (m, 2H), 1.47 (d, J=6.4 Hz, 3H).
Example 27 was prepared in analogy to the preparation of Example 3 by using Intermediate C instead of Intermediate A and 2-bromo-6-(bromomethyl)pyridine instead of compound 3a. Example 27 was obtained as a light brown solid (20 mg). LCMS (M+H)+: 483, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 9.12 (dd, J=1.5, 4.6 Hz, 1H), 8.97 (dd, J=1.5, 8.6 Hz, 1H), 8.32 (d, J=7.9 Hz, 1H), 7.91-7.77 (m, 2H), 7.50 (d, J=8.1 Hz, 1H), 7.11 (d, J=8.8 Hz, 1H), 7.02 (d, J=7.2 Hz, 1H), 4.63-4.51 (m, 1H), 4.47 (s, 2H), 4.23-4.12 (m, 1H), 4.08-3.97 (m, 5H), 3.94-3.70 (m, 6H), 3.56-3.37 (m, 7H), 1.57 (d, J=6.5 Hz, 3H).
Example 28 was prepared in analogy to the preparation of Example 3 by using 5-[(4R,9aS)-8-[2-(4-bromophenyl)ethyl]-4-methyl-3,4,6,7,9,9a-hexahydro-1H-pyrazino[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile (compound 7b) instead of compound 3b and tert-butyl 5-oxa-2,8-diazaspiro[3.5]nonane-8-carboxylate instead of tert-butyl piperazine-1-carboxylate. Example 28 was obtained as a brown solid (27 mg). LCMS (M+H)+: 538, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 8.90 (dd, J=1.7, 4.2 Hz, 1H), 8.52 (dd, J=1.7, 8.6 Hz, 1H), 8.06 (d, J=8.1 Hz, 1H), 7.56 (dd, J=4.2, 8.6 Hz, 1H), 7.17 (d, J=8.1 Hz, 1H), 7.06 (d, J=8.6 Hz, 2H), 6.43 (d, J=8.4 Hz, 2H), 3.90 (d, J=8.6 Hz, 2H), 3.86-3.79 (m, 2H), 3.62 (d, J=7.9 Hz, 3H), 3.54-3.31 (m, 6H), 3.28-3.22 (m, 2H), 3.18-3.13 (m, 2H), 3.11-3.03 (m, 1H), 2.99-2.69 (m, 7H), 2.49-2.36 (m, 1H), 1.10 (d, J=5.9 Hz, 3H).
The title compound was prepared according to the following scheme:
A mixture of 2,4-dichloropyrimidine (compound 30a, 100 mg, 671 μmol), K2CO3 (185 mg, 1340 μmol) and tert-butyl piperazine-1-carboxylate (138 mg, 738 μmol) in DMF (3 mL) was stirred at 50° C. for 2 hours. Then the reaction mixture was diluted with EtOAc (40 mL) and washed with water. The organic layer was dried over Na2SO4 and concentrated. The residue was purified by flash column chromatography to give compound 30b (100 mg) as a white solid. LCMS (M+H)+: 299, LCMS (M+H+2)+: 301.
A mixture of tert-butyl 4-(2-chloropyrimidin-4-yl)piperazine-1-carboxylate (compound 30b, 43 mg, 143 μmol), K2CO3 (36 mg, 260 μmol) and 5-[(4R,9aS)-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrazino[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile (Intermediate C, 40 mg, 130 μmol) in MeCN (1 mL) was stirred at 120° C. overnight. Then the reaction mixture was concentrated and the residue was purified by flash column chromatography to give the coupling product, which was dissolved in dioxane (3 mL) and treated with a solution of HCl in dioxane (4 M, 2 mL). After the reaction mixture was stirred at rt for 2 hours, it was concentrated to give Example 30 (60 mg) as a yellow solid. LCMS (M+H)+: 470. 1H NMR (400 MHz, METHANOL-d4) δ ppm: 8.99 (dd, J=1.3, 4.5 Hz, 1H), 8.85 (dd, J=1.4, 8.6 Hz, 1H), 8.21 (d, J=7.9 Hz, 1H), 7.85 (d, J=7.5 Hz, 1H), 7.76 (dd, J=4.6, 8.6 Hz, 1H), 7.41 (d, J=8.1 Hz, 1H), 6.62 (d, J=7.6 Hz, 1H), 4.75-4.62 (m, 2H), 4.26-4.13 (m, 2H), 4.13-4.04 (m, 1H), 4.00 (br d, J=12.5 Hz, 1H), 3.95 (br s, 1H), 3.90-3.82 (m, 1H), 3.82-3.62 (m, 3H), 3.59-3.45 (m, 2H), 3.45-3.25 (m, 7H), 1.48 (d, J=6.4 Hz, 3H).
The title compound was prepared according to the following scheme:
A solution of 2,4-dichloro-6-methylpyrimidine (compound 31a, 29 mg, 179 μmol), 5-[(4R,9aS)-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrazino[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile (Intermediate C, 50 mg, 163 μmol) and Et3N (16.5 mg, 163 μmol) in ethanol (4 mL) was stirred at rt for 12 hours. Then the mixture was concentrated and purified by flash column chromatography to give compound 31b (60 mg) as a yellow oil. LCMS (M+H)+: 434, LCMS (M+H+2)+: 436.
To a solution of 5-[(4R,9aR)-8-(2-chloro-6-methyl-pyrimidin-4-yl)-4-methyl-3,4,6,7,9,9a-hexahydro-1H-pyrazino[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile (compound 31b, 60 mg, 138 μmol) in dioxane (5 mL) was added tert-butyl piperazine-1-carboxylate (31 mg, 166 μmol) and K2CO3 (38 mg, 277 μmol). The suspension was bubbled with N2 for 5 minutes, then RuPhos Pd G2 (11 mg, 14 μmol) was added. The reaction mixture was stirred at 100° C. overnight and then concentrated. The residue was purified by prep-HPLC to give the coupling product, which was dissolved in dioxane (5 mL) and treated with a solution of HCl in dioxane (4 M, 2 mL). After the reaction mixture was stirred at rt for 2 hours, it was concentrated to give Example 31 (17 mg) as a yellow solid. LCMS (M+H)+: 484. 1H NMR (400 MHz, METHANOL-d4) δ ppm: 9.09 (br d, J=3.8 Hz, 1H), 8.90 (br d, J=8.1 Hz, 1H), 8.30 (d, J=7.7 Hz, 1H), 7.83 (br dd, J=4.2, 8.1 Hz, 1H), 7.50 (br d, J=7.7 Hz, 1H), 6.68 (s, 1H), 5.38-5.22 (m, 1H), 4.69-4.54 (m, 1H), 4.23-4.06 (m, 6H), 4.03-3.83 (m, 3H), 3.81-3.74 (m, 1H), 3.55-3.37 (m, 7H), 3.61-3.36 (m, 1H), 2.49 (s, 3H), 1.59 (br d, J=5.9 Hz, 3H).
The title compound was prepared according to the following scheme:
A solution of tert-butyl piperazine-1-carboxylate (111 mg, 597 μmol), 4-bromo-2-fluoropyridine (compound 32a, 70 mg, 398 μmol) and K2CO3 (165 mg, 1.19 mmol) in DMSO (3 mL) was stirred at 100° C. overnight. The mixture was diluted with EtOAc (40 mL) and washed with water. The organic layer was dried over Na2SO4 and concentrated. The residue was purified by flash column chromatography to give compound 32b (110 mg) as a white solid. LCMS (M+H)+: 342, LCMS (M+H+2)+: 344.
To a solution of tert-butyl 4-(4-bromo-2-pyridyl)piperazine-1-carboxylate (compound 32b, 67 mg, 195 μmol) in dioxane (5 mL) was added 5-[(4R,9aS)-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrazino[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile (Intermediate C, 40 mg, 130 μmol) and Cs2CO3 (127 mg, 390 μmol). The suspension was bubbled with N2 for 5 minutes, then Ruphos Pd G2 (10 mg, 13 μmol) was added. After the reaction mixture was heated at 100° C. overnight, it was concentrated. The residue was purified by flash column chromatography to give the coupling product, which was dissolved in dioxane (5 mL) and treated with a solution of HCl in dioxane (4 M, 2 mL). After the yellow suspension was stirred at rt for 2 hours, it was concentrated to give Example 32 (46 mg) as a yellow solid. LCMS (M+H)+: 469. 1H NMR (400 MHz, METHANOL-d4) δ ppm: 8.98 (dd, J=1.5, 4.4 Hz, 1H), 8.80 (dd, J=1.5, 8.6 Hz, 1H), 8.19 (d, J=7.9 Hz, 1H), 7.76-7.69 (m, 2H), 7.39 (d, J=8.1 Hz, 1H), 6.81 (dd, J=1.9, 7.4 Hz, 1H), 6.48 (d, J=1.8 Hz, 1H), 4.63-4.46 (m, 2H), 4.05-3.94 (m, 2H), 3.85 (br s, 1H), 3.82-3.77 (m, 4H), 3.71-3.60 (m, 2H), 3.58-3.55 (m, 1H), 3.46-3.26 (m, 8H), 1.47 (d, J=6.5 Hz, 3H).
The title compound was prepared according to the following scheme:
A mixture of 2,4-dichloropyrimidine (compound 30a, 27 mg, 179 μmol), K2CO3 (45 mg, 325 μmol) and 5-[(4R,9aS)-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrazino[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile (Intermediate C, 50 mg, 163 μmol) in DMF (3 mL) was stirred at 50° C. for 2 hours, then the reaction was diluted with EtOAc (40 mL) and washed with water. The organic layer was dried over Na2SO4 and concentrated to give compound 33a (crude 70 mg) as a yellow oil. LCMS (M+H)+: 420, LCMS (M+H+2)+: 422.
A suspension of 5-[(4R,9aR)-8-(2-chloropyrimidin-4-yl)-4-methyl-3,4,6,7,9,9a-hexahydro-1H-pyrazino[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile (compound 33a, 68 mg, 162 μmol), K2CO3 (45 mg, 324 μmol) and tert-butyl piperazine-1-carboxylate (36 mg, 194 μmol) in MeCN (1 mL) was stirred at 120° C. overnight and then concentrated. The residue was purified by prep-HPLC to give the coupling product, which was dissolved in dioxane (2 mL) and treated with a solution of HCl in dioxane (4 M, 2 mL). The yellow suspension was stirred at rt for 2 hours. The reaction mixture was concentrated to give Example 33 (32 mg) as a yellow solid. LCMS (M+H)+: 470. 1H NMR (400 MHz, METHANOL-d4) δ ppm: 8.98 (d, J=3.9 Hz, 1H), 8.79 (br d, J=8.3 Hz, 1H), 8.19 (d, J=7.9 Hz, 1H), 7.85 (d, J=7.5 Hz, 1H), 7.72 (dd, J=4.5, 8.5 Hz, 1H), 7.39 (d, J=7.9 Hz, 1H), 6.68 (br d, J=7.5 Hz, 1H), 5.31-5.11 (m, 1H), 4.59-4.43 (m, 1H), 4.00 (br s, 6H), 3.84 (br d, J=2.8 Hz, 2H), 3.70-3.61 (m, 2H), 3.60-3.52 (m, 2H), 3.33 (br s, 6H), 1.47 (br d, J=6.2 Hz, 3H).
The title compound was prepared according to the following scheme:
To a solution of 5-[(4R,9aS)-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrazino[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile (Intermediate C, 40 mg, 130 μmol) in DMSO (3 mL) was added 4-bromo-2-fluoropyridine (compound 32a, 28 mg, 156 μmol) and K2CO3 (54 mg, 390 μmol). The reaction mixture was stirred at 120° C. overnight, and then the reaction was diluted with EtOAc (40 mL), washed with water, the organic layer was dried over Na2SO4 and concentrated. The residue was purified by flash column chromatography to give compound 34a (52 mg) as a yellow oil. LCMS (M+H)+: 463, LCMS (M+H+2)+: 465.
To a solution of 5-[(4R,9aR)-8-(4-bromo-2-pyridyl)-4-methyl-3,4,6,7,9,9a-hexahydro-1H-pyrazino[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile (compound 34a, 50 mg, 108 μmol) in dioxane (5 mL) was added tert-butyl piperazine-1-carboxylate (30 mg, 162 μmol) and Cs2CO3 (105 mg, 324 μmol). The suspension was bubbled with N2 for 5 minutes, then Ruphos Pd G2 (8 mg, 10 μmol) was added. After the reaction mixture was heated at 100° C. overnight, it was filtered and the filtrate was concentrated. The residue was purified by prep-HPLC to give the coupling product, which was then dissolved in dioxane (5 mL), and treated with a solution of HCl in dioxane (4 M, 2 mL), the yellow suspension was stirred at rt for 2 hours. The reaction mixture was concentrated to give Example 34 (13 mg) as a yellow solid. LCMS (M+H)+: 469.
1H NMR (400 MHz, METHANOL-d4) δ ppm: 9.06 (dd, J=1.7, 4.3 Hz, 1H), 8.78 (dd, J=1.6, 8.6 Hz, 1H), 8.26 (d, J=7.9 Hz, 1H), 7.86 (d, J=7.5 Hz, 1H), 7.75 (dd, J=4.3, 8.6 Hz, 1H), 7.46 (d, J=8.1 Hz, 1H), 6.88 (dd, J=2.5, 7.5 Hz, 1H), 6.57 (d, J=2.3 Hz, 1H), 4.50-4.36 (m, 2H), 4.13 (br d, J=12.0 Hz, 2H), 4.03-3.97 (m, 4H), 3.97-3.91 (m, 1H), 3.88-3.74 (m, 3H), 3.55 (br d, J=13.1 Hz, 1H), 3.45-3.38 (m, 7H), 1.59 (d, J=6.5 Hz, 3H).
The title compound was prepared according to the following scheme:
A solution of 5-fluoroquinoline-8-carbonitrile (258 mg, 1.5 mmol), tert-butyl 1,3,4,6,7,8,9,9a-octahydropyrazino[1,2-a]pyrazine-2-carboxylate (compound 35a, 241 mg, 1 mmol) and DIPEA (241 mg, 1 mmol) in DMSO (5 mL) was stirred at 120° C. overnight, and then diluted with EtOAc (40 mL), washed with water, dried over Na2SO4. The organic layer was concentrated and the residue was purified by flash column chromatography to give compound 35b (390 mg) as a yellow oil. LCMS (M+H)+:394.
To a solution of tert-butyl 8-(8-cyano-5-quinolyl)-3,4,6,7,9,9a-hexahydro-1H-pyrazino[1,2-a]pyrazine-2-carboxylate (compound 35b, 390 mg, 1 mmol) in dioxane (4 mL), was added HCl in dioxane (4 M, 2 mL) slowly. The yellow suspension was stirred at rt for 2 hours and concentrated. The residue was dissolved in MeOH (4 mL), few drops of NaOMe in MeOH was added to adjust the system to slightly basic, and then NaHCO3 solid was added, the suspension was stirred at rt for 30 minutes. The suspension was filtered and concentrated to give compound 35c (280 mg) as a yellow oil. LCMS (M+H)+:294.
To a solution of 5-(1,3,4,6,7,8,9,9a-octahydropyrazino[1,2-a]pyrazin-2-yl)quinoline-8-carbonitrile (compound 35c, 50 mg, 170 μmol) in dioxane (5 mL) was added tert-butyl 4-bromoisoindoline-2-carboxylate (76 mg, 256 μmol) and tBuONa (49 mg, 511 μmol). The suspension was bubbled with N2 for 5 minutes, then Pd2(dba)3 (16 mg, 17 μmol) and BINAP (21 mg, 34 μmol) was added. After the reaction mixture was stirred at 100° C. overnight, it was concentrated. The residue was purified by prep-HPLC to give coupling product, which was dissolved in dioxane (5 mL), and then treated with a solution of HCl in dioxane (4 M, 2 mL), the yellow suspension was stirred at rt for 2 hours. The reaction mixture was concentrated to give Example 35 (25 mg) as a yellow solid. LCMS (M+H)+: 411. 1H NMR (400 MHz, METHANOL-d4) δ ppm: 8.94 (dd, J=1.7, 4.3 Hz, 1H), 8.65 (dd, J=1.7, 8.6 Hz, 1H), 8.13 (d, J=8.1 Hz, 1H), 7.62 (dd, J=4.3, 8.6 Hz, 1H), 7.38-7.30 (m, 2H), 7.09 (dd, J=7.8, 13.8 Hz, 2H), 4.60 (s, 2H), 4.54 (s, 2H), 4.04-3.93 (m, 1H), 3.70-3.62 (m, 5H), 3.54-3.49 (m, 1H), 3.48-3.43 (m, 1H), 3.41 (br d, J=3.7 Hz, 1H), 3.39-3.32 (m, 1H), 3.31-3.25 (m, 1H), 3.23 (br d, J=1.7 Hz, 1H), 3.07 (dd, J=11.0, 13.3 Hz, 1H).
The title compound was prepared in analogy to the preparation of Example 33 by using tert-butyl N-[(3R,4R)-4-methoxypyrrolidin-3-yl]carbamate instead of tert-butyl piperazine-1-carboxylate. Example 36 (18 mg) was obtained as a yellow solid. LCMS (M+H)+: 500. 1H NMR (400 MHz, METHANOL-d4) δ ppm: 9.06 (dd, J=1.6, 4.3 Hz, 1H), 8.74 (d, J=8.4 Hz, 1H), 8.25 (d, J=7.9 Hz, 1H), 7.94 (d, J=7.6 Hz, 1H), 7.73 (dd, J=4.2, 8.5 Hz, 1H), 7.45 (d, J=7.9 Hz, 1H), 6.75 (d, J=7.6 Hz, 1H), 4.94 (br s, 2H), 4.32-4.19 (m, 1H), 4.14-3.96 (m, 5H), 3.92-3.64 (m, 6H), 3.63-3.58 (m, 1H), 3.55-3.35 (m, 6H), 1.56 (d, J=6.4 Hz, 3H).
The title compound was prepared in analogy to the preparation of Example 30 by using tert-butyl N-[(3R,4R)-4-methoxypyrrolidin-3-yl]carbamate instead of tert-butyl piperazine-1-carboxylate. Example 37 (24 mg) was obtained as a yellow solid. LCMS (M+H)+: 500. 1H NMR (400 MHz, METHANOL-d4) δ ppm: 9.08 (d, J=4.4 Hz, 1H), 8.90-8.82 (m, 1H), 8.29 (dd, J=2.2, 7.9 Hz, 1H), 7.92 (d, J=7.3 Hz, 1H), 7.85-7.76 (m, 1H), 7.50 (d, J=8.1 Hz, 1H), 6.48 (dd, J=3.9, 7.3 Hz, 1H), 4.86-4.75 (m, 2H), 4.29-4.05 (m, 6H), 4.05-3.90 (m, 2H), 3.87-3.75 (m, 4H), 3.72-3.57 (m, 2H), 3.51-3.49 (m, 3H), 3.48-3.39 (m, 2H), 1.59 (d, J=6.4 Hz, 3H).
The title compound was prepared according to the following scheme:
A solution of 5-bromo-2-fluoro-4-methyl-pyridine (compound 38a, 190 mg, 1 mmol), tert-butyl piperazine-1-carboxylate (223 mg, 1.2 mmol) and DIPEA (616 mg, 5 mmol) in DMSO (5 mL) was stirred at 120° C. overnight, then diluted with EtOAc (40 mL). The organic layer was washed with water, dried over Na2SO4 and concentrated. The residue was purified by flash chromatography to give compound 38b (282 mg) as a white solid. LCMS (M+H)+: 356, LCMS (M+H+2)+: 358.
To a solution of tert-butyl 4-(5-bromo-4-methyl-2-pyridyl)piperazine-1-carboxylate (compound 38b, 63 mg, 177 μmol) in dioxane (5 mL) was added 5-(1,3,4,6,7,8,9,9a-octahydropyrazino[1,2-a]pyrazin-2-yl)quinoline-8-carbonitrile (compound 35c, 40 mg, 136 μmol) and tBuONa (26 mg, 273 μmol). The suspension was bubbled with N2 for 5 minutes, then Pd2(dba)3 (13 mg, 14 μmol) and BINAP (17 mg, 27 μmol) was added. After the reaction mixture was stirred at 110° C. overnight, it was concentrated. The residue was purified by prep-HPLC to give the coupling product, which was dissolved in dioxane (5 mL), and then treated with a solution of HCl in dioxane (4 M, 2 mL), the yellow suspension was stirred at rt for 2 hours. The reaction mixture was concentrated to give Example 38 (4 mg) as a yellow solid. LCMS (M+H)+: 469. 1H NMR (400 MHz, METHANOL-d4) δ ppm: 9.08 (dd, J=1.4, 4.3 Hz, 1H), 8.84 (dd, J=1.5, 8.6 Hz, 1H), 8.28 (d, J=7.9 Hz, 1H), 7.86 (s, 1H), 7.80 (dd, J=4.4, 8.6 Hz, 1H), 7.50-7.44 (m, 2H), 4.20-4.10 (m, 1H), 4.03-3.96 (m, 4H), 3.83-3.74 (m, 5H), 3.82-3.73 (m, 1H), 3.62 (s, 3H), 3.53-3.45 (m, 7H), 3.30-3.22 (m, 1H), 2.61 (s, 3H).
The title compound was prepared in analogy to the preparation of Example 30 by using tert-butyl N-(azetidin-3-yl)carbamate instead of tert-butyl piperazine-1-carboxylate. Example 39 (17 mg) was obtained as a yellow solid. LCMS (M+H)+: 456. 1H NMR (400 MHz, METHANOL-d4) δ ppm: 8.96 (dd, J=1.4, 4.3 Hz, 1H), 8.71 (br d, J=8.6 Hz, 1H), 8.16 (d, J=7.9 Hz, 1H), 7.76 (d, J=7.2 Hz, 1H), 7.67 (dd, J=4.3, 8.4 Hz, 1H), 7.36 (d, J=8.1 Hz, 1H), 6.18 (d, J=7.3 Hz, 1H), 4.72-4.49 (m, 4H), 4.31-4.19 (m, 3H), 4.09-3.96 (m, 2H), 3.90-3.79 (m, 1H), 3.73-3.62 (m, 3H), 3.56 (s, 1H), 3.50 (s, 1H), 3.47-3.40 (m, 1H), 3.36-3.25 (m, 3H), 1.46 (d, J=6.4 Hz, 3H).
The title compound was prepared in analogy to the preparation of Example 32 by using tert-butyl N-[(3S,4R)-4-fluoropyrrolidin-3-yl]carbamate instead of tert-butyl piperazine-1-carboxylate. Example 40 (19 mg) was obtained as a yellow solid. LCMS (M+H)+: 487. 1H NMR (400 MHz, METHANOL-d4) δ ppm: 9.03 (dd, J=1.6, 4.3 Hz, 1H), 8.68 (dd, J=1.7, 8.6 Hz, 1H), 8.21 (d, J=8.1 Hz, 1H), 7.75-7.62 (m, 2H), 7.36 (d, J=8.1 Hz, 1H), 6.82 (dd, J=2.4, 7.6 Hz, 1H), 6.07 (d, J=2.3 Hz, 1H), 5.68-5.45 (m, 1H), 4.43-4.19 (m, 3H), 4.18-4.11 (m, 1H), 4.10-3.88 (m, 2H), 3.78-3.57 (m, 4H), 3.48-3.37 (m, 1H), 3.32-3.22 (m, 2H), 3.20-3.01 (m, 3H), 2.82-2.69 (m, 1H), 1.37 (d, J=6.4 Hz, 3H).
The title compound was prepared in analogy to the preparation of Example 32 by using tert-butyl N-(azetidin-3-yl)carbamate instead of tert-butyl piperazine-1-carboxylate. Example 41 (6 mg) was obtained as a yellow solid. LCMS (M+H)+: 455. 1H NMR (400 MHz, METHANOL-d4) δ ppm: 8.94 (dd, J=1.6, 4.4 Hz, 1H), 8.72-8.64 (m, 1H), 8.15 (d, J=7.9 Hz, 1H), 7.67-7.59 (m, 2H), 7.35 (d, J=8.1 Hz, 1H), 6.69 (dd, J=2.6, 7.3 Hz, 1H), 5.99 (d, J=2.2 Hz, 1H), 4.57-4.39 (m, 4H), 4.27-4.19 (m, 2H), 4.01-3.93 (m, 2H), 3.89 (br d, J=3.3 Hz, 1H), 3.85-3.73 (m, 2H), 3.70-3.53 (m, 4H), 3.50 (s, 1H), 3.36-3.24 (m, 3H), 1.46 (d, J=6.4 Hz, 3H).
The title compound was prepared according to the following scheme:
To a solution of 5-[(4R,9aR)-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrazino[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile (Intermediate D, 50 mg, 163 μmol) in dioxane (5 mL) was added tert-butyl 5-bromo-3,4-dihydro-1H-2,7-naphthyridine-2-carboxylate (compound 42a, 61 mg, 195 μmol, CAS: 1251012-16-4, vendor: Bepharm) and t-BuONa (31 mg, 325 μmol). The suspension was bubbled with N2 for 5 minutes, then Pd2(dba)3 (15 mg, 16 μmol) and BINAP (20 mg, 33 μmol) was added. After being stirred at 110° C. overnight, the reaction mixture was concentrated.
The residue was purified by prep-HPLC to give the coupling product, which was dissolved in dioxane (5 mL), and then treated with a solution of HCl in dioxane (4 M, 2 mL), the yellow suspension was stirred at rt for 2 hours. The reaction mixture was concentrated to give Example 42 (4 mg) as a yellow solid. LCMS (M+H)+: 440. 1H NMR (400 MHz, METHANOL-d4) δ ppm: 8.95 (d, J=4.2 Hz, 1H), 8.78-8.72 (m, 1H), 8.59-8.52 (m, 2H), 8.14 (d, J=7.9 Hz, 1H), 7.66 (dd, J=4.3, 8.6 Hz, 1H), 7.35 (d, J=7.9 Hz, 1H), 4.53 (s, 2H), 3.95-3.88 (m, 1H), 3.75-3.62 (m, 5H), 3.57-3.48 (m, 8H), 3.41-3.31 (m, 3H), 1.76 (br d, J=6.6 Hz, 3H).
The title compound was prepared according to the following scheme:
To a solution of 2,4-dichloro-5-methyl-pyrimidine (compound 43a, 53 mg, 322 μmol) in CH3CN (3 mL) was added tert-butyl piperazine-1-carboxylate (50 mg, 268 μmol) and K2CO3 (74 mg, 537 μmol). The reaction mixture was stirred at rt overnight, then concentrated. The residue was purified by flash column chromatography to give compound 43b (70 mg) as a white solid. LCMS (M+H)+: 313, LCMS (M+H+2)+: 315.
To a solution of tert-butyl 4-(2-chloro-5-methyl-pyrimidin-4-yl)piperazine-1-carboxylate (compound 43b, 56 mg, 179 μmol) in dioxane (5 mL) was added 5-[(4R,9aS)-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrazino[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile (Intermediate C, 50 mg, 163 μmol) and K2CO3 (45 mg, 325 μmol). The suspension was bubbled with N2 for 5 minutes, then Ruphos Pd G2 (13 mg, 16 μmol) was added. The reaction mixture was stirred at 100° C. overnight, the solid was filtered off and the filtrate was concentrated. The residue was purified by prep-HPLC (Boc group was removed during the separation by using TFA system) to give Example 43 (20 mg) as a yellow solid. LCMS (M+H)+: 484. 1H NMR (400 MHz, METHANOL-d4) δ ppm: 8.91 (dd, J=1.6, 4.3 Hz, 1H), 8.57 (dd, J=1.5, 8.6 Hz, 1H), 8.09 (d, J=7.9 Hz, 1H), 7.80 (s, 1H), 7.58 (dd, J=4.3, 8.6 Hz, 1H), 7.28 (d, J=8.1 Hz, 1H), 4.72-4.53 (m, 2H), 3.85 (br d, J=12.2 Hz, 1H), 3.82-3.75 (m, 4H), 3.72-3.54 (m, 4H), 3.44-3.31 (m, 1H), 3.30-3.23 (m, 4H), 3.20-2.94 (m, 4H), 2.14 (s, 3H), 1.37 (d, J=6.4 Hz, 3H).
The title compound was prepared in analogy to the preparation of Example 42 by using 5-[(4R,9aS)-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrazino[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile (Intermediate C) instead of 5-[(4R,9aR)-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrazino[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile (Intermediate D). Example 44 (25 mg) was obtained as a yellow solid. LCMS (M+H)+: 440. 1H NMR (400 MHz, METHANOL-d4) δ ppm: 8.95 (dd, J=1.6, 4.4 Hz, 1H), 8.72 (dd, J=1.6, 8.7 Hz, 1H), 8.58 (s, 1H), 8.55 (s, 1H), 8.15 (d, J=7.9 Hz, 1H), 7.66 (dd, J=4.3, 8.6 Hz, 1H), 7.35 (d, J=8.1 Hz, 1H), 4.53 (s, 2H), 4.16 (br t, J=10.9 Hz, 1H), 3.98 (br d, J=11.4 Hz, 1H), 3.94-3.86 (m, 1H), 3.72-3.63 (m, 2H), 3.60-3.40 (m, 7H), 3.39-3.32 (m, 4H), 3.32-3.25 (m, 1H), 1.48 (d, J=6.5 Hz, 3H).
The title compound was prepared in analogy to the preparation of Example 31 by using tert-butyl N-[(3R,4R)-4-methoxypyrrolidin-3-yl]carbamate instead of tert-butyl piperazine-1-carboxylate. Example 45 (30 mg) was obtained as a yellow solid. LCMS (M+H)+: 514. 1H NMR (400 MHz, METHANOL-d4) δ ppm: 8.94 (dd, J=1.5, 4.3 Hz, 1H), 8.62 (dd, J=1.4, 8.6 Hz, 1H), 8.13 (d, J=7.9 Hz, 1H), 7.62 (dd, J=4.3, 8.6 Hz, 1H), 7.34 (d, J=7.9 Hz, 1H), 6.51 (s, 1H), 5.35-5.05 (m, 1H), 4.61-4.41 (m, 1H), 4.20-4.09 (m, 1H), 4.06-3.59 (m, 12H), 3.38 (td, J=1.6, 3.2 Hz, 4H), 3.26 (br s, 2H), 2.36 (s, 3H), 1.45 (br d, J=6.4 Hz, 3H).
The title compound was prepared in analogy to the preparation of Example 38 by using tert-butyl N-[(6R)-1,4-oxazepan-6-yl]carbamate (catalog NO: PB97931, vendor: PharmaBlock) instead of tert-butyl piperazine-1-carboxylate. Example 46 (2 mg) was obtained as a yellow solid. LCMS (M+H)+: 499. 1H NMR (400 MHz, METHANOL-d4) δ ppm: 8.96 (d, J=3.4 Hz, 1H), 8.71 (d, J=7.7 Hz, 1H), 8.16 (d, J=7.9 Hz, 1H), 7.70-7.64 (m, 2H), 7.37 (s, 1H), 7.34 (d, J=8.1 Hz, 1H), 4.25-4.16 (m, 2H), 4.12-3.88 (m, 6H), 3.85-3.72 (m, 4H), 3.70-3.62 (m, 5H), 3.50 (s, 2H), 3.40-3.25 (m, 4H), 3.17-3.08 (m, 1H), 2.50 (s, 3H).
The title compound was prepared in analogy to the preparation of Example 2 by using Intermediate B instead of Intermediate A. Example 47 (3.9 mg) was obtained as a yellow solid. LCMS (M+H)+: 439. 1H NMR (400 MHz, METHANOL-d4) δ ppm: 9.04 (dd, J=1.5, 4.3 Hz, 1H), 8.78 (br d, J=8.2 Hz, 1H), 8.23 (d, J=7.9 Hz, 1H), 7.73 (dd, J=4.3, 8.7 Hz, 1H), 7.42 (br d, J=7.7 Hz, 1H), 7.39-7.33 (m, 1H), 7.25 (br s, 1H), 7.09 (d, J=7.8 Hz, 1H), 4.39 (s, 3H), 4.02 (br s, 1H), 3.89-3.34 (m, 9H), 3.31-2.94 (m, 5H), 1.87 (br s, 3H).
The title compound was prepared in analogy to the preparation of Example 32 by using tert-butyl N-[(6S)-1,4-oxazepan-6-yl]carbamate (catalog NO: PB97932, vendor: PharmaBlock) instead of tert-butyl piperazine-1-carboxylate. Example 53 (10 mg) was obtained as a yellow solid. LCMS (M+H)+: 499. 1H NMR (400 MHz, METHANOL-d4) δ ppm: 8.95 (dd, J=1.5, 4.3 Hz, 1H), 8.69 (s, 1H), 8.15 (d, J=7.9 Hz, 1H), 7.68-7.63 (m, 2H), 7.36 (d, J=7.9 Hz, 1H), 6.75 (dd, J=2.1, 7.6 Hz, 1H), 6.44 (d, J=1.8 Hz, 1H), 4.72-4.63 (m, 1H), 4.62-4.53 (m, 1H), 4.22-4.14 (m, 1H), 4.06-3.94 (m, 4H), 3.94-3.85 (m, 3H), 3.83-3.63 (m, 6H), 3.63-3.56 (m, 1H), 3.41-3.24 (m, 4H), 1.47 (d, J=6.4 Hz, 3H).
The title compound was prepared in analogy to the preparation of Example 32 by using tert-butyl N-[(6R)-1,4-oxazepan-6-yl]carbamate (catalog NO: PB97931, vendor: PharmaBlock) instead of tert-butyl piperazine-1-carboxylate. Example 54 (10 mg) was obtained as a yellow solid. LCMS (M+H)+: 499. 1H NMR (400 MHz, METHANOL-d4) δ ppm: 8.95 (dd, J=1.5, 4.3 Hz, 1H), 8.74 (dd, J=1.5, 8.6 Hz, 1H), 8.16 (d, J=7.9 Hz, 1H), 7.71-7.60 (m, 2H), 7.36 (d, J=8.1 Hz, 1H), 6.74 (dd, J=2.0, 7.6 Hz, 1H), 6.48 (d, J=1.3 Hz, 1H), 4.74 (br d, J=1.7 Hz, 1H), 4.53 (br d, J=14.5 Hz, 1H), 4.21-4.13 (m, 1H), 4.07-3.91 (m, 5H), 3.90-3.87 (m, 1H), 3.87-3.80 (m, 2H), 3.79-3.73 (m, 2H), 3.72 (s, 1H), 3.66 (br dd, J=4.0, 13.5 Hz, 2H), 3.62-3.56 (m, 1H), 3.41-3.24 (m, 4H), 1.47 (d, J=6.4 Hz, 3H).
The title compound was prepared according to the following scheme:
A solution of 2,4-dichloro-6-methylpyrimidine (compound 31a, 117 mg, 716 μmol), 5-[(4R,9aS)-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrazino[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile (Intermediate C, 200 mg, 651 μmol) and K2CO3 (269 mg, 1.95 mmol) in DMF (3 mL) was stirred at 50° C. for 2 hours, then the reaction was diluted with EtOAc (40 mL), washed with water. The organic layer was dried and concentrated, the residue was purified by flash column chromatography to give compound 31b (170 mg) as a yellow oil. LCMS (M+H)+: 434, LCMS (M+H+2)+: 436.
To a solution of 5-[(4R,9aR)-8-(2-chloro-6-methyl-pyrimidin-4-yl)-4-methyl-3,4,6,7,9,9a-hexahydro-1H-pyrazino[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile (compound 31b, 50 mg, 115 μmol) in dioxane (5 mL) was added tert-butyl N-(3-methylazetidin-3-yl)carbamate (26 mg, 138 μmol) and K2CO3 (32 mg, 230 μmol). The suspension was bubbled with N2 for 5 minutes, then Ruphos Pd G2 (9 mg, 12 μmol) was added. After being stirred at 110° C. overnight, the reaction mixture was concentrated. The residue was purified by prep-HPLC to give the coupling product, which was dissolved in dioxane (5 mL), and then treated with a solution of HCl in dioxane (4 M, 2 mL), the yellow suspension was stirred at rt for 2 hours. The reaction mixture was concentrated to give Example 55 (10 mg) as a yellow solid. LCMS (M+H)+: 484. 1H NMR (400 MHz, METHANOL-d4) δ ppm: 8.95 (dd, J=1.5, 4.3 Hz, 1H), 8.69 (dd, J=1.6, 8.7 Hz, 1H), 8.16 (d, J=7.9 Hz, 1H), 7.66 (dd, J=4.4, 8.6 Hz, 1H), 7.36 (d, J=8.1 Hz, 1H), 6.50 (s, 1H), 4.52-4.41 (m, 1H), 4.40-4.19 (m, 4H), 3.97 (br d, J=11.5 Hz, 2H), 3.90-3.60 (m, 4H), 3.57-3.44 (m, 2H), 3.41-3.25 (m, 3H), 2.32 (br s, 3H), 1.63 (br s, 3H), 1.46 (br d, J=6.2 Hz, 3H).
The title compound was prepared in analogy to the preparation of Example 32 by using tert-butyl N-(3-methylazetidin-3-yl)carbamate instead of tert-butyl piperazine-1-carboxylate and TFA/DCM (1:2) instead of 1 M HCl in EA. Example 56 (6 mg) was obtained as a yellow solid. LCMS (M+H)+: 469. 1H NMR (400 MHz, METHANOL-d4) δ ppm: 8.90 (td, J=1.5, 4.2 Hz, 1H), 8.57 (dd, J=1.5, 8.6 Hz, 1H), 8.09 (dd, J=1.0, 7.9 Hz, 1H), 7.65-7.54 (m, 2H), 7.26 (d, J=7.9 Hz, 1H), 6.67 (dd, J=2.4, 7.6 Hz, 1H), 5.88 (d, J=2.1 Hz, 1H), 4.38-4.23 (m, 4H), 4.20-4.11 (m, 2H), 3.81 (br d, J=12.3 Hz, 1H), 3.68-3.34 (m, 5H), 3.19-3.01 (m, 3H), 3.01-2.86 (m, 1H), 1.62 (s, 3H), 1.40-1.30 (m, 3H).
The title compound was prepared in analogy to the preparation of Example 3 by using Intermediate C instead of Intermediate A and 3-bromo-5-(bromomethyl)pyridine instead of compound 3a. Example 57 was obtained as a yellow foam (20 mg). LCMS (M+H)+: 483, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 9.15-9.06 (m, 1H), 8.99-8.88 (m, 1H), 8.57 (d, J=2.4 Hz, 1H), 8.46 (br s, 1H), 8.42 (s, 1H), 8.31 (d, J=8.1 Hz, 1H), 7.93-7.80 (m, 1H), 7.48 (d, J=8.1 Hz, 1H), 4.31-4.21 (m, 2H), 3.91-3.82 (m, 4H), 3.80-3.53 (m, 11H), 3.51-3.43 (m, 5H), 1.55 (d, J=6.5 Hz, 3H).
The title compound was prepared in analogy to the preparation of Example 11 by using compound 21c instead of compound 11d and tert-butyl (2R)-2-methylpiperazine-1-carboxylate instead of tert-butyl piperazine-1-carboxylate. Example 58 was obtained as an orange solid (11 mg). LCMS (M+H)+: 511, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 9.08 (dd, J=1.5, 4.4 Hz, 1H), 8.88-8.78 (m, 1H), 8.27 (d, J=7.9 Hz, 1H), 7.88 (br t, J=7.1 Hz, 1H), 7.79 (dd, J=4.3, 8.7 Hz, 1H), 7.45 (d, J=7.9 Hz, 1H), 7.14 (br d, J=8.7 Hz, 1H), 6.99 (d, J=7.0 Hz, 1H), 4.66-4.47 (m, 2H), 4.24-4.08 (m, 2H), 4.03-3.78 (m, 3H), 3.78-3.63 (m, 5H), 3.62-3.48 (m, 4H), 3.47-3.37 (m, 6H), 3.26-3.17 (m, 1H), 1.52 (d, J=6.1 Hz, 3H), 1.44 (d, J=6.6 Hz, 3H).
The title compound was prepared in analogy to the preparation of Example 3 by using 5-[(4R,9aS)-8-[2-(6-chloro-3-pyridyl)ethyl]-4-methyl-3,4,6,7,9,9a-hexahydro-1H-pyrazino[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile (compound 11d) instead of compound 3b, tert-butyl 5-oxa-2,8-diazaspiro[3.5]nonane-8-carboxylate instead of tert-butyl piperazine-1-carboxylate and TFA/DCM (1:2) instead of 1 M HCl in EA. Example 59 was obtained as a light yellow solid (36 mg). LCMS (M+H)+: 539, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 8.99 (dd, J=1.6, 4.3 Hz, 1H), 8.64 (dd, J=1.7, 8.6 Hz, 1H), 8.16 (d, J=8.1 Hz, 1H), 7.92 (d, J=2.0 Hz, 1H), 7.66 (dd, J=4.2, 8.6 Hz, 1H), 7.51 (dd, J=2.2, 8.6 Hz, 1H), 7.25 (d, J=8.1 Hz, 1H), 6.46 (d, J=8.7 Hz, 1H), 3.96 (d, J=8.9 Hz, 2H), 3.81 (d, J=8.7 Hz, 2H), 3.74-3.65 (m, 2H), 3.48-3.37 (m, 3H), 3.14-3.07 (m, 1H), 3.01 (s, 2H), 2.97 (br d, J=11.0 Hz, 1H), 2.90-2.70 (m, 8H), 2.66-2.54 (m, 2H), 2.33 (br t, J=6.6 Hz, 2H), 2.04 (br t, J=10.5 Hz, 1H), 1.19 (d, J=5.9 Hz, 3H).
The title compound was prepared according to the following scheme:
The title compound was prepared in analogy to the preparation of Example 11 by using compound 60a instead of compound 11a. Example 60 was obtained as a yellow solid (47 mg). LCMS (M+H)+: 497, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 8.99 (dd, J=1.6, 4.6 Hz, 1H), 8.83 (dd, J=1.6, 8.7 Hz, 1H), 8.27-8.13 (m, 2H), 7.75 (dd, J=4.6, 8.6 Hz, 1H), 7.39 (d, J=8.1 Hz, 1H), 7.26 (d, J=9.4 Hz, 1H), 4.37-4.15 (m, 3H), 4.12-4.03 (m, 1H), 4.02-3.93 (m, 4H), 3.89-3.78 (m, 1H), 3.73-3.61 (m, 4H), 3.54-3.44 (m, 2H), 3.43-3.32 (m, 7H), 2.76-2.65 (m, 3H), 1.45 (d, J=6.4 Hz, 3H).
The title compound was prepared in analogy to the preparation of Example 1 by using Intermediate G instead of Intermediate A. Example 61 was obtained as an orange solid (165 mg). LCMS (M+H)+: 454, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 8.89 (d, J=8.7 Hz, 1H), 8.31 (d, J=8.1 Hz, 1H), 7.83 (d, J=8.6 Hz, 1H), 7.61-7.55 (m, 2H), 7.48 (d, J=8.1 Hz, 1H), 7.42 (d, J=7.9 Hz, 1H), 4.68-4.49 (m, 2H), 4.45 (s, 2H), 4.43-4.34 (m, 1H), 4.22 (br d, J=13.1 Hz, 1H), 3.95 (br d, J=2.6 Hz, 1H), 3.91-3.58 (m, 7H), 3.54 (t, J=6.3 Hz, 2H), 3.51-3.41 (m, 2H), 3.18 (t, J=6.4 Hz, 2H), 1.56 (d, J=6.4 Hz, 3H).
The title compound was prepared according to the following scheme:
The title compound was prepared in analogy to the preparation of Example 11 by using tert-butyl N-[(3R,4R)-4-methoxypyrrolidin-3-yl]carbamate instead of tert-butyl piperazine-1-carboxylate and Intermediate G instead of Intermediate C. Example 62 was obtained as an orange solid (86 mg). LCMS (M+H)+: 528, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 8.93 (d, J=8.7 Hz, 1H), 8.32 (d, J=7.9 Hz, 1H), 8.16 (dd, J=2.0, 9.4 Hz, 1H), 8.11-8.07 (m, 1H), 7.86 (d, J=8.6 Hz, 1H), 7.51 (d, J=8.1 Hz, 1H), 7.24 (d, J=9.4 Hz, 1H), 4.45 (br t, J=11.1 Hz, 1H), 4.38-4.31 (m, 1H), 4.26 (br d, J=12.7 Hz, 1H), 4.19-4.05 (m, 5H), 4.03-3.95 (m, 1H), 3.90-3.59 (m, 9H), 3.56-3.44 (m, 5H), 3.25 (t, J=7.9 Hz, 2H), 1.58 (d, J=6.5 Hz, 3H).
The title compound was prepared in analogy to the preparation of Example 11 by using tert-butyl N-[(3R,4S)-4-fluoropyrrolidin-3-yl]carbamate instead of tert-butyl piperazine-1-carboxylate and Intermediate G instead of Intermediate C. Example 63 was obtained as an orange solid (60 mg). LCMS (M+H)+: 516, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 9.03 (d, J=8.7 Hz, 1H), 8.37 (d, J=8.1 Hz, 1H), 8.19 (dd, J=2.1, 9.4 Hz, 1H), 8.12 (d, J=1.6 Hz, 1H), 7.93 (d, J=8.6 Hz, 1H), 7.55 (d, J=8.1 Hz, 1H), 7.26 (d, J=9.4 Hz, 1H), 5.71 (t, J=2.9 Hz, 0.5H), 5.58 (t, J=3.1 Hz, 0.5H), 4.50 (br t, J=11.2 Hz, 1H), 4.41-4.23 (m, 3H), 4.22-3.98 (m, 5H), 3.96-3.41 (m, 10H), 3.27 (t, J=8.0 Hz, 2H), 1.59 (d, J=6.4 Hz, 3H).
The title compound was prepared in analogy to the preparation of Example 22 by using compound 62a instead of Intermediate 11d. Example 64 was obtained as a light yellow solid (70 mg). LCMS (M+H)+: 524, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 8.52 (d, J=8.7 Hz, 1H), 8.04 (d, J=8.1 Hz, 1H), 7.79 (d, J=2.0 Hz, 1H), 7.54 (d, J=8.6 Hz, 1H), 7.37 (dd, J=2.3, 8.6 Hz, 1H), 7.13 (d, J=8.1 Hz, 1H), 6.29 (d, J=8.4 Hz, 1H), 3.94 (s, 4H), 3.36 (s, 4H), 3.34-3.25 (m, 2H), 3.19-3.10 (m, 1H), 3.04-2.93 (m, 1H), 2.85 (br d, J=11.0 Hz, 1H), 2.75-2.57 (m, 6H), 2.52-2.43 (m, 2H), 2.31-2.16 (m, 5H), 1.91 (br t, J=10.5 Hz, 1H), 1.07 (d, J=6.0 Hz, 3H).
The title compound was prepared in analogy to the preparation of Example 11 by using tert-butyl N-(3-methylazetidin-3-yl)carbamate instead of tert-butyl piperazine-1-carboxylate and TFA/DCM (1:2) instead of 1 M HCl in EA. Example 65 was obtained as a light yellow solid (40 mg). LCMS (M+H)+: 497, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 8.99 (dd, J=1.6, 4.3 Hz, 1H), 8.64 (dd, J=1.7, 8.6 Hz, 1H), 8.16 (d, J=8.1 Hz, 1H), 7.91 (d, J=1.8 Hz, 1H), 7.66 (dd, J=4.3, 8.6 Hz, 1H), 7.50 (dd, J=2.3, 8.6 Hz, 1H), 7.25 (d, J=8.1 Hz, 1H), 6.44 (d, J=8.6 Hz, 1H), 3.93-3.81 (m, 4H), 3.49-3.37 (m, 2H), 3.29 (br d, J=2.7 Hz, 1H), 3.16-3.07 (m, 1H), 2.97 (br d, J=11.0 Hz, 1H), 2.88-2.68 (m, 6H), 2.65-2.54 (m, 2H), 2.41-2.27 (m, 2H), 2.04 (t, J=10.5 Hz, 1H), 1.54 (s, 3H), 1.18 (d, J=6.0 Hz, 3H).
The title compound was prepared according to the following scheme:
The title compound was prepared in analogy to the preparation of Example 11 by using tert-butyl N-[(3R,4R)-4-methoxypyrrolidin-3-yl]carbamate instead of tert-butyl piperazine-1-carboxylate, compound 7a instead of compound 11c and Intermediate F instead of Intermediate C. Example 66 was obtained as a yellow solid (55 mg). LCMS (M+H)+: 533, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 8.08 (d, J=3.5 Hz, 1H), 7.50 (d, J=7.9 Hz, 1H), 7.23 (d, J=8.7 Hz, 2H), 6.68 (dd, J=3.9, 8.3 Hz, 3H), 4.25-4.10 (m, 2H), 3.99 (br d, J=11.6 Hz, 3H), 3.94-3.84 (m, 4H), 3.78-3.54 (m, 5H), 3.52-3.38 (m, 8H), 3.27 (dd, J=3.5, 10.8 Hz, 1H), 3.17-3.04 (m, 2H), 1.53 (d, J=6.4 Hz, 3H).
The title compound was prepared according to the following scheme:
The title compound was prepared in analogy to the preparation of Example 11 by using tert-butyl N-[(3R,4R)-4-methoxypyrrolidin-3-yl]carbamate instead of tert-butyl piperazine-1-carboxylate and Intermediate F instead of Intermediate C. Example 67 was obtained as a yellow solid (55 mg). LCMS (M+H)+: 534, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 8.09-8.00 (m, 1H), 7.98-7.92 (m, 2H), 7.38 (d, J=7.8 Hz, 1H), 7.12 (d, J=9.3 Hz, 1H), 6.56 (d, J=7.9 Hz, 1H), 4.27-4.16 (m, 1H), 4.06-3.90 (m, 5H), 3.89-3.71 (m, 5H), 3.68-3.62 (m, 1H), 3.60-3.34 (m, 9H), 3.33-3.25 (m, 2H), 3.14-2.99 (m, 2H), 1.41 (d, J=6.4 Hz, 3H).
The title compound was prepared according to the following scheme:
The title compound was prepared in analogy to the preparation of Example 11 by using tert-butyl N-[(3R,4R)-4-methoxypyrrolidin-3-yl]carbamate instead of tert-butyl piperazine-1-carboxylate, compound 7a instead of compound 11c and Intermediate E instead of Intermediate C. Example 68 was obtained as an orange solid (70 mg). LCMS (M+H)+: 515, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 8.11 (d, J=2.4 Hz, 1H), 7.55 (d, J=7.9 Hz, 1H), 7.23 (d, J=8.6 Hz, 2H), 7.03 (d, J=2.4 Hz, 1H), 6.79 (d, J=7.9 Hz, 1H), 6.69 (d, J=8.6 Hz, 2H), 4.34-3.98 (m, 7H), 3.94-3.76 (m, 4H), 3.70-3.59 (m, 3H), 3.58-3.42 (m, 8H), 3.31-3.22 (m, 1H), 3.17-3.07 (m, 2H), 1.59 (d, J=6.5 Hz, 3H).
The title compound was prepared in analogy to the preparation of Example 1 by using Intermediate E instead of Intermediate A. Example 69 was obtained as an orange solid (8 mg). LCMS (M+H)+: 460, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 7.92 (d, J=3.7 Hz, 1H), 7.45-7.34 (m, 3H), 7.28 (d, J=8.1 Hz, 1H), 6.49 (d, J=7.9 Hz, 1H), 4.32 (s, 2H), 4.21 (br s, 2H), 3.77-3.57 (m, 3H), 3.50-3.37 (m, 5H), 3.15-2.82 (m, 8H), 1.27 (br d, J=6.2 Hz, 3H).
The title compound was prepared in analogy to the preparation of Example 1 by using Intermediate C instead of Intermediate A and tert-butyl 5-(bromomethyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (CAS: 2031269-14-2, Catalog NO: PB98143, PharmaBlock) instead of compound 1b. Example 70 was obtained as an orange foam (10 mg). LCMS (M+H)+: 453, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 9.23-9.13 (m, 1H), 9.11-9.04 (m, 1H), 8.40 (d, J=8.1 Hz, 1H), 8.01-7.91 (m, 1H), 7.75-7.65 (m, 1H), 7.57 (d, J=8.1 Hz, 1H), 7.49-7.35 (m, 2H), 4.73-4.52 (m, 3H), 4.44 (s, 2H), 4.08-3.89 (m, 4H), 3.87-3.50 (m, 9H), 3.47-3.39 (m, 2H), 1.60 (d, J=6.4 Hz, 3H)
The title compound was prepared in analogy to the preparation of Example 1 by using Intermediate C instead of Intermediate A and tert-butyl 8-(bromomethyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (CAS: 2268818-17-1, Catalog NO: PB98142, PharmaBlock) instead of compound 1b. Example 71 was obtained as an orange foam (18 mg). LCMS (M+H)+: 453, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 9.13-9.01 (m, 1H), 8.87-8.71 (m, 1H), 8.26 (d, J=7.9 Hz, 1H), 7.91-7.66 (m, 1H), 7.52-7.27 (m, 4H), 4.79-4.59 (m, 2H), 4.29-3.83 (m, 5H), 3.81-3.34 (m, 11H), 3.19 (br t, J=6.4 Hz, 2H), 1.53 (d, J=6.5 Hz, 3H).
The title compound was prepared in analogy to the preparation of Example 1 by using Intermediate C instead of Intermediate A and tert-butyl 4-(bromomethyl)isoindoline-2-carboxylate (CAS: 1123176-01-1, Catalog NO: PB98141, PharmaBlock) instead of compound 1b. Example 72 was obtained as an orange foam (20 mg). LCMS (M+H)+: 439, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 9.14-9.05 (m, 1H), 8.94-8.81 (m, 1H), 8.30 (d, J=7.9 Hz, 1H), 7.88-7.75 (m, 1H), 7.62 (br d, J=6.0 Hz, 1H), 7.57-7.51 (m, 2H), 7.47 (d, J=8.1 Hz, 1H), 4.98 (br d, J=8.6 Hz, 2H), 4.70 (s, 2H), 4.43-4.26 (m, 3H), 4.13 (br d, J=12.0 Hz, 1H), 4.00-3.88 (m, 1H), 3.82-3.56 (m, 6H), 3.48-3.36 (m, 3H), 1.55 (d, J=6.5 Hz, 3H).
The title compound was prepared in analogy to the preparation of Example 32 by using tert-butyl N-(3-methylazetidin-3-yl)carbamate instead of tert-butyl piperazine-1-carboxylate, 4-bromo-2-fluoro-6-methylpyridine instead of 4-bromo-2-fluoropyridine and TFA/DCM (1:2) instead of 1 M HCl in EA. Example 73 (35 mg) was obtained as a yellow foam. LCMS (M+H)+: 483. 1H NMR (400 MHz, METHANOL-d4) δ ppm: 8.88 (dd, J=1.6, 4.3 Hz, 1H), 8.54 (dd, J=1.7, 8.6 Hz, 1H), 8.05 (d, J=8.1 Hz, 1H), 7.55 (dd, J=4.2, 8.6 Hz, 1H), 7.16 (d, J=8.1 Hz, 1H), 6.12 (d, J=1.7 Hz, 1H), 5.48 (d, J=2.0 Hz, 1H), 3.81 (br d, J=11.7 Hz, 1H), 3.77-3.69 (m, 3H), 3.64 (d, J=7.8 Hz, 2H), 3.46-3.38 (m, 1H), 3.37-3.25 (m, 2H), 2.89-2.61 (m, 5H), 2.51 (s, 1H), 2.18 (s, 4H), 1.38 (s, 3H), 1.11 (d, J=6.1 Hz, 3H).
The title compound was prepared in analogy to the preparation of Example 11 by using tert-butyl N-(3-methylazetidin-3-yl)carbamate instead of tert-butyl piperazine-1-carboxylate, Intermediate F instead of Intermediate C and TFA/DCM (1:2) instead of 1 M HCl in EA. Example 74 was obtained as a light yellow solid (14 mg). LCMS (M+H)+: 504, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 7.88 (d, J=3.7 Hz, 1H), 7.79 (d, J=1.8 Hz, 1H), 7.37 (dd, J=2.3, 8.5 Hz, 1H), 7.31 (d, J=7.9 Hz, 1H), 6.38 (d, J=7.9 Hz, 1H), 6.31 (d, J=8.6 Hz, 1H), 3.83-3.73 (m, 2H), 3.71-3.63 (m, 2H), 3.52-3.34 (m, 2H), 3.17-3.09 (m, 1H), 2.95 (br dd, J=1.7, 11.0 Hz, 1H), 2.84 (br d, J=11.0 Hz, 1H), 2.72-2.57 (m, 4H), 2.56-2.37 (m, 4H), 2.25-2.05 (m, 2H), 1.91 (t, J=10.8 Hz, 1H), 1.41 (s, 3H), 1.06 (d, J=6.2 Hz, 3H).
The title compound was prepared in analogy to the preparation of Example 11 by using tert-butyl N-(3-methylazetidin-3-yl)carbamate instead of tert-butyl piperazine-1-carboxylate and Intermediate F instead of Intermediate C. Example 74 was obtained as a light yellow solid (21 mg). LCMS (M+H)+: 522, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 8.00 (d, J=3.5 Hz, 1H), 7.93 (d, J=2.1 Hz, 1H), 7.49 (dd, J=2.3, 8.7 Hz, 1H), 7.42 (d, J=7.9 Hz, 1H), 6.50 (d, J=8.2 Hz, 2H), 5.22-5.16 (m, 0.5H), 5.05 (t, J=3.1 Hz, 0.5H), 3.89-3.77 (m, 2H), 3.74-3.67 (m, 1H), 3.65-3.49 (m, 3H), 3.27 (br d, J=11.0 Hz, 1H), 3.18 (t, J=9.6 Hz, 1H), 3.12-3.05 (m, 1H), 2.97 (br d, J=11.0 Hz, 1H), 2.84-2.69 (m, 4H), 2.67-2.52 (m, 4H), 2.40-2.18 (m, 2H), 2.03 (t, J=10.8 Hz, 1H), 1.18 (d, J=6.2 Hz, 3H).
The title compound was prepared according to the following scheme:
The title compound was prepared in analogy to the preparation of Example 11 by using tert-butyl N-(3-methylazetidin-3-yl)carbamate instead of tert-butyl piperazine-1-carboxylate, compound 60d instead of compound 11d and TFA/DCM (1:2) instead of 1 M HCl in EA. Example 76 was obtained as a light yellow solid (25 mg). LCMS (M+H)+: 497, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 9.02 (dd, J=1.6, 4.3 Hz, 1H), 8.67 (dd, J=1.6, 8.6 Hz, 1H), 8.20 (d, J=7.9 Hz, 1H), 7.94 (d, J=9.0 Hz, 1H), 7.68 (dd, J=4.3, 8.6 Hz, 1H), 7.36 (d, J=7.9 Hz, 1H), 6.73 (d, J=8.9 Hz, 1H), 4.48 (dd, J=2.5, 10.3 Hz, 2H), 4.40-4.29 (m, 2H), 3.95-3.84 (m, 1H), 3.83-3.58 (m, 6H), 3.28-3.06 (m, 5H), 2.78-2.68 (m, 1H), 2.63 (s, 3H), 2.48 (br t, J=11.6 Hz, 1H), 1.74 (s, 3H), 1.45 (d, J=6.4 Hz, 3H).
The title compound was prepared in analogy to the preparation of Example 11 by using tert-butyl (4aR,7aR)-3,4a,5,6,7,7a-hexahydro-2H-pyrrolo[3,4-b][1,4]oxazine-4-carboxylate (CAS: 1932337-68-2, catalog: PBXA8123, vendor: Pharmablock) instead of tert-butyl piperazine-1-carboxylate and Intermediate G instead of Intermediate C. Example 77 was obtained as a light yellow solid (44 mg). LCMS (M+H)+: 540, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 8.65 (d, J=8.7 Hz, 1H), 8.16 (d, J=8.1 Hz, 1H), 7.91 (d, J=2.2 Hz, 1H), 7.66 (d, J=8.6 Hz, 1H), 7.48 (dd, J=2.3, 8.6 Hz, 1H), 7.25 (d, J=8.1 Hz, 1H), 6.48 (d, J=8.7 Hz, 1H), 3.99 (dd, J=2.4, 11.9 Hz, 1H), 3.84-3.71 (m, 3H), 3.69-3.61 (m, 1H), 3.47-3.36 (m, 3H), 3.26-3.08 (m, 3H), 3.04-2.94 (m, 4H), 2.88-2.67 (m, 6H), 2.64-2.54 (m, 2H), 2.40-2.29 (m, 2H), 2.11-2.00 (m, 1H), 1.19 (d, J=6.0 Hz, 3H).
Example 78 was prepared in analogy to the preparation of Example 3 by using Intermediate G instead of Intermediate A and 2-bromo-5-(bromomethyl)pyridine instead of compound 3a. Example 78 was obtained as a light yellow solid (15 mg). LCMS (M+H)+: 484, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 8.61 (d, J=8.7 Hz, 1H), 8.14 (d, J=8.1 Hz, 1H), 8.06 (d, J=2.2 Hz, 1H), 7.68-7.55 (m, 2H), 7.23 (d, J=8.1 Hz, 1H), 6.84 (d, J=8.8 Hz, 1H), 3.58-3.45 (m, 6H), 3.44-3.39 (m, 1H), 3.29-3.23 (m, 2H), 3.00-2.92 (m, 5H), 2.88-2.64 (m, 5H), 2.37-2.21 (m, 2H), 2.00 (br t, J=10.3 Hz, 1H), 1.17 (d, J=6.0 Hz, 3H).
The title compound was prepared in analogy to the preparation of Example 11 by using tert-butyl N-(3-methylazetidin-3-yl)carbamate instead of tert-butyl piperazine-1-carboxylate, Intermediate G instead of Intermediate C and TFA/DCM (1:2) instead of 1 M HCl in EA. Example 79 was obtained as a light yellow solid (27 mg). LCMS (M+H)+: 498, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 8.61 (d, J=8.6 Hz, 1H), 8.14 (d, J=8.1 Hz, 1H), 7.63 (d, J=8.6 Hz, 1H), 7.42 (d, J=8.3 Hz, 1H), 7.23 (d, J=8.1 Hz, 1H), 6.24 (d, J=8.3 Hz, 1H), 3.95-3.85 (m, 2H), 3.84-3.75 (m, 2H), 3.48-3.38 (m, 3H), 3.30-3.22 (m, 2H), 2.92 (br d, J=8.9 Hz, 1H), 2.88-2.69 (m, 5H), 2.46 (s, 3H), 2.34-2.22 (m, 2H), 2.07-1.95 (m, 1H), 1.52 (s, 3H), 1.17 (d, J=6.1 Hz, 3H).
The title compound was prepared according to the following scheme:
A mixture of 5-[(4R,9aS)-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrazino[1,2-a]pyrazin-2-yl]-2-deuterio-quinoline-8-carbonitrile (intermediate G, 500 mg, 1.6 mmol), 6-chloro-3-(chloromethyl)-2-methylpyridine (428 mg, 2.4 mmol) and K2CO3 (672 mg, 4.9 mmol) in MeCN (10 mL) was stirred at 80° C. for 16 hours. Then the reaction was concentrated, the residue was purified by silica gel to give compound 80b as a light yellow solid, 500 mg. LCMS (M+H)+: 448.
A mixture of 5-[(4R,9aS)-8-[(6-chloro-2-methyl-3-pyridyl)methyl]-4-methyl-3,4,6,7,9,9a-hexahydro-1H-pyrazino[1,2-a]pyrazin-2-yl]-2-deuterio-quinoline-8-carbonitrile (compound 80b, 80 mg, 179 μmol), 2-methyl-2,6-diazaspiro[3.3]heptane (30 mg, 268 μmol), Cs2CO3 (116 mg, 357 μmol) and Ruphos Pd G2 (13.9 mg, 17.9 μmol) in dioxane (5 mL) was stirred at 120° C. for 16 hours. Then the reaction was concentrated and the residue was purified by HPLC-preparation to give Example 80 as light yellow powder, 30 mg. LCMS (M+H)+: 524, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 8.61 (d, J=8.6 Hz, 1H), 8.14 (d, J=7.9 Hz, 1H), 7.63 (d, J=8.6 Hz, 1H), 7.42 (d, J=8.3 Hz, 1H), 7.23 (d, J=8.1 Hz, 1H), 6.23 (d, J=8.3 Hz, 1H), 4.06 (s, 4H), 3.48 (s, 4H), 3.46-3.38 (m, 3H), 3.31-3.22 (m, 2H), 2.96-2.87 (m, 1H), 2.84-2.68 (m, 5H), 2.45 (s, 3H), 2.36 (s, 3H), 2.32-2.23 (m, 2H), 2.05-1.93 (m, 1H), 1.17 (d, J=6.1 Hz, 3H).
The title compound was prepared according to the following scheme:
A mixture of 5-[(4R,9aS)-8-[(6-chloro-2-methyl-3-pyridyl)methyl]-4-methyl-3,4,6,7,9,9a-hexahydro-1H-pyrazino[1,2-a]pyrazin-2-yl]-2-deuterio-quinoline-8-carbonitrile (compound 80b, 80 mg, 179 μmol), tert-butyl (R)-(3-methylpyrrolidin-3-yl)carbamate (53.6 mg, 268 μmol), Cs2CO3 (116 mg, 357 μmol) and Ruphos Pd G2 (14 mg, 18 μmol) in dioxane (5 mL) was stirred at 120° C. for 16 hours. The reaction was concentrated and the residue was purified by HPLC-preparation to give compound 81a (40 mg) as a light yellow solid. Then compound 81a (40 mg, 65.4 μmol) was treated with 1 M HCl in EA (3 mL) and stirred at rt for 16 hours. The reaction mixture was concentrated to give Example 81 (32 mg) as an orange solid. LCMS (M+H)+: 512, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 8.90 (d, J=8.6 Hz, 1H), 8.31 (d, J=7.9 Hz, 1H), 8.21 (d, J=9.3 Hz, 1H), 7.84 (d, J=8.6 Hz, 1H), 7.49 (d, J=8.1 Hz, 1H), 7.07 (d, J=9.4 Hz, 1H), 4.40-4.22 (m, 3H), 4.19-4.10 (m, 1H), 4.03-3.89 (m, 4H), 3.87-3.82 (m, 1H), 3.82-3.70 (m, 4H), 3.65-3.52 (m, 2H), 3.51-3.35 (m, 3H), 2.80 (s, 3H), 2.50-2.42 (m, 2H), 1.66 (s, 3H), 1.56 (d, J=6.5 Hz, 3H).
The title compound was prepared in analogy to the preparation of Example 81 by using tert-butyl (3S,4R)-3-amino-4-fluoropyrrolidine-1-carboxylate instead of tert-butyl (R)-(3-methylpyrrolidin-3-yl)carbamate. Example 82 was obtained as an orange solid, 32 mg. LCMS (M+H)+: 516, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 8.88 (d, J=8.7 Hz, 1H), 8.30 (d, J=8.1 Hz, 1H), 8.24 (d, J=9.2 Hz, 1H), 7.83 (d, J=8.7 Hz, 1H), 7.48 (d, J=7.9 Hz, 1H), 7.21 (d, J=9.2 Hz, 1H), 5.57 (t, J=2.9 Hz, 0.5H), 5.44 (t, J=2.9 Hz, 0.5H), 5.19-5.01 (m, 1H), 4.36-4.17 (m, 3H), 4.13 (br d, J=11.9 Hz, 1H), 4.01-3.83 (m, 3H), 3.82-3.60 (m, 5H), 3.58-3.37 (m, 5H), 3.27-3.21 (m, 1H), 2.79 (s, 3H), 1.56 (d, J=6.4 Hz, 3H).
The title compound was prepared in analogy to the preparation of Example 81 by using tert-butyl 9-oxa-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate instead of tert-butyl (R)-(3-methylpyrrolidin-3-yl)carbamate. Example 83 was obtained as an orange solid, 12 mg. LCMS (M+H)+: 540, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 8.84 (d, J=8.6 Hz, 1H), 8.28 (d, J 20=7.9 Hz, 2H), 7.80 (d, J=8.6 Hz, 1H), 7.45 (d, J=7.9 Hz, 1H), 7.34 (d, J=9.2 Hz, 1H), 4.41 (br s, 2H), 4.30 (br d, J=12.8 Hz, 2H), 4.16-3.98 (m, 4H), 3.94-3.82 (m, 1H), 3.81-3.63 (m, 7H), 3.61-3.38 (m, 8H), 2.84 (s, 3H), 1.54 (d, J=6.4 Hz, 3H).
The title compound was prepared in analogy to the preparation of Example 11 by using tert-butyl (R)-(3-methylpyrrolidin-3-yl)carbamate instead of tert-butyl piperazine-1-carboxylate and Intermediate G instead of Intermediate C. Example 84 was obtained as an orange solid, 50 mg. LCMS (M+H)+: 512, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 8.85 (d, J=8.7 Hz, 1H), 8.28 (d, J=8.1 Hz, 1H), 8.19-8.11 (m, 1H), 8.07 (s, 1H), 7.81 (d, J=8.6 Hz, 1H), 7.47 (d, J=8.1 Hz, 1H), 7.21 (d, J=9.4 Hz, 1H), 4.44-4.31 (m, 1H), 4.22 (br d, J=13.3 Hz, 1H), 4.06 (br t, J=10.9 Hz, 2H), 3.98-3.83 (m, 4H), 3.81-3.71 (m, 4H), 3.69-3.54 (m, 4H), 3.54-3.38 (m, 2H), 3.27-3.17 (m, 2H), 2.55-2.38 (m, 2H), 1.67 (s, 3H), 1.56 (d, J=6.4 Hz, 3H).
The title compound was prepared in analogy to the preparation of Example 11 by using tert-butyl (3S)-3-methylpiperazine-1-carboxylate instead of tert-butyl piperazine-1-carboxylate and compound 60d instead of compound 11d. Example 85 was obtained as a light yellow solid, 5 mg. LCMS (M+H)+: 511, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 9.01-8.94 (m, 1H), 8.69-8.56 (m, 1H), 8.14 (d, J=7.9 Hz, 1H), 7.71-7.59 (m, 1H), 7.41 (d, J=8.6 Hz, 1H), 7.23 (d, J=8.1 Hz, 1H), 6.53 (d, J=8.6 Hz, 1H), 4.45 (br d, J=4.8 Hz, 1H), 3.99-3.88 (m, 1H), 3.55-3.38 (m, 5H), 3.32-3.21 (m, 1H), 3.12-2.86 (m, 6H), 2.85-2.67 (m, 7H), 2.37-2.23 (m, 2H), 2.04-1.93 (m, 1H), 1.20-1.13 (m, 6H).
The title compound was prepared in analogy to the preparation of Example 11 by using tert-butyl (2R)-2-methylpiperazine-1-carboxylate instead of tert-butyl piperazine-1-carboxylate and compound 60d instead of compound 11d. Example 86 was obtained as a light yellow solid, 15 mg. LCMS (M+H)+: 511, 1H NMR (400 MHz, METHANOL-d4) δ ppm 9.02-8.91 (m, 1H), 8.67-8.54 (m, 1H), 8.14 (d, J=8.1 Hz, 1H), 7.68-7.56 (m, 1H), 7.42 (d, J=8.6 Hz, 1H), 7.23 (d, J=8.1 Hz, 1H), 6.59 (d, J=8.4 Hz, 1H), 4.23-4.04 (m, 2H), 3.54-3.36 (m, 3H), 3.32-3.21 (m, 2H), 3.10-3.02 (m, 1H), 2.98-2.66 (m, 9H), 2.51-2.38 (m, 4H), 2.37-2.20 (m, 2H), 2.00 (t, J=10.2 Hz, 1H), 1.18-1.15 (m, 6H).
The title compound was prepared according to the following scheme:
The title compound was prepared in analogy to the preparation of Example 11 by using compound 87a instead of compound 11c and intermediate G instead of intermediate C. Example 87 was obtained as an orange solid, 27 mg. LCMS (M+H)+: 498, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 8.98 (d, J=8.6 Hz, 1H), 8.34 (d, J=8.1 Hz, 1H), 8.24 (s, 1H), 7.89 (d, J=8.6 Hz, 1H), 7.51 (d, J=8.1 Hz, 1H), 7.44 (s, 1H), 4.31-4.09 (m, 4H), 4.08-4.02 (m, 4H), 3.98-3.90 (m, 1H), 3.77 (br d, J=12.7 Hz, 2H), 3.67 (br d, J=9.7 Hz, 2H), 3.59-3.36 (m, 8H), 3.22-3.09 (m, 1H), 2.66 (s, 3H), 1.56 (J=6.5 Hz, 3H).
The title compound was prepared in analogy to the preparation of Example 11 by using 6-chloro-2-(chloromethyl)-3-methyl-pyridine instead of compound 11c and intermediate G instead of intermediate C. Example 88 was obtained as an orange solid, 16 mg. LCMS (M+H)+: 498, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 8.94 (d, J=8.7 Hz, 1H), 8.30 (d, J=7.9 Hz, 1H), 7.84 (d, J=8.6 Hz, 1H), 7.71 (d, J=8.8 Hz, 1H), 7.48 (d, J=8.1 Hz, 1H), 7.06 (d, J=8.8 Hz, 1H), 4.69-4.57 (m, 1H), 4.53 (d, J=2.1 Hz, 2H), 4.17 (br d, J=12.5 Hz, 1H), 4.09-4.03 (m, 1H), 4.00-3.89 (m, 5H), 3.89-3.67 (m, 5H), 3.59-3.39 (m, 7H), 2.32 (s, 3H), 1.57 (d, J=6.5 Hz, 3H).
The title compound was prepared in analogy to the preparation of Example 11 by using 2-(2-chloro-4-pyridyl)acetic acid instead of compound 11a, intermediate G instead of intermediate C and tert-butyl N-[(3R,4S)-4-fluoropyrrolidin-3-yl]carbamate instead of tert-butyl piperazine-1-carboxylate. Example 89 was obtained as an orange solid, 60 mg. LCMS (M+H)+: 516, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 8.93 (d, J=8.6 Hz, 1H), 8.32 (d, J=7.9 Hz, 1H), 8.01 (d, J=6.6 Hz, 1H), 7.86 (d, J=8.6 Hz, 1H), 7.51 (d, J=8.1 Hz, 1H), 7.35 (s, 1H), 7.18-7.11 (m, 1H), 5.71 (br s, 0.5H), 5.58 (t, J=3.1 Hz, 0.5H), 4.45 (br t, J=11.2 Hz, 1H), 4.39-4.16 (m, 4H), 4.15-4.04 (m, 3H), 4.03-3.94 (m, 1H), 3.89-3.63 (m, 8H), 3.57-3.37 (m, 4H), 1.58 (d, J=6.4 Hz, 3H).
The title compound was prepared in analogy to the preparation of Example 81 by using tert-butyl 3,6-diazabicyclo[3.1.1]heptane-6-carboxylate instead of tert-butyl (R)-(3-methylpyrrolidin-3-yl)carbamate and TFA/DCM (1:2) instead of 1 M HCl in EA. Example 90 was obtained as a light solid, 15 mg. LCMS (M+H)+: 510, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 8.63 (d, J=8.6 Hz, 1H), 8.17 (d, J=7.9 Hz, 1H), 7.83 (d, J=8.9 Hz, 1H), 7.65 (d, J=8.6 Hz, 1H), 7.32 (d, J=8.1 Hz, 1H), 6.85 (d, J=8.8 Hz, 1H), 4.59 (d, J=6.2 Hz, 2H), 4.20-4.02 (m, 4H), 3.95 (br s, 2H), 3.83-3.73 (m, 1H), 3.66-3.50 (m, 3H), 3.48-3.33 (m, 3H), 3.17-2.97 (m, 3H), 2.96-2.83 (m, 2H), 2.70-2.57 (m, 4H), 2.01-1.94 (m, 1H), 1.36 (d, J=6.4 Hz, 3H).
The title compound was prepared in analogy to the preparation of Example 81 by using tert-butyl 3,8-diazabicyclo[3.2.1]octane-8-carboxylate instead of tert-butyl (R)-(3-methylpyrrolidin-3-yl)carbamate. Example 91 was obtained as an orange solid, 15 mg. LCMS (M+H)+: 524, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 8.80 (d, J=8.6 Hz, 1H), 8.26 (d, J=7.9 Hz, 1H), 8.17 (d, J=9.2 Hz, 1H), 7.77 (d, J=8.6 Hz, 1H), 7.43 (d, J=8.1 Hz, 1H), 7.26 (d, J=9.0 Hz, 1H), 4.38-4.25 (m, 4H), 4.17-3.93 (m, 4H), 3.91-3.79 (m, 1H), 3.76-3.61 (m, 4H), 3.56-3.34 (m, 4H), 3.29-3.08 (m, 2H), 3.01-2.84 (m, 1H), 2.77 (s, 3H), 2.28-2.09 (m, 4H), 1.53 (d, J=6.4 Hz, 3H).
The title compound was prepared in analogy to the preparation of Example 81 by using tert-butyl (1S,4S)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate instead of tert-butyl (R)-(3-methylpyrrolidin-3-yl)carbamate. Example 92 was obtained as a light brown solid, 15 mg. LCMS (M+H)+: 510, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 8.88 (d, J=8.6 Hz, 1H), 8.30 (d, J=7.9 Hz, 1H), 8.21 (d, J=9.4 Hz, 1H), 7.83 (d, J=8.7 Hz, 1H), 7.48 (d, J=8.1 Hz, 1H), 7.15 (br d, J=9.0 Hz, 1H), 5.30 (br s, 1H), 4.74 (s, 1H), 4.39-4.08 (m, 4H), 4.04-3.86 (m, 3H), 3.82-3.60 (m, 5H), 3.58-3.36 (m, 5H), 3.30-3.15 (m, 1H), 2.79 (s, 3H), 2.47-2.37 (m, 1H), 2.31-2.21 (m, 1H), 1.55 (d, J=6.4 Hz, 3H).
The title compound was prepared according to the following scheme:
A mixture of 4-[(4R,9aS)-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrazino[1,2-a]pyrazin-2-yl]-1-methyl-1,8-naphthyridin-2-one (intermediate L, 150 mg, 479 μmol), 5-bromo-2-fluoro-3-methylpyridine (136 mg, 718 μmol) and DIPEA (309 mg, 2.39 mmol) in NMP (5 mL) was stirred at 180° C. for 16 hours. Then the reaction was diluted with EA, washed with water and brine, the organic layer was dried and concentrated. The residue was purified by silica gel to give compound 93a as light brown foam, 100 mg. LCMS (M+H)+: 483.
A mixture of 4-[(4R,9aR)-8-(5-bromo-3-methyl-2-pyridyl)-4-methyl-3,4,6,7,9,9a-hexahydro-1H-pyrazino[1,2-a]pyrazin-2-yl]-1-methyl-1,8-naphthyridin-2-one (compound 93a, 100 mg, 207 μmol), tert-butyl piperazine-1-carboxylate (57.8 mg, 310 μmol), Cs2CO3 (135 mg, 414 μmol) and Ruphos Pd G2 (16.1 mg, 20.7 μmol) in dioxane (5 mL) was stirred at 115° C. for 16 hours. Then the reaction was concentrated and the residue was purified by HPLC to give compound 93b as a light yellow solid, 30 mg. LCMS (M+H)+: 589.
A mixture of tert-butyl 4-[6-[(4R,9aR)-4-methyl-2-(1-methyl-2-oxo-1,8-naphthyridin-4-yl)-3,4,6,7,9,9a-hexahydro-1H-pyrazino[1,2-a]pyrazin-8-yl]-5-methyl-3-pyridyl]piperazine-1-carboxylate (compound 93b, 15 mg, 25.5 μmol) in 1 M HCl in EA (2 mL) was stirred at rt for 16 hours, then the reaction was concentrated to give Example 93 as a yellow solid, 14 mg. LCMS (M+H)+: 489, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 8.74-8.66 (m, 1H), 8.44-8.37 (m, 1H), 8.14 (d, J=2.6 Hz, 1H), 7.85 (d, J=2.9 Hz, 1H), 7.45-7.35 (m, 1H), 6.34 (s, 1H), 4.25-4.15 (m, 1H), 4.08 (br d, J=12.3 Hz, 1H), 4.01-3.87 (m, 3H), 3.87-3.77 (m, 6H), 3.69-3.59 (m, 5H), 3.56-3.41 (m, 5H), 3.40-3.33 (m, 2H), 2.55 (s, 3H), 1.59 (d, J=6.5 Hz, 3H).
The title compound was prepared in analogy to the preparation of Example 81 by using tert-butyl (1S,4S)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate instead of tert-butyl (R)-(3-methylpyrrolidin-3-yl)carbamate and compound 87b instead of compound 80b. Example 94 was obtained as an orange solid, 33 mg. LCMS (M+H)+: 510, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 8.94 (d, J=8.6 Hz, 1H), 8.33 (d, J=8.1 Hz, 1H), 8.13 (br s, 1H), 7.87 (d, J=8.7 Hz, 1H), 7.49 (d, J=8.1 Hz, 1H), 7.23 (br s, 1H), 5.19 (s, 1H), 4.74 (s, 1H), 4.27-4.02 (m, 4H), 3.99-3.84 (m, 3H), 3.81-3.70 (m, 2H), 3.69-3.56 (m, 3H), 3.54-3.36 (m, 5H), 3.12-2.97 (m, 1H), 2.66 (s, 3H), 2.46-2.38 (m, 1H), 2.31-2.20 (m, 1H), 1.56 (d, J=6.5 Hz, 3H).
The title compound was prepared in analogy to the preparation of Example 93 by using tert-butyl (1S,4S)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate instead of tert-butyl piperazine-1-carboxylate and intermediate G instead of intermediate L. Example 95 was obtained as a dark brown solid, 8 mg. LCMS (M+H)+: 496, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 8.80 (d, J=8.7 Hz, 1H), 8.25 (d, J=8.1 Hz, 1H), 7.81-7.70 (m, 2H), 7.62 (d, J=3.1 Hz, 1H), 7.44 (d, J=7.9 Hz, 1H), 4.83 (s, 1H), 4.60 (s, 1H), 4.31-4.15 (m, 1H), 4.07 (br d, J=12.3 Hz, 1H), 4.01-3.94 (m, 1H), 3.84-3.66 (m, 6H), 3.63-3.35 (m, 7H), 2.52 (s, 3H), 2.36-2.23 (m, 1H), 2.13 (br d, J=11.5 Hz, 1H), 1.57 (d, J=6.5 Hz, 3H).
The title compound was prepared in analogy to the preparation of Example 93 by using tert-butyl N-[(3R,4S)-4-methoxypyrrolidin-3-yl]carbamate instead of tert-butyl piperazine-1-carboxylate and intermediate G instead of intermediate L. Example 96 was obtained as a dark brown solid, 14 mg. LCMS (M+H)+: 514, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 8.86 (d, J=8.6 Hz, 1H), 8.27 (d, J=8.1 Hz, 1H), 7.79 (d, J=8.6 Hz, 1H), 7.71 (d, J=2.8 Hz, 1H), 7.52 (d, J=2.9 Hz, 1H), 7.46 (d, J=8.1 Hz, 1H), 4.35-4.19 (m, 2H), 4.16-4.02 (m, 2H), 4.02-3.93 (m, 1H), 3.87-3.72 (m, 6H), 3.70-3.56 (m, 3H), 3.55-3.36 (m, 7H), 2.53 (s, 3H), 1.58 (d, J=6.5 Hz, 3H).
The title compound was prepared in analogy to the preparation of Example 93 by using tert-butyl (R)-(3-methylpyrrolidin-3-yl)carbamate instead of tert-butyl piperazine-1-carboxylate and intermediate G instead of intermediate L. Example 97 was obtained as a light brown solid, 5 mg. LCMS (M+H)+: 498, 1H NMR (400 MHz, METHANOL-d4) δ ppm 8.79 (d, J=8.6 Hz, 1H), 8.25 (d, J=7.9 Hz, 1H), 7.74 (d, J=8.7 Hz, 1H), 7.69 (d, J=2.7 Hz, 1H), 7.51 (d, J=3.1 Hz, 1H), 7.44 (d, J=8.1 Hz, 1H), 4.28-4.16 (m, 1H), 4.12-4.04 (m, 1H), 4.02-3.92 (m, 1H), 3.83-3.69 (m, 6H), 3.67-3.36 (m, 7H), 2.53 (s, 3H), 2.34 (br d, J=7.9 Hz, 2H), 1.65-1.51 (m, 6H).
The title compound was prepared in analogy to the preparation of Example 81 by using tert-butyl (4aR,7aR)-3,4a,5,6,7,7a-hexahydro-2H-pyrrolo[3,4-b][1,4]oxazine-4-carboxylate (CAS: 1932337-68-2, catalog: PBXA8123, vendor: Pharmablock) instead of tert-butyl (R)-(3-methylpyrrolidin-3-yl)carbamate. Example 98 was obtained as a light yellow solid, 30 mg. LCMS (M+H)+: 540, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 8.58 (d, J=8.6 Hz, 1H), 8.12 (d, J=7.9 Hz, 1H), 7.61 (d, J=8.6 Hz, 1H), 7.37 (d, J=8.6 Hz, 1H), 7.21 (d, J=8.1 Hz, 1H), 6.26 (d, J=8.4 Hz, 1H), 4.05-3.92 (m, 1H), 3.84-3.69 (m, 3H), 3.68-3.55 (m, 1H), 3.49-3.36 (m, 3H), 3.28-3.06 (m, 4H), 3.05-2.88 (m, 4H), 2.85-2.67 (m, 5H), 2.44 (s, 3H), 2.35-2.20 (m, 2H), 1.97 (t, J=10.0 Hz, 1H), 1.15 (d, J=6.1 Hz, 3H).
The title compound was prepared in analogy to the preparation of Example 93 by using tert-butyl N-[(3R,4R)-4-methoxypyrrolidin-3-yl]carbamate instead of tert-butyl piperazine-1-carboxylate and intermediate G instead of intermediate L. Example 99 was obtained as an orange solid, 5 mg. LCMS (M+H)+: 514, 1H NMR (400 MHz, METHANOL-d4) δ ppm 8.79 (d, J=8.6 Hz, 1H), 8.25 (d, J=7.9 Hz, 1H), 7.77-7.66 (m, 2H), 7.54 (d, J=2.9 Hz, 1H), 7.44 (d, J=8.1 Hz, 1H), 4.27-4.16 (m, 2H), 4.14-4.04 (m, 1H), 4.04-3.94 (m, 2H), 3.94-3.86 (m, 1H), 3.83-3.70 (m, 6H), 3.61-3.35 (m, 9H), 2.53 (s, 3H), 1.57 (d, J=6.4 Hz, 3H).
The title compound was prepared in analogy to the preparation of Example 93 by using tert-butyl (4aR,7aR)-3,4a,5,6,7,7a-hexahydro-2H-pyrrolo[3,4-b][1,4]oxazine-4-carboxylate (CAS: 1932337-68-2, catalog: PBXA8123, vendor: Pharmablock) instead of tert-butyl piperazine-1-carboxylate and intermediate G instead of intermediate L. Example 100 was obtained as an orange solid, 5 mg. LCMS (M+H)+: 526, 1H NMR (400 MHz, METHANOL-d4) δ ppm 8.75 (d, J=8.6 Hz, 1H), 8.23 (d, J=7.9 Hz, 1H), 7.72 (d, J=8.6 Hz, 1H), 7.61 (d, J=2.7 Hz, 1H), 7.52 (d, J=2.9 Hz, 1H), 7.42 (d, J=7.9 Hz, 1H), 4.32-4.11 (m, 3H), 4.10-3.92 (m, 3H), 3.90-3.60 (m, 8H), 3.58-3.35 (m, 8H), 2.51 (s, 3H), 1.56 (d, J=6.5 Hz, 3H).
The title compound was prepared in analogy to the preparation of Example 93 by using tert-butyl N-(2-azaspiro[3.3]heptan-6-yl)carbamate instead of tert-butyl piperazine-1-carboxylate, intermediate G instead of intermediate L and TFA/DCM (1:2) instead of 1 M HCl in EA. Example 101 was obtained as a light yellow solid, 30 mg. LCMS (M+H)+: 510, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 8.72 (d, J=8.7 Hz, 1H), 8.23 (d, J=7.9 Hz, 1H), 7.71 (d, J=8.7 Hz, 1H), 7.47-7.35 (m, 2H), 7.07 (d, J=2.6 Hz, 1H), 4.11 (br s, 1H), 4.06-3.99 (m, 3H), 3.92 (s, 3H), 3.82-3.71 (m, 3H), 3.66-3.53 (m, 2H), 3.46-3.37 (m, 2H), 3.31-3.21 (m, 3H), 2.75-2.65 (m, 2H), 2.49-2.36 (m, 5H), 1.53 (d, J=6.5 Hz, 3H).
The title compound was prepared according to the following scheme:
A mixture of 5-[(4R,9aS)-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrazino[1,2-a]pyrazin-2-yl]-2-deuterio-quinoline-8-carbonitrile (intermediate G, 100 mg, 324 μmol), 6-fluoro-5-methylnicotinic acid (101 mg, 648 μmol) and DIPEA (210 mg, 1.62 mmol) in DMSO (5 mL) was stirred at 120° C. for 16 hours, then the reaction was purified by flash preparation (TFA in water, MeCN) to give compound 102a as a light yellow solid, 100 mg, LCMS (M+H)+: 444.
A mixture of 6-[(4R,9aR)-2-(8-cyano-2-deuterio-5-quinolyl)-4-methyl-3,4,6,7,9,9a-hexahydro-1H-pyrazino[1,2-a]pyrazin-8-yl]-5-methyl-pyridine-3-carboxylic acid (compound 102a, 100 mg, 225 μmol), 2-methyl-2,6-diazaspiro[3.3]heptane (50.6 mg, 451 μmol), HATU (103 mg, 271 μmol) and DIPEA (87.4 mg, 676 μmol) in DMF (5 mL) was stirred at rt for 1 hour, then the reaction was diluted with EA, washed with water and brine. The organic layer was dried and concentrated, the residue was purified by HPLC-preparation to give Example 102 as a light yellow solid, 45 mg. LCMS (M+H)+: 538, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 8.62 (d, J=8.6 Hz, 1H), 8.35 (d, J=2.1 Hz, 1H), 8.11 (d, J=8.1 Hz, 1H), 7.74 (d, J=1.7 Hz, 1H), 7.62 (d, J=8.6 Hz, 1H), 7.23 (d, J=8.1 Hz, 1H), 4.48 (br s, 2H), 4.21 (br s, 2H), 3.74-3.64 (m, 1H), 3.58 (br d, J=12.1 Hz, 1H), 3.49-3.39 (m, 6H), 3.35 (br d, J=11.4 Hz, 1H), 3.15-3.01 (m, 1H), 2.94-2.74 (m, 5H), 2.44-2.36 (m, 1H), 2.34 (s, 3H), 2.31 (s, 3H), 1.19 (d, J=5.6 Hz, 3H).
The title compound was prepared in analogy to the preparation of Example 102 by using intermediate K instead of intermediate G. Example 103 was obtained as a light yellow solid, 35 mg. LCMS (M+H)+: 538, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 8.73 (d, J=8.6 Hz, 1H), 8.36 (d, J=2.3 Hz, 1H), 8.15 (d, J=7.9 Hz, 1H), 7.78-7.72 (m, 1H), 7.65 (d, J=8.6 Hz, 1H), 7.27 (d, J=8.1 Hz, 1H), 4.49 (br s, 2H), 4.22 (br s, 2H), 3.69-3.54 (m, 2H), 3.48 (s, 4H), 3.44-3.32 (m, 5H), 3.16-2.97 (m, 2H), 2.86-2.72 (m, 3H), 2.36 (s, 3H), 2.34 (s, 3H), 1.46 (d, J=6.5 Hz, 3H).
The title compound was prepared in analogy to the preparation of Example 32 by using tert-butyl N-[(3R)-3-methylpyrrolidin-3-yl]carbamate instead of tert-butyl piperazine-1-carboxylate. Example 105 (20 mg) was obtained as an orange solid. LCMS (M+H)+: 483. 1H NMR (400 MHz, METHANOL-d4) δ ppm: 9.06 (dd, J=1.6, 4.3 Hz, 1H), 8.77 (dd, J=1.7, 8.6 Hz, 1H), 8.26 (d, J=7.9 Hz, 1H), 7.78-7.72 (m, 2H), 7.46 (d, J=8.1 Hz, 1H), 6.83 (dd, J=2.2, 7.6 Hz, 1H), 6.19 (d, J=2.2 Hz, 1H), 4.68-4.52 (m, 2H), 4.15-4.02 (m, 2H), 3.95-3.83 (m, 4H), 3.82-3.64 (m, 4H), 3.48-3.35 (m, 4H), 2.45-2.36 (m, 2H), 1.64 (s, 3H), 1.58 (d, J=6.5 Hz, 3H).
The title compound was prepared in analogy to the preparation of Example 2 by using 5-[(4S,9aS)-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrazino[1,2-a]pyrazin-2-yl]-2-deuterio-quinoline-8-carbonitrile (Intermediate K) instead of 5-[cis-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrazino[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile (Intermediate A), and tert-butyl (2R)-2-(4-bromophenyl)morpholine-4-carboxylate (CAS: 1312566-00-9, procedure see Patent WO 2014041007 A1 20140320) instead of tert-butyl 5-bromo-3,4-dihydro-1H-isoquinoline-2-carboxylate (Compound 2a). Example 106 (11 mg) was obtained as an orange solid. LCMS (M+H)+: 470. 1H NMR (400 MHz, METHANOL-d4) δ ppm: 8.71 (d, J=8.6 Hz, 1H), 8.13 (d, J=8.1 Hz, 1H), 7.65 (d, J=8.6 Hz, 1H), 7.27-7.21 (m, 3H), 6.97 (d, J=8.8 Hz, 2H), 4.38 (dd, J=2.3, 10.5 Hz, 1H), 3.95 (dd, J=2.4, 11.6 Hz, 1H), 3.73 (dt, J=3.2, 11.4 Hz, 1H), 3.62 (br t, J=12.8 Hz, 2H), 3.44 (br d, J=11.4 Hz, 1H), 3.34 (br d, J=2.6 Hz, 2H), 3.30-3.25 (m, 2H), 3.03-2.79 (m, 6H), 2.78-2.66 (m, 2H), 2.51 (br, 1H), 1.43 (d, J=6.5 Hz, 3H).
The title compound was prepared in analogy to the preparation of Example 2 by using 5-[(4S,9aS)-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrazino[1,2-a]pyrazin-2-yl]-2-deuterio-quinoline-8-carbonitrile (Intermediate K) instead of 5-[cis-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrazino[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile (Intermediate A) and tert-butyl (2S)-2-(4-bromophenyl)morpholine-4-carboxylate (CAS: 1131220-37-5, procedure see Patent WO 2014041007 A1 20140320) instead of tert-butyl 5-bromo-3,4-dihydro-1H-isoquinoline-2-carboxylate (Compound 2a). Example 107 (10 mg) was obtained as an orange solid. LCMS (M+H)+: 470. 1H NMR (400 MHz, METHANOL-d4) δ ppm: 8.83 (d, J=8.4 Hz, 1H), 8.26 (d, J=7.9 Hz, 1H), 7.77 (d, J=8.6 Hz, 1H), 7.45 (d, J=7.9 Hz, 1H), 7.38 (br d, J=8.7 Hz, 2H), 7.12 (d, J=8.7 Hz, 2H), 4.8-4.8 (m, 1H), 4.4-4.3 (m, 1H), 4.24 (dd, J=3.3, 13.2 Hz, 1H), 4.1-3.9 (m, 4H), 3.9-3.6 (m, 6H), 3.5-3.4 (m, 2H), 3.3-3.2 (m, 1H), 3.2-3.1 (m, 2H), 2.98 (br, 1H), 1.82 (d, J=6.8 Hz, 3H).
The title compound was prepared according to the following scheme:
A solution of 5-bromo-2-fluoro-3-methylpyridine (compound 108a, 462 mg, 2.43 mmol), 5-[(4S,9aS)-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrazino[1,2-a]pyrazin-2-yl]-2-deuterio-quinoline-8-carbonitrile (Intermediate K, 500 mg, 1.62 mmol) and DIPEA (1.1 g, 8.1 mmol) in NMP (6 mL) was stirred at 185° C. for 20 hours, then the reaction was diluted with EtOAc (40 mL), washed with water. The organic layer was dried and concentrated, the residue was purified by flash column chromatography to give compound 108b (640 mg) as an orange oil. LCMS (M+1)+: 478, LCMS (M+3)+: 480.
To a solution of 5-[(4S,9aR)-8-(5-bromo-3-methyl-2-pyridyl)-4-methyl-3,4,6,7,9,9a-hexahydro-1H-pyrazino[1,2-a]pyrazin-2-yl]-2-deuterio-quinoline-8-carbonitrile (compound 108b, 100 mg, 209 μmol) in dioxane (4 mL) was added tert-butyl 3,6-diazabicyclo[3.1.1]-heptane-6-carboxylate (83 mg, 418 μmol) and tBuONa (41 mg, 418 μmol). The suspension was bubbled with N2 for 5 minutes, then tBuXPhos Pd G3 (33 mg, 41.8 μmol) was added. After the reaction mixture was heated at 110° C. overnight, it was filtered and the filtrate was concentrated. The residue was dissolved in DCM/TFA (4 mL, 1:1), after stirring at r.t. for 10 mins, the reaction mixture was concentrated and the residue was purified by prep-HPLC to give Example 108 (11 mg) as a light yellow foam. LCMS (M+H)+: 496. 1H NMR (400 MHz, METHANOL-d4) δ ppm: 8.79 (d, J=8.6 Hz, 1H), 8.24 (d, J=7.9 Hz, 1H), 7.80 (d, J=2.6 Hz, 1H), 7.73 (d, J=8.7 Hz, 1H), 7.42 (d, J=8.2 Hz, 1H), 7.22 (d, J=2.8 Hz, 1H), 4.58 (d, J=6.4 Hz, 2H), 4.43-4.30 (m, 1H), 3.95-3.90 (m, 2H), 3.84-3.78 (m, 2H), 3.52-3.43 (m, 8H), 3.30-3.24 (m, 2H), 3.12-3.03 (m, 2H), 2.43 (s, 3H), 2.05 (br, 1H), 1.85 (br, 3H).
The title compound was prepared according to the following scheme:
A mixture of 2-(6-chloro-3-pyridyl)ethyl methanesulfonate (compound 11c, 288 mg, 1.1 mmol), tert-butyl N-[(3S,4S)-4-methoxypyrrolidin-3-yl]carbamate (216 mg, 1 mmol) and potassium carbonate (276 mg, 2 mmol) in MeCN (6 mL) was stirred at 80° C. for 16 hours. Then the mixture was filtered, the filtrate was concentrated, the residue was purified by silica gel column to give compound 109a as a yellow oil (278 mg), LCMS (M)+: 356, LCMS (M+2)+: 358.
A mixture of tert-butyl N-[(3S,4S)-1-[2-(6-chloro-3-pyridyl)ethyl]-4-methoxy-pyrrolidin-3-yl]carbamate (compound 109a, 90 mg, 253 μmol), 5-[(4R,9aS)-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrazino[1,2-a]pyrazin-2-yl]-2-deuterio-quinoline-8-carbonitrile (Intermediate G, 60 mg, 195 μmol), cesium carbonate (190 mg, 584 μmol) and RuPhos Pd G2 (28 mg, 39 μmol) in dioxane (6 mL) was stirred at 110° C. overnight. Then the reaction was concentrated and the residue was purified by silica gel column to give compound 109b as a yellow oil (65 mg), LCMS (M+H)+: 628.
A mixture of tert-butyl N-[(3S,4S)-1-[2-[6-[(4R,9aR)-2-(8-cyano-2-deuterio-5-quinolyl)-4-methyl-3,4,6,7,9,9a-hexahydro-1H-pyrazino[1,2-a]pyrazin-8-yl]-3-pyridyl]ethyl]-4-methoxy-pyrrolidin-3-yl]carbamate (compound 109b, 65 mg, 104 μmol) in 1 M HCl in EA (5 mL) was stirred at rt for 16 hours. Then the reaction was concentrated, and the residue was lyophilized to give Example 109 as an orange solid (57 mg). LCMS (M+H)+: 528. 1H NMR (400 MHz, METHANOL-d4) δ ppm: 8.83 (d, J=8.6 Hz, 1H), 8.28 (d, J=7.9 Hz, 1H), 8.23-8.17 (m, 2H), 7.78 (d, J=8.6 Hz, 1H), 7.57 (d, J=9.3 Hz, 1H), 7.49 (d, J=7.9 Hz, 1H), 4.62 (br dd, J=11.3, 12.3 Hz, 2H), 4.32 (td, J=2.7, 5.2 Hz, 1H), 4.26-4.03 (m, 4H), 4.01-3.62 (m, 10H), 3.54-3.40 (m, 5H), 3.36-3.34 (m, 1H), 3.24-3.16 (m, 2H), 1.59 (d, J=6.4 Hz, 3H).
The title compound was prepared in analogy to the preparation of Example 108 by using tert-butyl N-[(6R)-1,4-oxazepan-6-yl]carbamate instead of tert-butyl 3,6-diazabicyclo[3.1.1]-heptane-6-carboxylate (Compound 108c). Example 110 (11 mg) was obtained as an orange solid. LCMS (M+H)+: 514. 1H NMR (400 MHz, METHANOL-d4) δ ppm: 8.82 (br d, J=7.8 Hz, 1H), 8.23 (d, J=7.9 Hz, 1H), 7.77 (s, 2H), 7.73 (d, J=8.6 Hz, 1H), 7.42 (d, J=8.1 Hz, 1H), 4.49-4.35 (m, 1H), 4.15-4.04 (m, 3H), 3.98 (br dd, J=2.1, 14.1 Hz, 2H), 3.87 (br d, J=3.3 Hz, 1H), 3.85-3.81 (m, 2H), 3.80-3.66 (m, 9H), 3.62-3.54 (m, 3H), 2.49 (s, 3H), 1.83 (br, 3H).
The title compound was prepared in analogy to the preparation of Example 108 by using tert-butyl (1S,4S)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate instead of tert-butyl 3,6-diazabicyclo[3.1.1]-heptane-6-carboxylate (Compound 108c). Example 111 (11 mg) was obtained as an orange solid. LCMS (M+H)+: 496. 1H NMR (400 MHz, METHANOL-d4) δ ppm: 9.17-8.97 (m, 1H), 8.32 (d, J=7.8 Hz, 1H), 7.88 (br d, J=1.7 Hz, 1H), 7.80 (br s, 1H), 7.62 (br s, 1H), 7.51 (br d, J=7.9 Hz, 1H), 4.86-4.81 (m, 2H), 4.60 (br, 1H), 4.57-4.45 (m, 1H), 4.02 (br d, J=3.2 Hz, 1H), 3.92-3.83 (m, 2H), 3.83-3.71 (m, 4H), 3.67-3.49 (m, 4H), 3.42 (br, 2H), 3.29-3.24 (m, 1H), 2.55 (br, 3H), 2.32 (br d, J=10.9 Hz, 1H), 2.14 (br d, J=11.0 Hz, 1H), 1.83 (br d, J=5.6 Hz, 3H).
The title compound was prepared in analogy to the preparation of Example 32 by using 5-bromo-2-fluoro-pyridine instead of 4-bromo-2-fluoropyridine (compound 32a), tert-butyl 3,8-diazabicyclo[3.2.1]octane-8-carboxylate instead of tert-butyl piperazine-1-carboxylate, and 5-[(4S,9aS)-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrazino[1,2-a]pyrazin-2-yl]-2-deuterio-quinoline-8-carbonitrile (Intermediate K) instead of 5-[(4R,9aS)-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrazino[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile (Intermediate C). Example 112 was obtained as an orange solid (90 mg). LCMS (M+H)+: 496, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 8.79 (d, J=8.6 Hz, 1H), 8.23 (d, J=7.9 Hz, 1H), 8.12 (dd, J=2.9, 9.8 Hz, 1H), 7.75 (d, J=8.7 Hz, 1H), 7.71 (d, J=2.7 Hz, 1H), 7.46-7.38 (m, 2H), 4.40-4.26 (m, 5H), 4.09 (br d, J=12.6 Hz, 3H), 3.76 (br d, J=12.1 Hz, 3H), 3.61 (br, 4H), 3.46-3.36 (m, 1H), 3.22-3.03 (m, 2H), 2.25-2.17 (m, 2H), 2.16-2.09 (m, 2H), 1.80 (br, 3H).
The title compound was prepared in analogy to the preparation of Example 108 by using 2-methyl-2,6-diazaspiro[3.3]heptane instead of tert-butyl 3,6-diazabicyclo[3.1.1]-heptane-6-carboxylate, 4-[(4S,9aS)-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrazino[1,2-a]pyrazin-2-yl]-1-methyl-1,8-naphthyridin-2-one (Intermediate M) instead of 5-[(4S,9aS)-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrazino[1,2-a]pyrazin-2-yl]-2-deuterio-quinoline-8-carbonitrile (Intermediate K). Example 113 (15 mg) was obtained as a white solid. LCMS (M+H)+: 515. 1H NMR (400 MHz, METHANOL-d4) δ ppm: 8.63 (dd, J=1.8, 4.6 Hz, 1H), 8.30 (dd, J=1.8, 8.0 Hz, 1H), 7.35 (d, J=2.8 Hz, 1H), 7.32 (dd, J=4.6, 8.1 Hz, 1H), 6.80 (d, J=2.3 Hz, 1H), 6.16 (s, 1H), 3.97 (s, 4H), 3.91 (s, 4H), 3.76 (s, 3H), 3.37 (br d, J=11.1 Hz, 2H), 3.29-3.21 (m, 2H), 3.20-3.08 (m, 3H), 3.05-2.94 (m, 2H), 2.78 (br d, J=9.0 Hz, 1H), 2.75-2.66 (m, 2H), 2.64 (s, 3H), 2.29 (s, 3H), 1.41 (d, J=6.6 Hz, 3H).
The title compound was prepared in analogy to the preparation of Example 108 by using tert-butyl (4aR,7aR)-3,4a,5,6,7,7a-hexahydro-2H-pyrrolo[3,4-b][1,4]oxazine-4-carboxylate instead of tert-butyl 3,6-diazabicyclo[3.1.1]-heptane-6-carboxylate. Example 114 (30 mg) was obtained as an orange solid. LCMS (M+H)+: 526. 1H NMR (400 MHz, METHANOL-d4) δ ppm: 9.07-8.88 (m, 1H), 8.28 (d, J=7.9 Hz, 1H), 7.81 (br d, J=8.6 Hz, 1H), 7.72 (br, 1H), 7.61-7.53 (m, 1H), 7.48 (d, J=8.1 Hz, 1H), 4.51 (br t, J=10.1 Hz, 1H), 4.33-4.18 (m, 2H), 4.06 (dt, J=2.7, 12.7 Hz, 2H), 3.87 (td, J=8.0, 19.7 Hz, 4H), 3.77 (br d, J=10.8 Hz, 3H), 3.73-3.65 (m, 2H), 3.65-3.59 (m, 2H), 3.58-3.49 (m, 3H), 3.49-3.41 (m, 1H), 3.41-3.35 (m, 1H), 3.25 (br t, J=12.1 Hz, 1H), 2.56 (s, 3H), 1.86 (d, J=6.7 Hz, 3H).
The title compound was prepared in analogy to the preparation of Example 32 by using 5-bromo-2-fluoro-pyridine instead of 4-bromo-2-fluoropyridine (compound 32a), tert-butyl N-[(3R,4R)-4-methoxypyrrolidin-3-yl]carbamate instead of tert-butyl piperazine-1-carboxylate, and 5-[(4S,9aS)-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrazino[1,2-a]pyrazin-2-yl]-2-deuterio-quinoline-8-carbonitrile (Intermediate K) instead of 5-[(4R,9aS)-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrazino[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile (Intermediate C). Example 115 was obtained as a light yellow foam (13 mg). LCMS (M+H)+: 500, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 8.72 (d, J=8.6 Hz, 1H), 8.14 (d, J=8.1 Hz, 1H), 7.76 (d, J=2.7 Hz, 1H), 7.65 (d, J=8.6 Hz, 1H), 7.41 (dd, J=2.9, 9.2 Hz, 1H), 7.26 (d, J=8.1 Hz, 1H), 6.51 (d, J=9.2 Hz, 1H), 3.79-3.72 (m, 2H), 3.61 (dd, J=5.8, 10.2 Hz, 1H), 3.52 (td, J=2.8, 5.7 Hz, 1H), 3.46-3.32 (m, 10H), 3.29-3.27 (m, 1H), 3.24 (dd, J=3.2, 10.1 Hz, 1H), 3.07-2.97 (m, 1H), 2.92-2.81 (m, 2H), 2.75 (t, J=10.8 Hz, 1H), 2.50 (br t, J=10.8 Hz, 1H), 1.44 (d, J=6.5 Hz, 3H).
The title compound was prepared in analogy to the preparation of Example 109 by using tert-butyl N-[(3R,4S)-4-fluoropyrrolidin-3-yl]carbamate instead of tert-butyl N-[(3S,4S)-4-methoxypyrrolidin-3-yl]carbamate, 2-(5-bromo-2-pyridyl)ethyl methanesulfonate (compound 13b) instead of 2-(6-chloro-3-pyridyl)ethyl methanesulfonate (compound 11c), and 5-[(4S,9aS)-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrazino[1,2-a]pyrazin-2-yl]-2-deuterio-quinoline-8-carbonitrile (Intermediate K) instead of 5-[(4R,9aS)-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrazino[1,2-a]pyrazin-2-yl]-2-deuterio-quinoline-8-carbonitrile (Intermediate G). Example 117 was obtained as a yellow solid (48 mg). LCMS (M+H)+: 516, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 8.96 (br d, J=7.1 Hz, 1H), 8.27 (d, J=8.1 Hz, 1H), 8.18 (dd, J=2.1, 9.4 Hz, 1H), 8.10 (d, J=1.8 Hz, 1H), 7.81 (d, J=8.6 Hz, 1H), 7.46 (d, J=8.1 Hz, 1H), 7.25 (d, J=9.3 Hz, 1H), 5.73-5.55 (m, 1H), 4.61-4.49 (m, 1H), 4.40-4.24 (m, 3H), 4.21-4.09 (m, 2H), 4.03-3.72 (m, 9H), 3.68-3.58 (m, 2H), 3.48-3.35 (m, 2H), 3.27-3.18 (m, 2H), 1.67 (br, 3H).
The title compound was prepared in analogy to the preparation of Example 108 by using tert-butyl N-(3-methylazetidin-3-yl)carbamate instead of tert-butyl 3,6-diazabicyclo[3.1.1]-heptane-6-carboxylate. Example 118 (20 mg) was obtained as a light yellow foam. LCMS (M+H)+: 484. 1H NMR (400 MHz, METHANOL-d4) δ ppm: 8.71-8.62 (m, 1H), 8.12 (dd, J=1.2, 7.9 Hz, 1H), 7.67 (d, J=2.8 Hz, 0.6H), 7.61 (dd, J=1.5, 8.6 Hz, 1H), 7.39 (d, J=2.7 Hz, 0.4H), 7.30 (dd, J=2.4, 7.9 Hz, 1H), 7.14 (br, 0.6H), 6.83 (br, 0.4H), 4.46 (d, J=6.4 Hz, 1H), 4.23 (br, 1H), 3.93-3.87 (m, 1H), 3.84-3.77 (m, 3H), 3.73-3.67 (m, 1H), 3.65-3.46 (m, 4H), 3.44-3.32 (m, 4H), 2.97 (td, J=6.5, 10.5 Hz, 1H), 2.31 (s, 1.8H), 2.25 (s, 1.2H), 1.99-1.83 (m, 1.2H), 1.72 (br, 3H), 1.61-1.49 (m, 1.8H).
The preparation of Example 121 was the same as Example 2 by using Intermediate K instead of Intermediate A and tert-butyl 2-chloro-7,8-dihydro-5H-1,6-naphthyridine-6-carboxylate instead of tert-butyl 5-bromo-3,4-dihydro-1H-isoquinoline-2-carboxylate (compound 2a). Example 121 was obtained as a light brown solid (84 mg). LCMS (M+H)+: 441, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 8.76 (d, J=8.7 Hz, 1H), 8.21 (dd, J=1.0, 8.1 Hz, 1H), 7.72 (d, J=8.7 Hz, 1H), 7.48 (d, J=8.6 Hz, 1H), 7.39 (dd, J=1.9, 7.9 Hz, 1H), 6.91 (br d, J=8.8 Hz, 1H), 4.49 (br, 2H), 4.30 (s, 2H), 4.02-3.81 (m, 2H), 3.73-3.62 (m, 2H), 3.59 (t, J=6.5 Hz, 2H), 3.52-3.36 (m, 4H), 3.27-3.12 (m, 2H), 3.09 (t, J=6.4 Hz, 2H), 1.66 (br, 3H).
The preparation of Example 122 was the same as Example 2 by using Intermediate K instead of Intermediate A and tert-butyl N-[(3S,4S)-1-[2-(6-chloro-3-pyridyl)ethyl]-4-methoxy-pyrrolidin-3-yl]carbamate (compound 122a) instead of tert-butyl 5-bromo-3,4-dihydro-1H-isoquinoline-2-carboxylate (compound 2a). Example 122 was obtained as a light brown solid (64 mg). LCMS (M+H)+: 528, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 8.76 (d, J=8.6 Hz, 1H), 8.21 (d, J=7.9 Hz, 1H), 8.08 (d, J=2.2 Hz, 1H), 7.71 (d, J=8.6 Hz, 1H), 7.63 (dd, J=2.1, 8.7 Hz, 1H), 7.38 (d, J=7.9 Hz, 1H), 6.99 (d, J=8.8 Hz, 1H), 4.37 (br t, J=11.4 Hz, 2H), 4.01-3.96 (m, 1H), 3.95-3.81 (m, 2H), 3.74-3.70 (m, 1H), 3.66 (br t, J=12.0 Hz, 2H), 3.44 (br d, J=13.6 Hz, 2H), 3.41 (s, 4H), 3.39-3.34 (m, 2H), 3.27-3.11 (m, 3H), 3.00-2.87 (m, 4H), 2.86-2.79 (m, 2H), 1.64 (br d, J=6.6 Hz, 3H).
The compound 122a was prepared according to the following scheme:
To a tube was added 2-(6-chloropyridin-3-yl)ethyl methanesulfonate (288 mg, 1.1 mmol, Eq: 1.1), tert-butyl N-[(3S,4S)-4-methoxypyrrolidin-3-yl]carbamate (216 mg, 1 mmol), K2CO3 (276 mg, 2 mmol) and Acetonitrile (3 mL). The suspension was heated to 80° C. for 16 hours. The mixture was filtered; the filtrate was concentrated to give an oil. Then the oil was purified by silica gel to give compound 122a (278 mg) as a yellow oil. LCMS (M+H)+: 356.
The preparation of Example 123 was the same as Example 2 by using Intermediate K instead of Intermediate A and tert-butyl N-[(3R,4R)-1-[(6-chloro-2-methyl-3-pyridyl)methyl]-4-methoxy-pyrrolidin-3-yl]carbamate (compound 123a) instead of tert-butyl 5-bromo-3,4-dihydro-1H-isoquinoline-2-carboxylate (compound 2a). Example 123 was obtained as a light brown solid (82 mg). LCMS (M+H)+: 528, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 8.64 (d, J=8.7 Hz, 1H), 8.08 (dd, J=2.1, 7.9 Hz, 1H), 7.65 (br d, J=8.8 Hz, 1H), 7.62-7.56 (m, 1H), 7.29 (d, J=8.1 Hz, 1H), 6.83 (br d, J=8.7 Hz, 1H), 4.63-4.40 (m, 2H), 4.32 (s, 2H), 4.12 (br s, 3H), 3.90 (br d, J=5.1 Hz, 1H), 3.88-3.69 (m, 2H), 3.69-3.53 (m, 4H), 3.53-3.35 (m, 5H), 3.33 (s, 3H), 3.20-3.07 (m, 1H), 2.45 (s, 3H), 1.63 (br d, J=5.3 Hz, 3H).
The compound 123a was prepared according to the following scheme:
To a tube was added 6-chloro-3-(chloromethyl)-2-methylpyridine (88 mg, 500 μmol), tert-butyl N-[(3R,4R)-4-methoxypyrrolidin-3-yl]carbamate (108 mg, 500 μmol), K2CO3 (138 mg, 1000 μmol) and Acetonitrile (3 mL). The suspension was heated to 86° C. for 2 hours. The mixture was filtered; the filtrate was concentrated to give an oil. Then the oil was purified by silica gel to give compound 123a (170 mg) as a pale yellow oil. LCMS (M+H)+: 356
The title compound was prepared in analogy to the preparation of Example 11 by using tert-butyl (4aR,7aR)-3,4a,5,6,7,7a-hexahydro-2H-pyrrolo[3,4-b][1,4]oxazine-4-carboxylate (CAS: 1932337-68-2, catalog: PBXA8123, vendor: Pharmablock) instead of tert-butyl piperazine-1-carboxylate. Example 124 was obtained as a light yellow solid (60 mg). LCMS (M+H)+: 539, 1H NMR (400 MHz, METHANOL-d4) δ ppm: 9.09 (dd, J=1.6, 4.5 Hz, 1H), 8.90 (dd, J=1.5, 8.6 Hz, 1H), 8.30 (d, J=7.9 Hz, 1H), 8.15 (dd, J=2.1, 9.4 Hz, 1H), 8.07 (d, J=1.7 Hz, 1H), 7.84 (dd, J=4.5, 8.6 Hz, 1H), 7.48 (d, J=8.1 Hz, 1H), 7.21 (d, J=9.3 Hz, 1H), 4.53-4.37 (m, 1H), 4.37-4.20 (m, 3H), 4.18-3.94 (m, 6H), 3.87-3.35 (m, 14H), 3.23 (t, J=8.1 Hz, 2H), 1.56 (d, J=6.5 Hz, 3H).
The title compound was prepared according to the following scheme:
A solution of tert-butyl (6S,9aR)-6-methyl-1,3,4,6,7,8,9,9a-octahydropyrazino[1,2-a]pyrazine-2-carboxylate (compound K-3, 751 mg, 2.94 mmol), 5-fluoroquinoline-8-carbonitrile (compound 125a, 460 mg, 2.67 mmol) and DIPEA (1.7 g, 13.4 mmol) in DMSO (10 mL) was stirred at 130° C. overnight, then the reaction was diluted with EtOAc (40 mL), washed with water. The organic layer was dried and concentrated, the residue was purified by flash column chromatography to give 1.1 g orange oil. The orange oil was dissolved in DCM/TFA (8 mL, 1:1) and stirred at rt for 10 mins, then the reaction mixture was concentrated. The residue was dissolved in NaOH (2 N), then extracted with DCM/iPrOH (2:1), the organic phase was dried and concentrated to give compound 125b (700 mg) as a yellow solid. LCMS (M+H)+: 308.
To a solution of 5-[(4S,9aS)-4-methyl-1,3,4,6,7,8,9,9a-octahydropyrazino[1,2-a]pyrazin-2-yl]quinoline-8-carbonitrile (compound 125b, 180 mg, 586 μmol) in dioxane (6 mL) was added tert-butyl (2R)-2-(4-bromophenyl)morpholine-4-carboxylate (CAS: 1312566-00-9, procedure see Patent WO 2014041007 A1 20140320, 240 mg, 703 μmol) and Cs2CO3 (572 mg, 1.76 mmol). The suspension was bubbled with N2 for 5 minutes, then RuPhos Pd G2 (46 mg, 58.6 μmol) was added. After the reaction mixture was heated at 100° C. overnight, it was filtered and the filtrate was concentrated. The residue was dissolved in DCM/TFA (4 mL, 1:1), after stirring at r.t. for 10 mins, the reaction mixture was concentrated and the residue was purified by prep-HPLC to give Example 125 (38 mg) as a yellow foam. LCMS (M+H)+: 469. 1H NMR (400 MHz, METHANOL-d4) δ ppm: 9.00-8.93 (m, 1H), 8.71 (dd, J=1.3, 8.6 Hz, 1H), 8.14 (dd, J=1.4, 8.0 Hz, 1H), 7.69-7.61 (m, 1H), 7.29-7.20 (m, 3H), 6.97 (d, J=8.6 Hz, 2H), 4.38 (dd, J=2.3, 10.5 Hz, 1H), 4.03-3.87 (m, 1H), 3.73 (dt, J=3.2, 11.4 Hz, 1H), 3.62 (br t, J=12.5 Hz, 2H), 3.44 (br d, J=11.5 Hz, 1H), 3.35 (br s, 2H), 3.27 (br s, 2H), 3.02-2.80 (m, 6H), 2.79-2.65 (m, 2H), 2.51 (br t, J=10.7 Hz, 1H), 1.43 (d, J=6.2 Hz, 3H).
The following tests were carried out in order to determine the activity of the compounds of formula (I) and (Ia) in HEK293-Blue-hTLR-7/8/9 cells assay.
HEK293-Blue-hTLR-7 cells assay:
A stable HEK293-Blue-hTLR-7 cell line was purchased from InvivoGen (Cat. #: hkb-htlr7, San Diego, Calif., USA). These cells were originally designed for studying the stimulation of human TLR7 by monitoring the activation of NF-κB. A SEAP (secreted embryonic alkaline phosphatase) reporter gene was placed under the control of the IFN-D minimal promoter fused to five NF-κB and AP-1-binding sites. The SEAP was induced by activating NF-κB and AP-1 via stimulating HEK-Blue hTLR7 cells with TLR7 ligands. Therefore, the reporter expression was declined by TLR7 antagonist under the stimulation of a ligand, such as R848 (Resiquimod), for incubation of 20 hrs. The cell culture supernatant SEAP reporter activity was determined using QUANTI-Blue™ kit (Cat. #: rep-qb1, Invivogen, San Diego, Calif., USA) at a wavelength of 640 nm, a detection medium that turns purple or blue in the presence of alkaline phosphatase.
HEK293-Blue-hTLR7 cells were incubated at a density of 250,000˜450,000 cells/mL in a volume of 170 μL, in a 96-well plate in Dulbecco's Modified Eagle's medium (DMEM) containing 4.5 g/L glucose, 50 U/mL penicillin, 50 mg/mL streptomycin, 100 mg/mL Normocin, 2 mM L-glutamine, 10% (v/v) heat-inactivated fetal bovine serum with addition of 20 μL test compound in a serial dilution in the presence of final DMSO at 1% and 10 μL of 20 uM R848 in above DMEM, perform incubation under 37° C. in a CO2 incubator for 20 hrs. Then 20 μL of the supernatant from each well was incubated with 180 t Quanti-blue substrate solution at 37° C. for 2 hrs and the absorbance was read at 620-655 nm using a spectrophotometer. The signaling pathway that TLR7 activation leads to downstream NF-κB activation has been widely accepted, and therefore similar reporter assay was modified for evaluating TLR7 antagonist.
HEK293-Blue-hTLR-8 Cells Assay:
A stable HEK293-Blue-hTLR-8 cell line was purchased from InvivoGen (Cat. #: hkb-htlr8, San Diego, Calif., USA). These cells were originally designed for studying the stimulation of human TLR8 by monitoring the activation of NF-κB. A SEAP (secreted embryonic alkaline phosphatase) reporter gene was placed under the control of the IFN-β minimal promoter fused to five NF-κB and AP-1-binding sites. The SEAP was induced by activating NF-κB and AP-1 via stimulating HEK-Blue hTLR8 cells with TLR8 ligands. Therefore, the reporter expression was declined by TLR8 antagonist under the stimulation of a ligand, such as R848, for incubation of 20 hrs. The cell culture supernatant SEAP reporter activity was determined using QUANTI-Blue™ kit (Cat. #: rep-qb1, Invivogen, San Diego, Calif., USA) at a wavelength of 640 nm, a detection medium that turns purple or blue in the presence of alkaline phosphatase.
HEK293-Blue-hTLR8 cells were incubated at a density of 250,000-450,000 cells/m in a volume of 170 μL in a 96-well plate in Dulbecco's Modified Eagle's medium (DMEM) containing 4.5 g/L glucose, 50 U/LI penicillin, 50 mg/mL streptomycin, 100 mg/mL Normocin, 2 nM L-glutamine, 10% (v/v) heat-inactivated fetal bovine serum with addition of 20 μL test compound in a serial dilution in the presence of final DMSO at 1% and 10 μL of 60 uM R848 in above DMEM, perform incubation under 37° C. in a CO2 incubator for 20 hrs. Then 20 μL of the supernatant from each well was incubated with 180 μL Quanti-blue substrate solution at 37° C. for 2 hrs and the absorbance was read at 620-655 nm using a spectrophotometer. The signaling pathway that TLR8 activation leads to downstream NF-κB activation has been widely accepted, and therefore similar reporter assay was modified for evaluating TLR8 antagonist.
HEK293-Blue-hTLR-9 Cells Assay:
A stable HEK293-Blue-hTLR-9 cell line was purchased from InvivoGen (Cat. #: hkb-htlr9, San Diego, Calif., USA). These cells were originally designed for studying the stimulation of human TLR9 by monitoring the activation of NF-κB. A SEAP (secreted embryonic alkaline phosphatase) reporter gene was placed under the control of the IFN-D minimal promoter fused to five NF-κB and AP-1-binding sites. The SEAP was induced by activating NF-κB and AP-1 via stimulating HEK-Blue hTLR9 cells with TLR9 ligands. Therefore, the reporter expression was declined by TLR9 antagonist under the stimulation of a ligand, such as ODN2006 (Cat. #: tlr1-2006-1, Invivogen, San Diego, Calif., USA), for incubation of 20 hrs. The cell culture supernatant SEAP reporter activity was determined using QUANTI-Blue™ kit (Cat. #: rep-qb1, Invivogen, San Diego, Calif., USA) at a wavelength of 640 nm, a detection medium that turns purple or blue in the presence of alkaline phosphatase.
HEK293-Blue-hTLR9 cells were incubated at a density of 250,000˜450,000 cells/mL in a volume of 170 μL in a 96-well plate in Dulbecco's Modified Eagle's medium (DMEM) containing 4.5 g/L glucose, 50 U/mL penicillin, 50 mg/mL streptomycin, 100 mg/mL Normocin, 2 mM L-glutamine, 10% (v/v) heat-inactivated fetal bovine serum with addition of 20 μL test compound in a serial dilution in the presence of final DMSO at 1% and 10 μL of 20 uM ODN2006 in above DMEM, perform incubation under 37° C. in a CO2 incubator for 20 hrs. Then 20 μL of the supernatant from each well was incubated with 180 μL Quanti-blue substrate solution at 37° C. for 2 h and the absorbance was read at 620-655 nm using a spectrophotometer. The signaling pathway that TLR9 activation leads to downstream NF-κB activation has been widely accepted, and therefore similar reporter assay was modified for evaluating TLR9 antagonist.
The compounds of formula (I) or (Ia) have human TLR7 and/or TLR8 inhibitory activities (IC50 value)<0.5 μM. Moreover, compounds of this invention also have human TLR9 inhibitory activity<0.5 μM. Activity data of the compounds of the present invention were shown in Table 2.
hERG Channel Inhibition Assay:
The hERG channel inhibition assay is a highly sensitive measurement that identifies compounds exhibiting hERG inhibition related to cardiotoxicity in vivo. The hERG K+ channels were cloned in humans and stably expressed in a CHO (Chinese hamster ovary) cell line. CHOhERG cells were used for patch-clamp (voltage-clamp, whole-cell) experiments. Cells were stimulated by a voltage pattern to activate hERG channels and conduct IKhERG currents (rapid delayed outward rectifier potassium current of the hERG channel). After the cells were stabilized for a few minutes, the amplitude and kinetics of IKhERG were recorded at a stimulation frequency of 0.1 Hz (6 bpm). Thereafter, the test compound was added to the preparation at increasing concentrations. For each concentration, an attempt was made to reach a steady-state effect, usually, this was achieved within 3-10 min at which time the next highest concentration was applied. The amplitude and kinetics of IKhERG are recorded in each concentration of the drug which were compared to the control values (taken as 100%). (references: Redfern W S, Carlsson L, Davis A S, Lynch W G, MacKenzie I, Palethorpe S, Siegl P K, Strang I, Sullivan A T, Wallis R, Camm A J, Hammond T G. 2003; Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc. Res. 58:32-45, Sanguinetti M C, Tristani-Firouzi M. 2006; hERG potassium channels and cardiac arrhythmia. Nature 440:463-469, Webster R, Leishman D, Walker D. 2002; Towards a drug concentration effect relationship for QT prolongation and torsades de pointes. Curr. Opin. Drug Discov. Devel. 5:116-26).
Results of hERG are given in Table 3. A safety ratio (hERG IC20/EC50)>30 suggests a sufficient window to differentiate the pharmacology by inhibiting TLR7/8/9 pathways from the potential hERG related cardiotoxicity. The calculation of hERG IC20/TLR7/8/9 IC50 below serves as early selectivity index to assess hERG liability.
Phototoxicity is defined as a toxic response that is elicited after the first exposure of the skin to certain chemicals and subsequent exposure to light, or that is induced similarly by skin irradiation after systemic administration of a chemical substance. The assay used in this study is designed to detect the phototoxic potential of a chemical by using a simple in vitro cytotoxicity assay with Balb/c 3T3 mouse fibroblasts. The principle of this test is a comparison of the cytotoxicity of a chemical when tested with and without exposure to a non-toxic dose of UVA-light. Cytotoxicity is expressed as a dose dependent reduction of the growth rate of cells as determined by uptake of the vital dye Neutral Red one day after treatment.
1. Method
A small amount of substance was weighed and formulated freshly in DMSO just before the start of the exposure of the cells. This stock solution or appropriate dilutions with DMSO were added to the cell suspensions to obtain the required final concentrations. All solutions were generally prepared in Eppendorf caps and discarded after use.
Chlorpromazine (HCL) (Sigma, Batch/Lot No.: 120M1328V), test concentration: 300 μg/mL, Solvent: PBS/3% DMSO
The absorption spectra as such or with UV-A or with UV-B pre-irradiation were recorded between 240 nm and 400 nm with a Lambda-2 spectral photometer (Perkin Elmer).
for UV-B: Philips TL 20 W/12
For this study the Neutral Red uptake (NRU) assay of Borenfreund and Puemer (Borenfreund, E, Puemer J A. Toxicity determined in vitro by morphological alterations and Neutral Red absorption. Toxicology Lett. 1985; 24:119-124) modified according to INVITTOX protocol No 78 (ERGATT/FRAME data bank of in vitro techniques in toxicology. INVITTOX PROTOCOL No 78. 3T3 NRU Phototoxicity Assay. March 1994) has been adapted to examine a possible phototoxic potential of the test item. This assay is based on the active uptake of the Neutral Red dye into the lysosomes of cultured murine fibroblasts. Because lysosomal membranes are known to be a site of action of many phototoxic compounds, this assay can provide a measure of potential for phototoxic injury.
A murine fibroblasts clone A 31 (ATCC no. CCL 163—passage No. 108) were cultured in 175 cm2 tissue culture grade flasks, containing sDMEM (Dulbecco's Minimal Essential Medium, supplemented with 10% fetal calf serum, 2 mM L-glutamine, 100 units/ml Penicillin and 100 μg/ml streptomycin) at 37° C. in a humidified atmosphere of 6% CO2. Before cells approach confluence they were removed from flasks by trypsinisation. Prior to use in an assay, the cells were transferred to 96-well microtiter plates at a concentration of 1×104 cells/well in 100 μl volumes of sDMEM and allowed to attach for 24 h.
For incubation with murine fibroblasts, the test item was diluted in PBS/3% DMSO (detailed concentrations see in results).
Culture medium (Dulbecco's Modified Eagle Medium (DMEM), GlutaMAX (Gibco Ref 21885-025), 10% Fetal Bovine Serum (FBS) (Gibco Ref 10270-106), 100 IU/ml Penicillin and 100 μg/ml Streptomycin (Gibco Ref 15140-122)) was removed from the wells and murine fibroblasts were washed with PBS. Afterwards 100 μL of PBS/3% DMSO containing the test item was added and target cells were incubated for 1 h at 37° C. with 6% CO2.
For each test item the microtiter plates were prepared according to Table 4. “UVA plates” were exposed to approx. 5 J/cm2 UVA light, the “Dark plates” were kept in the dark and served as cytotoxicity control. Plates with chlorpromazine hydrochloride served as positive control. UV flux was measured with a UV-meter (Dr. Gröbel RM21).
Following UV irradiation, the test item was removed from the wells (one washing step with PBS) and replaced with sDMEM. Target cells were then incubated overnight at 37° C. in 6% CO2.
96-well microtiter plates were prepared as follows:
Each plate contained wells with cells and solvent but without test item which were either not incubated with Neutral Red solution (0% standard—S1) or were stained with Neutral Red (100% standard—S2) for calculation of the standard cell viability curve. Wells labeled with U01-U08 contained the different test item concentrations.
The ready to use Neutral Red (NR) staining solution was freshly prepared as follows:
After the incubation the wells to be assayed were filled with 100 μL of the sDMEM containing Neutral Red. The target cells were incubated with the NR for 3 h at 37° C. in 6% CO2.
Unincorporated Neutral Red was removed from the target cells and the wells washed with at least 100 μL of PBS. 150 μL of Neutral Red desorb solution (1% glacial acetic acid, 50% ethanol in aqua bidest) was then added to quantitatively extract the incorporated dye. After at least 10 mins of vigorous shaking of the plates on a microtiter plate shaker until Neutral Red has been extracted from the cells and formed a homogeneous solution, the absorption of the resulting colored solution was measured with a SPECTRAmax PLUS microtiter plate reader (Molecular Devices) at 540 nm.
Cell viability was calculated with the SOFTmax Pro software package (Molecular Devices). First a two-point standard curve (0% and 100% viability) was calculated with the linear curve fit option of the program based on the following formula:
Y=A+(B×X)
(A=y-intercept of the line; B=slope of the line;
0% cell viability=cells with solvent, but without test item and Neutral Red;
100% cell viability=cells with solvent and Neutral Red, but without test item)
By this means the viability of the cells incubated with increasing concentrations of the test chemical was calculated. Chlorpromazine (HCl) served as positive control in the experiment.
All calculations were performed with the SOFTmax Pro analysis software package (Molecular Devices—for details see:
http://www.mbl.edu/jbpc/files/2014/05/SoftMax_Pro_User_Guide.pdf)
For evaluation of phototoxic potential, the IC50 values determined with and without UV exposure were compared.
Factor=IC50(−UV)/IC50(+UV)
For discrimination between phototoxic and non-phototoxic test chemicals a cut-off factor of >5 was applied (Liebsch M, Spielmann H, Balls M, Brand M, Döring B, Dupuis J, Holzhüter H G, Klecak G, L. Eplattenier H, Lovell W, Maurer T, Moldenhauer F, Moore L, Pape W, Pfannenbecker U, Potthast J M, De Silva O, Steiling W, Willshaw A. First results of the EC/COLIPA Validation Project. In Vitro Phototoxicity Testing. In: In Vitro Skin Toxicology: Irritation, Phototoxicity, Sensitization; Vol. 10. Alternative Methods in Toxicology,-Eds. Rougier A, Maibach H I, Goldberg A M; Mary Ann Liebert Publ.: New York, USA 1994, pp. 243-251).
Test items which are not cytotoxic to murine fibroblasts even at the highest concentrations tested, but show a strong dose dependent decrease in cell viability after UV exposure are considered also phototoxic (Spielmann H, Balls M, Dupuis J, Pape W J W, Pechovitch G, Silva DeO, Holzhütter, H G, Clothier R, Desolle P, Gerberick F, Liebsch M, Lowell W W, Maurer T, Pfannenbecker U, Potthast J M, Csato M, Sladowski D, Steiling W, Brantom P. The international EU/COLIPA in vitro phototoxicity validation study: Results of phase II (blind trial). Part 1: The 3T3 NRU phototoxicity test. Toxicology in Vitro 1998, 12: 305-327).
The test results were shown below, the compounds of this invention showed very good phototoxicity profile.
To assess compound efficacy in vivo against lupus nephritis, we utilized a murine model of TLR7 agonist-induced lupus-like disease, in which TLR7 activation leads to the development of systemic autoimmune symptoms with elevated levels of autoantibodies to double-stranded DNA (anti-dsDNA), inflammatory cytokines such as IP10, as well as multiple organs involvement especially in kidney and spleen.
BALB/c mice were purchased from Vital River Laboratories Co., Ltd., Beijing, China. All mice were 7 to 8-week old female. To induce disease, animals were topically treated on the right ear with 100 μg of Resiquimod (R848) solved in 20 μL of acetone for three times per week. Compound or vehicle treatment was administrated orally once daily and 30 minutes prior to the epicutanenous R848 treatment if they were on the same day.
Blood samples were collected once weekly to gauge the level of autoantibody against double stranded DNA and multiple cytokines in serum. The total anti-dsDNA Immunoglobulins in serum were measured according to the manufacturer's instruction with a commercially available ELISA assay (Cat #5110, Alpha Diagnostic Inti Inc.). Cytokine levels in serum were measured with a ProcartaPlex immunoassay Kit (Cat #PPX-08-MXNKR2Z, Thermo Fisher). Specifically, 10 μL of premixed magnetic capture beads were added to a DropArray DA-bead plate (Cat #969-CC-BD-05, Curiox). After washing, 10 μL of diluted sera (1:5) was incubated on the DA-bead plate overnight at 4° c. After washing for three times, 5 μL of premixed detection antibody was added to the plate with an incubation for 60 minutes at room temperature. After washing, 10 μL of Streptavidin-PE was added with an incubation for 30 minutes at room temperature. The beads were then re-suspended in 55 μL Reading Buffer. Samples were analyzed with a Luminex 200 (Millipore).
Urine samples were collected once weekly with the animals housed in metabolic cages for 24 hours, and were subjected to the measurements of urinary albumin (UALB), urinary creatinine (UCR) and urinary total protein (UTP) with a Roche Cobas 6000 Chemistry Analyzer (Roche Diagnostics, Mannheim, Germany).
To evaluate kidney histopathology, kidney samples were fixed with neutral buffered formalin and embedded in paraffin. The sliced sections were stained with hematoxylin and eosin, and with periodic acid-Schiff A pathologist then examined the samples in a blinded manner and graded glomerular lesions semi-quantitatively with a total glomerulonephritis score, the sum of glomerular score, inflammation score, PAS score, and tubular protein score.
Specifically, glomerular scores of 0 to 6 were based on assessment of the glomeruli in the outer one-half of the cortex, and on the most frequent grade encountered in this region. Grade 1: Minimally increased cellularity and/or mesangial expansion; Grade 2: Mildly increased cellularity and mesangial expansion; Grade 3: Moderately increased cellularity and some areas of prominent mesangial expansion and/or capillary proliferation in most affected glomeruli; Grade 4: Markedly increased cellularity and some areas of prominent mesangial expansion and/or capillary proliferation in most affected glomeruli; rare sclerotic glomeruli; may have hypertrophy of parietal cells; Grade 5: Above with <25% of glomeruli sclerotic and/or capillary proliferation in most affected glomeruli; Grade 6: Above with >25% of glomeruli sclerotic-characterized in part by decreased tuft cellularity+/−periglomerular fibrosis+/−hypertrophy of parietal cells.
Inflammation scores of 0 to 3 were based on both the number and size of inflamed area.
PAS scores of 0 to 3 were based upon the presence of increased staining of the glomerular mesangial matrix in the outer one-half of the cortex. Grade 1: Minimally increased mesangial staining of scattered glomeruli; Grade 2: More extensive expansion (and therefore PAS staining) of the mesangium affecting more of the glomeruli; Grade 3: Pronounced expansion of the mesangium in most of the glomeruli.
Tubular protein scores of 0 to 3 were based on the percentage of tubules containing proteinaceous fluid. Grade 1: <25% of tubules affected; Grade 2: 25 to 50% of tubules affected; Grade 3: >50% of tubules affected. Spleens were harvested and weighed upon study termination to evaluate splenomegaly.
Key findings for Example 106 in the R848 agonist induced mouse lupus nephritis disease model are as follows:
Taken together, the aforementioned experiment findings have demonstrate a good therapeutic potential of Example 106, and potentially the compounds of this invention, in treating systemic lupus erythematosus (SLE), lupus nephritis (LN).
| Number | Date | Country | Kind |
|---|---|---|---|
| PCT/CN2019/081900 | Apr 2019 | CN | national |
| PCT/CN2019/121598 | Nov 2019 | CN | national |
| PCT/CN2020/078225 | Mar 2020 | CN | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/EP2020/059831 | 4/7/2020 | WO |
